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ABSTRACT.
This thesis deals with a number of aspects of Epidermal 
Growth Factor Receptor (EGF-R) molecular biology and also EGF-R’s 
involvement in breast cancer.
The current literature on the biology of breast cancer 
and on the structure of both the EGF-R gene and protein are 
reviewed, as are the ways in which advances in technology have 
contributed to our knowledge in these areas.
The link between EGF-R structure and function is 
em phasised and this leads into a discussion on EGF-R signal 
transduction. EGF-R is a 160 K.D. polypeptide which has intrinsic 
tyrosine kinase activity. The cellular substrates of the kinase are 
largely unknown but many of those that have been identified have 
been shown to be important structural and regulatory proteins.
EGF-R also has autophosphorylation ability i.e. EGF-R 
phosphorylates itself as well as exogenous substrates. This is a very 
important process and is believed to have a regulatory function, 
possibly mediated by structural features of the receptor and is 
discussed in some depth.
In order to more clearly understand the ways in which 
EGF-R may be involved in human carcinogenesis, and to put the 
problem in context, a review of the very large and complicated area 
of cancer biology is included. In addition, the specific case of breast 
cancer molecular biology is examined in some detail.
EGF-R has been shown to be an important regulator of 
growth in both normal and cancerous cells. In breast cancer, EGF-R 
has been reported to be an index of poor prognosis, both in relation 
to disease free interval and total survival.
The current literature concerning EGF-R 's role in 
human breast cancer developm ent is often conflicting; Points 
reviewed in this thesis include the autocrine theory of growth factor 
involvem ent in growth regulation, EGF-R and breast cancer cell 
proliferation, and EGF-R as a potential therapuetic target.
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Chapter One: INTRODUCTION.
1 .Introduction.
C ancer is a disease that has been known since 
antiquity. As will be described later, despite this and our rapidly 
accum ulating bio-m edical know ledge, little  advance has been 
made in the treatment of solid cancers. Nowhere is this more true 
than in the specific example of breast cancer. This form of cancer 
kills many hundreds of thousands world wide per year.
For this reason, research into the causes and molecular 
mechanisms of breast cancer is a very large and active area 
encom passing disciplines such as cell biology, immunology, 
genetics and biochemistry. It is hoped that such an approachiwith 
a num ber o f d ifferen t, but com plem en ta ry  avenues being 
explored simultaneously will provide some answers to the many 
questions that remain about the natural history of tumours.
It is also anticipated that such basic and applied 
resea rch  p rog ram m es will a llow  new  drugs and o ther 
therapeutic  regim es to be designed and so facilita te  patient 
m a n a g e m e n t .
This thesis will examine the role of only one cellular 
protein in the genesis of one specific human cancer. The protein 
is the Epidermal Growth Factor Receptor or EGF-R and the cancer 
is breast cancer.
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EGF-R is, as its name would imply, the receptor for the 
growth factor Epidermal Growth Factor (EGF). It is held that the 
binding of ligand to EGF-R begins a cascade of actions which 
ev en tu a l ly  cu lm ina tes  in the e x p re ss io n  of certa in  cell 
proliferation regulation genes.
In normal circum stances, this signalling pathway is
stimulated such that the processes of cell death and replacement
are balanced. The theories state that in some way, for example by 
alteration of the structure of the EGF-R itself, this balance is 
disrupted as occurs in cell transform ation, and cell proliferation
occurs in an uncontrolled (or less controlled) way. The result is the
production of a unruly mass of cells-clinically diagnosable as a 
tu m o u r .
T he ex am ina tion  of g row th  fac to rs  and their
receptors-of which EGF-R is an example has proven to be a very 
profitable route to take. Since the initial discovery of growth factors 
in the nineteen-sixties their importance in cellular growth and its 
control has been beyond dispute. Their use, coupled with cell 
cu ltu re  system s has m eant tha t a co n tro l le d ,  m an ipu lab le  
e x p e r im e n ta l  e n v iro n m e n t  can be se t up to s tudy  the 
cause-and-effec t re la tionsh ip  betw een growth fac tors and cell 
division. Today, modern techniques such as reverse genetics, DNA 
sequencing, gene alteration and cloning have advanced and refined 
such studies.
It was studies using some of these techniques which 
demonstrated that EGF-R was involved in the process of breast 
cancer development. In the first instance the presence of EGF-R was 
detected, then theories as to the molecular mechanisms involved 
were able to be adumbrated. Today, it seems likely that EGF-R 
could be an important target for therapies against many forms of 
cancer, not just breast cancer.
Much data exist on many aspects of EGF-R and its 
relationship  to cancer. The intention of this thesis is to bring 
together and review certain areas of particular importance.
To set the scene, the biology of cancer will be 
discussed. A consideration of questions such as what is cancer?, 
how is cancer caused and an appreciation of the history of the 
problem and the various models of carcinogenesis will allow the 
problem of breast cancer to be put in context.
Breast cancer itself will then be discussed. A cellular 
biological and molecular genetical approach is taken here since I 
feel that these are the two more im portant areas in terms of 
contribution to and the advancement of knowledge and potential 
for the future.
Next is an analysis of the molecular biology of EGF-R. 
Many experiments have pointed to the crucial nature of the actual 
structure of the receptor to its functioning. Questions of structure at 
both DNA and protein levels and related aspects are reviewed.
Much weight in this thesis is given to EGF-R signal 
transduction. The reason for this is that it is believed that here lie 
the ultimate answers to questions about EGF-R and its role as a 
growth factor and in carcinogenesis. Briefly then, EGF-R's function 
as a protein kinase (tyrosine, serine or threonine) is reviewed along 
with EGF-R's effects upon the inositol lipid metabolism and ionic 
fluxes of a cell and the cotribution of G-proteins to these processes.
With sufficient background information having been 
discussed, the role of EGF-R in breast cancer is discussed. A number 
of points are raised, such as EGF-R and cell transformation, tumour 
size, stage, grade and sub-groups. Looking forward is a section on 
how EGF-R might be useful in terms of breast cancer therapy.
Chapter Two:
CANCER BIOLOGY.
2.1 .Introduction.
A tumour is a contiguous mass of cells derived from a 
progenitor cell which in some way has lost it's ability to respond 
to the normal cellular growth control mechanisms.
Tumours can be of two types. Firstly there are benign 
tumours which are encapsulated and cannnot invade the tissue 
which surrounds them. The second group of tumours are the 
malignant tumours. These cancers are marked by their ability to 
invade the surrounding tissue and spread to other sites in the 
body, a process known as metastasis. These two properties are 
responsible for the lethal nature of malignant tumours.
Malignant tumours can be Carcinomas (derived from 
epithelial cells); Sarcomas (arise in the supporting tissues of the 
body) or Leukaem ias/L ym phom as (w hich arise  in the blood 
forming cells in the bone marrow and lymph nodes).
In addition, the precise definition of a m alignant 
tumour depends on the organ in which it arose and upon the type 
of cell involved.In humans approximately 100 different types of 
malgnant tumours are known (Franks and Teich, 1986). However, 
cancers of three main organs are responsible for around half of all 
cancer deaths: those of the lung, the large intestine and in females, 
the breast.
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Cancer may affect all multi cellular organisms. Evidence 
has shown that alterations in cell growth and development and in 
the control of these processes lie at the centre of this disease. 
K now led ge  of the p rocesses  u n derly ing  ce ll  grow th  and 
differentiation will be of great importance to an understanding of 
m alignancy .
Cancer is a disease that has been known since antiquity 
(see Franks and Teich ,1986). In recen t tim es, though, the 
incidence of cancer has been increasing rapidly-and a notable 
accelera tion  has taken place this century . In 1986 it was 
estimated that some 20% of all those presently alive would die 
from some form of cancer (Franks and Teich,1986).
This increase in the incidence of cancer m ight be 
explained by the fact that advances in medicine (in the Western 
world at least) coupled with improvement in public health has 
m eant the people are living longer today. These breakthroughs 
have virtually  eradicated the threat to health from infectious 
diseases which at one time were the major killers. The main 
benefic iaries have proven to be the m ost vulnerable  in our 
society: the young and the old.
The increase in life span has caused a change in the age 
structure of the population that has been observed. This means
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that cancer: which is mainly a disease of the elderly, is accounting 
for proportionally more deaths.
Other contibutary factors to the increase in cancer
deaths is the fact that the general public are more aware of the
dangers and the warning signs of cancer. This, coupled with 
num erous screening program m es means that in m odern times 
more people are making themselves available to diagnosis, so 
more cases are being reported. As advances are made in the 
laboratory better diagnostic tools come into use, and consequently, 
cancers are being diagnosed at a controllable stage. Allied to this 
is the fact that improved therapeutic regimes mean that at least 
for some cancers, there is now a better chance of survival once a 
tumour has been diagnosed.
It should be noted that these increases in cancer
incidence are occuring in spite of the vast number of medical 
advances that have been made. It seems that science has made
little impact on the diseases of the aged-possibly because little of 
their underlying molecular nauture is known. The exam ple of 
breast cancer is particularly illustrative of this point.
Although diseases of the heart and vascular system will 
kill more people than will cancers (Franks and Teich,1986), cancer 
is much more feared. Many will develop cancer of some
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form at some stage in their lives but a great many more people 
will live in fear of the disease.
2.2 Causes of Cancer.
Apart from the possib le  excep tion  of c igarette  
smoking, the causes of human cancer remain largely obscure. The 
link between age and deaths from cancer suggests that prolonged 
e x p o su re  to c e r ta in  agen ts  (e n d o g e n o u s  and in the 
environment)are involved in the induction and/or progression of 
tumour growth. The lapse in time from exposure to presentation 
with clinical symptoms and the fact that the aged population is 
the one which most commonly developes this condition implies 
that a considerable period of time (i.e. either long exposure to a 
single agent or a number of separate insults)is required for 
carcinogenesis to be induced and/or proceed.
Among the endogenous causes of cancer can be 
counted various genetic p red isposing  sta tes, for exam ple  
mutations at the rb. and p 5 3 loci (reviewed in Glover and Harris, 
1989, Finlay et.al.,1989 and Vogelstein and Kinzer, 1992), and also 
conditions such as Xeroderma Pigmentosa (Darnell et.al., 1986).
The group of exogenous causative factors is very large 
indeed ranging from physical agents, for example, X-ray, ionising
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radiation and UV light to organic chemicals such as aromatic 
amines, creosote, mineral oils, soot, tobacco smoke, tar-pitch, 
po lycyclic  hydrocarbons, azo dyes, oestrogens and alkylating 
agents. In this grouping are also inorganic chemicals: asbestos, 
arsenic, chromium and benzene.
Viruses for example, Epste in-B arr virus, PAPOVA 
viruses and HTLV virus have for many years been associated with 
tumours. This area is outwith the field of this thesis but is 
reviewed in (Varmus, 1983).
Dietary factors, in particular a diet rich in animal fats, 
low amounts in fibre and high in animal protein is thought to 
contribute to the genesis of certain cancers-in particular, colon 
cancer. Alcohol and general over nutrition as well as the presence 
of a variety of preservatives and additives in food may also be 
involved in this process.
Finally, some miscellaneous factors and agents, such as 
repeated mechanical injury or abrasion, sexual promiscuity (see 
viruses above), the presence of particular parasites: S c h is to s o m a  
h e m a t o b i u m  and Chlonorchis sinensis (Franks and Teich, 1986) 
and the use of immuno-suppressive drugs are also associated with 
tumours and/or the process of tumour development.
2.3.Epidemiology of Cancer.
Epidemiology is the study of patterns of a disease (not 
necessarily cancer) in a population, with the ultimate aim being to 
eradicate/am eliorate  the effects of the etio logical agent(s) thus 
identified and so eradicate or control the disease. Epidemiology is 
s ta tis t ica l,  with the conclusions draw n being expressed  as 
p ro b ab il i t ie s .
Descriptive epidemiology identifies susceptible groups, 
for instance in terms of age, location or racial background. Such 
studies into breast cancer incidence have shown that diet has a 
large role to play in the development of this disease. Japan has a 
low rate of breast cancer, but immigrants from Japan to the U.S.A. 
where incidence is high, have, within one or two generations a 
breast cancer incidence rate which is the same as the host nation 
(Franks and Teich, 1986). This is because of the adoption by the 
immigrants of the local culture and lifestyle.
Such studies-which have often been repeated, show 
that the environment does exercise a considerable influence over 
the deveploment and evolution of cancers in humans. The level of 
c iv i l iz a t io n /d ev e lo p m en t of the soc iety  is o ften  pos itive ly  
correlated with tumour incidence, as revealed by the link between 
refined foods and fatty diet with cancer of the colon, and 
c ig a re t te
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smoking with the incidence of cancers of the lung.
Host factors are im portant too. One of the most 
significant of these factors is the role of the immune system in 
carcinogenesis (This topic is outwith the scope of this thesis but is 
reviewed in Rygaard and Povlsen, 1976, Young and Elliott, 1989 
and Johnson et.al., 1989(a)).
The one common factor for that all the agents listed 
above and identified by epidemiological studies is that they all, 
either directy or indirectly, damage DNA or affect gene expression. 
Thus, while many cellular changes have been dem onstrated to 
occur as a normal cell becomes cancerous, it would seem that at 
the most elementary level, cancer is a genetic disease (discussed 
in section(2.8)).
2.4. Models of Carcinogenesis.
A .H ippocrates.
In the fourth century B.C. H ippocrates named the 
spreading, deadly tumour that he often saw Carcinoma, and 
chronic ulcerations-including benign tumours Carcinos (De Moulin,
1989). Carcinomas were thought to depend on an excess of black 
bile. Even at this stage, the lack of an effective treatment for 
carcinomas especially those that were well advanced or
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metastasised was evident since Hippocrates and his followers did 
not even attempt to treat such cases. He noted people often
survived longer without intervention, and given the lack of sterile
surgery or anaesthetic, this course of action . was probably very 
wise (see also section (6.9) for specific details on breast cancer).
Such an approach still has value today.
B-Galen.
Practicing in the century following Hippocrates, Galen 
catergorised tumours in a very insightful way, defining "tumours 
according to nature" (such a the natural growth of the body); 
"tumours exceeding nature" (such as the healing of broken bones) 
and "tumours contrary to nature" (for exam ple neoplasia) (De 
Moulin, 1989). Galen had therefore distinguished between normal 
hyperproliferative states and diseases where proliferative control 
had been lost. Galen also described the similarity between the 
lesions caused by a tumour and the shape of the crab.
C.The Cellular Theories of the Nineteenth Century.
Early in the nineteenth century, Johannes Mueller 
showed a tumour was composed of a number of cells (Franks and 
Teich,1986). This led to research to identify the difference
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betw een  norm al and cancerous cells  w ith the underly ing
hypothesis that cancer was a disorder of cells.
Those working in the field were split into two main 
camps: those who though that normal cells were in some way 
converted to cancerous cells (such as Muller) and those who felt 
that cancer existed within the cancerous cell right from the 
creation of that cell and that this phenotype was only expressed 
later (such as Leannec). The later point of view was supported by 
the findings of Pasteur as illustrated by his Germ Theory.
Modern science has shown that elements of both
theories are accurate:the mutation theory (see section 6.9) being 
in line with (1) and the existence of anti-oncogenes and genomic 
imprinting (see Section 6.9)) supporting (2).
Parallel with these studies were experiments such as
those in tumour transplantation and cell culturing. These were
important not only in allowing certain features of carcinogenesis 
to be characterized but also as means of facilitating the in vitro 
analysis of the disease.
D. Twentieth Century Theories.
Building on the advances of previous years and using 
new techniques such as microscopy, theories as to how tumours 
were initiated and how they progress were proposed.
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Theodore Boveri in 1914 outlined his Somatic Mutaion 
Theory. This theory was based on two major observations: that
when studied under the m icroscope, cancer cells often have 
chrom osom al abnorm alities. Secondly, the genomic a ltera tions 
underlying carcinogenesis are heritable since cancer cells do not 
naturally revert to the normal state (Friedberg, 1986).
Viruses have also been implicated as causes of cancer. 
This subject was mentioned previously (see section 2.2.), but 
briefly, in chicks, cats and mice, certain leukemia viruses can
cause cancers to develop. Such viruses can be spread vertically as 
well as horizontally and it is likely that the immune system is 
intimately involved in virally induced carcinogenesis (that is to 
say a subversion of the immune system).
Cases of human childhood leukem ia often arise  in 
clusters. Originally viruses were suspected (reviewed in Galloway,
1990) but now it is thought that physical causes such as ionising 
radiation are more likely to be to blame. (See the following for a 
review  of this area concentrating on the recen t and current
controversies surrounding nuclear power stations: Gardner et.al., 
1990 (a) and (b) and Evans, 1990).
Some human tumours have been found to actually
contain parts of viral genomes, for example in lymphatic cancers
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and Hodgkin's Disease; Epsein-Barr virus (reviewed in Young et.al., 
1989 and Dawson et.al., 1990) and human Papilloma viruses in 
cervical cancer (reviewed in Martin et.al., 1989; Durst et.al., 1983; 
Androphy et.al., 1985; Schwartz et.al., 1985; Gius and Laimins, 
1989 and Phelps et.al., 1988).
A final point to note is that study of certain viruses 
(in particular retroviruses) has provided much insight into the 
m olecular mechanisms of carcinogenesis. The most noteable of 
th e se  a c h ie v e m e n ts  is the  id e n t i f ic a t io n  and e v e n tu a l  
characterization of ONCOGENES (See section 2.8.).
The multi-step theory of carcinogenesis is a genetic 
based theory stating that cell proliferation control depends upon a 
num ber of separate genetic controls, all of which have to be 
inactivated for a cancer to develop (Commings,1973). The chance 
of all the requ ired  changes happening  increases  in d irec t 
proportion to age. Evidence for this is provided by the previously 
outlined details on the age distribution of cancer statistics. Risk of 
cancer inceases as the nth power of age (Cairns, 1986). Plotting of 
the logarithm of incidence against the logarithm of age generates a 
slope which reveals the number of mutation events needed to 
create a cancer. For most cancers, five mutations are required 
(Cairns, 1986).
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Three phases must be gone through in order for a 
tumour to be clinically identifiable. Firstly there is I n i t i a t i o n .  
Initiation involves a change in the proliferative ability of the cell 
perhaps due to certain agents interacting with the DNA. Normal
control of cell proliferation is lost and this imparts upon the cell
an evolutionary advantage since it is more able to divide and so
replicate itself. In this way, the altered cell can overgrow the
neighbouring cells.
Cell proliferation is vital to initiation and it is thought 
that it may act to fix the geneomic change into the DNA in a way 
which may be related to the DNA repair mechanisms (Cailleau 
e t .a l . ,  1974). E xam ples of in i t ia t in g  agen ts  are  ch em ica l  
carcinogens, viruses, ionising radiation , UV light and DNA 
replication errors.
Promot i on  is the phase which follows initiation after a 
latent period which is usually of significant duration. This step 
sees the expansion of this one progenitor cell to a population of 
cells i.e. clonal expansion (Klein and Klein, 1986).
In addition, it is thought that the promoting agent in 
some way(s) alters the microenvironmet of these altered cells so 
that clonal expansion is possible.
Promoting agents themselves do not cause cancer, they 
induce cells which are already in an initiated state to divide. To 
act then, such agents require cell growth and certain protein
fac to rs . P rom oting  agents p robab ly  in te rfe re  w ith  norm al
differen tia tion  processes, and examples are in flam m ation  and 
h o rm o n es .
Finally there is P r o g r e s s i o n .  This is the advancing of
the mass of cells to more and more malignant states in a step-wise
process (Klein and Klien, 1986 and Foulds,1954). Again, the exact 
nature of the steps involved here is not known but it is likely that 
a num ber of separate genetic alterations are responsible; for 
exam ple , m uta tions  of oncogenes (see  sec tion  2 .8 .)  and
anti-oncogenes (see section 2.8.). There is also the role of a 
num ber of largely unidentified modulating agents which affect 
tumour spread such as expression of MHC antigens (Klein and 
Klein, 1986 and Dalianis et.al.,1979).
2.5.Tumour Development.
Once a cell has been initiated, a series of changes
occurs, the rate of which depends on changes in the cell and 
changes in the host. That is to say that there is a degree of
d e -d i f f e r e n t ia t io n  (or a n a p la s ia  ) in v o lv e d  and n o rm a l 
c h a ra c te r i s t ic s  are  lost (F ranks and T e ic h ,1 9 8 6 ) .  Such
de-differentiation can be graded by a pathologist and there is a
correlation between the grade of the tum our and the rate of 
tumour growth.
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For example, a grade I tumour is the most slowly 
growing and most d ifferentiated  type of tumour. Grade IV 
tumours are very anaplastic and grow very rapidly. Grading often 
correlates with survival statistics too with better differentiaed 
tumours having a better prognosis (see section 6.8.).
T um our g rad in g  d e sc r ib e s  the  d e g re e  of 
differentiation of a tumour cell as measured cytologically and 
histologically. Tumour staging, on the other hand, is concerned 
with the amount of metastatic spread. Tumour grade and stage 
are not directly related and the growth rate of the tumour is not 
directly related to it's metastatic potential.
Tumours are not homogeneous masses even though 
they arise from a single progenitor cell (or a small number of cells 
in the case of polyclonal tumours). This is because clinically 
detectable  tumours have usually been in ex is tence  for long 
periods of time. They have therefore undergone many rounds of 
cell division so that variation and selection will have occured 
resulting in different cellular populations being created.
The average tumour will therefore consist of a mixed 
population of cells differing in structure, function, growth potential, 
resistancies and ability to invade and metastasise.
2.6.Cancer Cell Biology.
2.6.1.General Details.
Cancerous cells can often be distinguished from normal 
cells by a number of cellular characteristics. Malignant cells are 
usually less well differentiated than their normal counterparts, as 
identified by alterations in cell surface antigens and the loss to 
varying degrees of cell specific functions.
M icroscopically , cancerous cells have the following 
charac teris tics : a high nuc leus-to -cy top lasm  ratio; many and
enlarged nucleoli; a large number of mitoses and a reduction in 
specialisations of intracellular structure (Darnell et.al., 1986). It 
should also be noted that these are in addition, characteristics of 
any rapidly growing cell. Some other characteristics are increased 
saturation density, loss of anchorage dependent growth, loss of 
Contact Inhibiton of Locom otion, altered cellu lar morphology, 
enhanced aggregation by lectins, reduction or total loss of surface 
fibronectin and the loss of microfilaments.
Some very important changes take place at the plasma 
membrane. For example, in normal cells, cell adhesion and a 
slowing down of amoeboid motions are usually observed upon 
co n tac t  w ith som e outside  surface: co n tac t  in h ib it io n  of
locomotion. Soon after this, actin filaments appear from under the 
ruffled edges and these areas loose their m orphological identity 
a n d
19
become indistinguishable from less active regions of the plasma 
membrane. In a cancer cell though, normal cellular affinities are 
lost and the cells cannot form tight adhesive junctions so can 
associate with virtually any other cell type. As a result, contact 
inhibition of locomotion is lost, and it is thought that this underlies 
the phenomenon of invasiveness.
2.6.2. Metastasis.
The ability to metastasise is the single most important 
feature of a maligant tumour because once a tumour has spread 
from it's original site and set up secondary tumours at distant 
locations, the chances of combating the cancer are very greatly 
reduced or even eliminated. If a tumour remained fixed in one 
site as a benign tumour does then it is likely that surgical 
intervention would be more successful.
Cancer may therefore be thought of as a condition 
characterized by the loss of positional determinants which, in 
turn, has it s basis at the genetic level. Thus, although various 
alterations of DNA are at they very centre of the problem, cancer 
can also be legitim ately regarded and studied as a cellu lar 
biological problem. Many therapeutic, diagnostic and prognostic 
approaches such as those using monoclonal antibodies (See Drebin 
et.al.,, 1985; Masui et.al., 1984 and Hudziak et.al., 1989 (a) and
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(b))and cytoskeletal disrupting agents (Darnell et.al., 1986) are
underpinned by cell biology.
A num ber of separate stages can be identified  in
m etas ta s is :
1-Separation of a tumour cell from the primary tumour mass.
2-Invasion of the subcellular matrix.
3 -Penetration of the basement membrane of a blood vessel.
4-Surv ival by the cell of the journey  through the vascular
system:the fighting off of various agents of the immune sysytem.
5 -Identification of a suitable secondary site and escape from the 
blood vessel.
6-Lodging at the new site and survival there.
7-Invasion of the substratum of the new site.
8-Inducion of angiogenesis (see below).
Cancer/normal cell hybrids were found to have normal 
phenotypes. This implies that the normal cell has certain factors 
which prevent the development of the cancerous state, i.e. growth 
was again brought under control (Thompson et.al., 1992). The 
most likely explanation is that metastasis in part at least depends 
upon the inac tiva tion  or the loss of inh ib ito ry  genes or 
’’anti-oncogenes”. This will be discussed in section 2.8.).
A gene: n m 2 3  has recenty been identified which is 
thought to have anti-metastatic properties (Hennnessy
et.al., 1991). The gene is associated with good prognosis in breast 
cancer (Hennessy et.al., 199l)and reduced levels at the mRNA and 
protein levels are associated with enhanced m etastatic potential 
(Bevilacqua et.a l.,1989).
Metastasis is not a random process, since patterns of 
spread are noted. For exam ple , neu rob las tom as usually  
m etastasise to the liver, osteosarcomas often spread to the lung 
and bresat cancers to the bones (Franks and Teich,1986).
This important observation has clinical significance yet 
it’s biological basis is very mysterious. The following theories have 
been proposed. Selectivity may be due to blood flow in the 
secondary organ because the most commonly affected sites are 
those with good blood supplies. Alternatively, it may be that the 
original and secondary sites are similar in certain ways such as in 
terms of growth factor, hormone or immunological status.
2 .6 .3 .Tumour Invasion.
The problem of how a tumour cell can either break 
into or out of a blood vessel and lodge in a secondary site is a 
crucial one. There are three likely ways for this to happen:firstly 
it could be the result of mechanical pressure due to the fact that 
the increased pro liferation  rate causing the tum our mass to 
ra p id ly
enlarge. Release of various lytic enzymes may also be responsible 
and is suported by the observation that the normal cells which 
surround a tumour are often badly dam aged
Tumours also have high levels of polymorphonuclear 
n e u tro p h ils  and m onocy tes  w hich  have  m any deg rad a tiv e  
enzymes. The fact that tumour cells have increased motilty might 
also mean that they are more able to cross these barriers. Finally, 
a combination of all these hypotheses could be reposonsible for 
invasion by tumour cells, with a different modes being adopted in 
different tissues.
2.6.4. Angiogenesis.
To grow, a tumour cell must be supplied with an 
adequate vascular system to bring to it nutrients and remove 
from it various wastes and toxins. A tumour at the in situ stage, 
approximately one millimeter in diameter (see Franks and Teich, 
1986) has no such blood supply and so it cannot expand in size 
and m etastasise.
Growth therefore depends on tumour vascularisation 
or angiogenesis, and this is thought to be due to the release of 
Tumour Agiogenesis Factor (TAF) from tumour cells. TAF causes 
blood vessels to penetrate the tumour and allow it to grow rapidly 
with spread as an ultimate consequence.
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Normal cells usually only express angiogenic molecules 
such as PD GF and TGF-alpha during em bryogenesis , growth, 
developm ent and wound repair (see Heldin et.al., 1985). This 
implies that angiogenesis is necessary for tumour growth, but it is 
not sufficient for this process to take place.
2.7.Cancer Genetics.
A .In trodu c tion .
A lthough the env ironm ent exerts  a considerab le  
influence over the induction and progression of cancer, there is 
much evidence to support the point of view that cancer has a 
genetic basis:
1-Cancers are clonal in origin.
2-Genetic markers can be used to identify the clonal origin of 
cancers at the cellular level.
3-Cancers often have genomic alterations, and particular cancers 
oftefi have specific chromosomal alterations.
4-Many carcinogens are also mutaens.
5-D efects in the ability to repair DNA increase  the somatic 
mutation rate and the rate of cancer incidence too. ’
B.Classical Genetical Analysis of Cancer.
Scrutinization of family data has show that in some
cases, inherited predisposition to cancer depends on a single
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recessive or dominant Mendelian assorting factor. An example is 
that of Xeroderma Pigmentosa (XP). This is a recessive condition 
which is due to an inherited defect in the DNA repair system .
Such cases however, constitute only a small proportion 
of cancer cases. The fact that Ataxia Telangiectasia heterozygotes 
may have an increased susceptibility to develop a number of 
cancers may mean that such conditions have practical significance 
(Swift e t.a l.,1980).
Cases involving only one gene are probably in the
m inority . It is m ore likely that cancer is a m utifac to ria l 
condition-that is to say that it depends on a number of individual 
genes.
M ultifactorial conditions are by their nature very 
difficult to analyse. The usual approach has been to study families 
in which the condition of interest commonly occurs.
This type of investigation is complicated by the fact 
that families also tend to share a common environment, as well as 
a genetic inheritance-that means they will have been exposed to
the same range of environmental factors, viruses and other forms
of carcinogens. The contribution of exogenous and endogenous
factors therefore becomes hard to separate out from each other.
For these reasons, the incidence of cancers in twins is 
often studied-with monozygotic twins being the most informative
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since they are genetically  concordant. This genetic identity  
underlies the studies. The principle is that twins are usually 
exposed to a common environment, and so any differences in the 
incidence of disease is likely to be due to differences at the DNA 
level. Analysis of their DNA may lead to the identification of the 
actual areas of the genome which are the root cause of the 
cond ition -and  m aybe even the genes responsib le  for the 
p h e n o ty p e .
Family studies are important too and have yielded 
significant information such as in the cases of colon carcinoma 
(Bussey e t .a l. ,1978). The question of the general significance of 
these studies remains.
The usefulness of such studies is limited because all 
genes work in a background of other genes: this is the concept of 
Penetrance. This means that although a gene may have been 
identified in the laboratory as being involved in this process of 
carcinogenesis, whether it actually does so in vivo is unanswered. 
This matter is further complicated by the fact that in addition, 
d if fe re n t  genes have d if fe ren t  leve ls  o f p e n e tran ce  and 
expressivity which will also affect how much they contribute to 
the phenotype.
C.Germ Line Mutations.
The importance of germ line mutations is that if it is 
held that carcinogenesis depends upon a num ber of mutational 
events, then if one of these required events has been inherited, all 
of the somatic cells will have this alteration too, i.e these cells 
aleady carry one of the genetic changes which is required for 
tumourigenesis (Knudson,1971). The individual who has inherited
such an alteration will therefore be at increased risk of developing
a tumour.
The Knudson theory is based on a model where two
mutational steps are required to produce a tumour (Knudson,
1971, 1985 and 1986). This hypothesis is controversial since often 
more that one genomic change is needed to induce tumour growth. 
The idea of pre-existing alterations inherited via the germ line 
which causes a dominant inherited susceptibility to cancer does 
now have much supporting evidence and effectively explains the 
clustering of certain cancers in families and the inherited tissue 
susceptib ility  to cancer a seen in Retinoblastom a (for further 
details see Dryja et.al., 1989; Zhu et.al., 1989; Sapienza, 1991 and 
W einberg, 1990).
Genomic alterations are obviously im portant in 
cancer development but these are not the only significant
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altera tions in this process. Changes in the pattern of gene 
expression are crucial too, but this need not depend on the 
physical alteration of DNA. Such epigenetic changes are also stably 
inherited at the cellular level and are difficult to separate from 
the effects due solely to mutation.
Data derived from studies on Retinoblastoma show the 
exact nature of the tumour and the tim ing of its occurence 
depends on whether one or both parent carry the appropriate 
gene (see the reviews cited above). The interpretation of such 
observations is that both genetic and epigenetic  factors are 
invo lved  in the fo rm ation  of re tin ob las to m a. The genetic  
predisposition to cancer development is reviewed in Hansen and 
Cavenee, 1987 and 1988.
D.Chromosomes and Cancer.
Improvem ents in m icroscopy showed that most 
tu m o u rs  have  s t ru c tu ra l  a n d /o r  n u m e r ic a l  c h ro m o so m a l  
alterations. Some of these changes are consistently associated with 
pa rt icu la r  types of tumours. The locations of chrom osom al 
rea rran g em en ts  often  iden tif ie s  genes w hich  are c r i t ic a lly  
involved in carcinogenesis.
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The first specific chromosomal abnormality observed in 
a human tumour was seen in Philadelphia in 1960 by Nowell and 
Hungerford (Nowell and Hungerford, 1960). They found that in 
the leukem ic  cells  of pa tien ts  w ith C hronic  M yelogenous 
Leukaemia (CML)there was an abnormally small chromosome: the 
Philadelphia chromosome (Ph').
In the early 1970s chrom osom e banding techniques 
were coming into use. This, along with short term culturing 
methods to improve the yields of divding cells, allowed a more 
p re c is e  d e f in i t io n  of the  re a r r a n g e m e n ts  in v o lv e d  in 
carcinogenesis and the identification of new ones.
There  are a large num ber of d iffe ren t  genom ic 
alterations associated with cancers, a summary of the ones which 
have been extensively studied is listed below.
Table One: Chromosomal Alterations and Cancer.
Type o f Alteration 
D N A  Structre
Details 
Changes in tautomeric 
form of bases are common in 
response to mutagens;
increased DNA supercoiling may 
facilitate integrative recombination.
References 
Tse-Dihn et.al., 
1984 and 
Wood and 
Lindahl, 1990.
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DNA Repair
DNA Replication
C hrom osom e
Structure.
G enom ic
Translocations
Is faulty in Xeroderma Pigmentosa 
and as a result UV induced DNA  
damage is not repaired.
Chromosomal non-disjunction 
is thought to underlie many of 
the genomic alterations seen 
in tumours. It has serious 
implications for the cell cycle 
and for proto-oncogene
expression. Genomic destablisation 
is also associated with secondary 
changes which may allow  
tumour progression.
Reduction in the size o f Telomeres 
has been found to be involved in 
tumour development and also ageing. 
Telomere lengths reflect the mitotic 
history of cells because 4 base 
pairs are believed to be lost from 
the telomere per division cycle.
Can affect the biochemical functions 
and expression of genes. The most 
studied example is that of c-m vc  
and it's role in Burkitt's lymphoma. 
Fusion of c-ah l and her is common 
in cases of Chronic Myelogenous 
Leukaemia which have a Philadelphia 
chromosome.
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Holliday, 1989; 
Fantes et.al., 
1975; Klien , 
1981 and Klein 
and Klein, 1986.
Jankovik et.al. 
1991.
Croce and 
N ow ell, 1986.
Amplifications
G en etic
Transposition
I n se r t io n a l
Mutagenesis
Common in cancers, especially the 
amplification o f oncogenes. Oncogene 
amplification may contribute to 
oncogenicity. Somatic amplificaton of 
genes is an adaptive response to 
environmnental stress which is often 
manifest as Heavily Staining Regions 
and Double Minute Chromosomes.
Recombination allowing the
movement of modules o f genetic 
information within and between 
genomes. This has been observed in 
Burkitt Lymphoma cells, as an 
effect secondary to EBV infection. It 
is unlikely such a mechanism is 
regularly and commonly in use in 
human carcinogenesis.
Closely related to transposition, such 
a mcchamism has been shown to be 
in action in human cancers. LINE-1 
sequences insert into c - m v c  in a 
human breast carcimona; canine 
transmissible venereal tumour 
and a rat immunocyloma.
Intcrcistcrnal-A particle genomes 
have been detected in c - m o s  gene 
causing the activaton of c - m o s .
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Dalla-Favera 
et.al., 1982.
Klcin,1981; 
Newmark, 1982;and 
Sager, 1979.
Morse et.al. 
1988; Cohen 
et.al., 1983 and 
Rechavi et.al., 
1988.
Gene Losses Recessive genetic damage is 
significant because it releases 
negative regulatory controls. This 
can result in the activation of 
oncogenes. The inhibitory effects 
of the recessive genes or 
anti-oncogenes is lost too.
Recessive mutations may also 
explain the hereditary nature o f  
some cancers where no oncogenes 
are implicated, such as retinoblastoma 
and Wilms Tumour.
Cooper, 1990;
Green, 1989;
Ponder, 1988; 
Knudson, 1971; 
Weinberg, 1990;
Chen et.al., 1989; 
DeCaprio et.al.,1989;
Van Heyningen et.al., 
1985 and 
Porteous et.al.,
1987.
E.Oncogenes.
An oncogene is a generic term which describes a 
gene which is capable of causing cancer/becoming a dominant 
transform ing gene.
Abnormal or altered expression of such a gene directly 
causes the generation of the malignant phenotype. An oncogene 
i.e. a cellular oncogene is derived from a normal cellular gene 
called a proto-oncogene. There are also viral or v-oncogenes which 
are carried into the cell by an acutely transforming retrovirus and 
are transduced cellular oncogenes. It should be noted that the 
cellular origin of the oncogenes of DNA tumour viruses is as yet 
unknown.
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The area of oncogenetics is somewhat outwith the scope 
of this thesis but it is reviewed in the following: Varmus,1984; 
Slamon et.al.,1987; B ishop ,1991 (a) and (b); Cooper, 1990; 
G arrett,1986; Nishimura and Sekiya,1987 and Verma, 1986.
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Chapter Three:
BREAST CANCER.
3.1. Introduction.
Hippocrates first wrote about the treatment of breast 
cancer in the fourth century B.C. Breast cancer however, remains a 
major killer of females-in fact the world wide age related data on 
the incidence of the disease shows that it is on the increase. In 
spite of the fact that this form of cancer has been studied over 
many centuries and that considerable sums of money and effort
have been expended trying to elucidate it's molecular nature, the
causes of breast cancer remain largely unknown. Moreover, there 
has been no substantial improvement in therapy and there is still 
no uniform approach to the treatment of the disease.
Some statistics reveal the extent of the problem: in the
U.K., there will be some 26,000 diagnoses of breast cancer and
approximately 16, 000 deaths per year from the disease. It is the 
commmonest cancer in females in the U.K. as a whole, with about 
nineteen percent of all new cases of cancer in females being 
cancers of the breast. In the U.S.A. and Europe it is the commonest 
cause of death of women in the 35-55 age group. A European or 
American female has a one in twelve chance of contracting the 
disease (Franks and Teich,1986 and Baum, 1982).
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3.2.Structure of the Breast.
The human breast develops in the sixth week of foetal 
life. Mammary ducts develop by growing down through the skin’s 
layers (Baum, 1982). The mature breast is composed of varying 
proportions of secreting glandular tissue and adipose tissue.
The glandular tissue is divided into fifteen to twenty 
lobes (Townsend, 1980). Each lobe contains hundreds of lobules 
which are connected by ductules which join together close to the 
nipple to produce the major lactiferous ducts which dilate into the
lactiferous sinuses (Baum, 1982). They narrow again as they pass
through the nipple to form the seven or so duct openings.
Breast tissue is enveloped in two layers of fibrous 
tissue: the deep layer overlying the m uscles and the thin
superficial layer beneath the skin (Townsend, 1980). Both of 
these layers of tissue are joined by thin fibrous ligaments called 
C ooper’s L igam ents (Baum, 1982) which support the breast 
against the chest. Commonly tumours infiltrate and cause these 
ligaments to shrink so causing the overlying skin to pucker. This is
clinically observed as peax d’orange.
The functional b reast is a secondary  sexual 
characteristic of the female. It functions principally as an
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endocrine  target organ and m ediates lac ta tion . Lactation is 
brought about by complex interactions of a number of hormones 
in the cells of the gland.
To do this the breast tissue is exquisitely sensitive to 
changes in it’s hormonal environment, in a long term and a short 
term manner throughout the life of the individual female. Such 
changes can also be prompted by specialised conditions such as 
pregnancy, lactation and the consumption of exogenous hormones.
The breast can therefore be thought of as a collection of 
interacting cells which have a diversity and specialization of 
p h e n o ty p e s .
3.3. Types of Hyperproliferative Breast Disease.
C o n d it io n s  of b rea s t  h y p e rp ro l i f e ra t io n  can  be 
catergorised in the following way:
BENIGN BREAST DISEASES.
Type o f Condition. Exam plc(s)of the Condition.
Inflammatory Disease Puerperal Abscess, Periductal
Mastitis,
Tuberculosis.
Trauma
Developmental
Nipple
Haematomas, Fat Necrosis. 
Supemumary Breast(s); Absent 
Breast;
Asymmetric Development. 
Paget's Disease.
MALIGNANT BREAST CONDITIONS.
O f Ductal Origin Pre-Invasive
Invasive
Intraductal Cancer. 
Invasive Ductal Cancer 
Scirrhous Cancer.
O f Lobular Origin Pre-Invasive
Invasive
O f Connective 
Tissue Origin
Lobular Carcinoma In 
Situ.
Lobular Invasive 
Carcinoma.
Sarcoma.
(From Baum, 1982).
Cancers spread through local invasion and d irect 
infiltration and metastasis. Spread occurs along the lymphatic 
channels and the blood stream. Both are connected so that a 
secondary tumour can become established anywhere in the body.
The most common site for secondaries to develop is in 
the regional lymph nodes from where the whole system becomes 
involved. Tumours in the inner quadrants of the breast can spread 
via the internal mammary chain of lymphatic tissue and into the
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chest cavity (Baum, 1982). There, heart and lung can become 
involved and this leads to complications of fluid in the chest 
cavity or around the heart.
The most important mode of spread though is 
through the blood stream. This is probably due to direct invasion 
of cancerous cells into the veins draining the breast. Not all cells 
escaping are viable but those that are can lodge in the bone, liver, 
lung or brain. Secondary tumours in these locations can result in 
death from bone marrow failure, liver failure or respira tory  
failure (Franks and Teich,1986).
It is known that a malignant breast tumour is a 
number of different populations of cells with varying metastatic 
abilities. As has been previously pointed out (see section 2.1.), 
histological examination of such a tumour reveals that there is 
great morphological variation among cells of the same tumour for 
example in terms of karyotype, antigenicity, biochemistry, growth 
behaviour and susceptibility to chemotherapeutic drugs, radiation 
and heat (Baum, 1982).
3.4. Staging of Breast Tumours.
There are a number of tumour staging systems such as 
the Columbia, M anchester, American T.N.M . and International 
T.N.M. systems. The T.N.M. systems describe:
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-Tumour size and attatchment to the underlying chest wall(T). 
-Presence or absence of palpable lymph nodes(N).
-Presence or absence of distant metastases(M).
Using such schemes clinicians can assess patients in 
terms of their likely survival and the optimal regime of therapy to 
be adopted. Those with the best outcomes will have small tumours 
which are not attatched to the underlying substratum, with no 
lymph node involvem ent and no apparent metastases. This is 
called a stage one tumour.
The corollary of this is that a person who is catergorised 
as having stage four breast cancer has the worst outcome with a 
tum our which is quite large (greater then or equal to five 
centimeters); fixed to the chest wall, enlarged lymph nodes with 
secondary tumours detectable and ulceration of the breast itself.
G rad in g  o f  tu m ou rs  c o n c e rn s  the  h is to lo g ic a l  
investigation of the tumour itself to determine the extent of cell 
de-differentiation. This is a very important factor in determining 
the course of theapy that the clinician will take.
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3 .5 .1 .  The M o le c u la r  B io lo g y  o f  B reast  
Cancer-Introduction.
Epidemiological studies suggest that genetic factors are 
important in the development of breast cancer. It has been shown 
that if a close family member has or has ever been affected by 
breast cancer then an individual female is at risk of developing 
the disease too. A second linked factor is whether or not the 
disease in the relative occurred pre- or post-menopausally and if 
it was bilateral or not.
Case histories show that breast cancer often behaves a 
simple autosomal Mendelain trait. Finally, breast cancer is known 
to occur in families in association with other malignancies such as 
Ataxia Telangiectasias (Gatti et.al., 1991 and Morrell et.al., 1990). 
It is thought that some five percent of breast cancer cases are 
associated with an autosomal dominant allele (Van de Vijver and 
Nusse,1991 (b)).
There may also be s ign if ican t genetica l based 
p re d is p o s i to n  to the d e v e lo p m e n t of b re a s t  c an c e r ,  as 
dem onstra ted  by patients with L i-F raum eni cancer syndrom e. 
These indviduals in addiditon to having an increased overall 
cancer risk, may heve germ-line mutatons in the p53 gene which
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pred isposes to the developm ent of b reast tum ours (M alkin 
et.al., 1990). A region of 17q21 has been implicated in the early
onset of some forms of breast cancer too Hall et.al., 1990). This
phenomenon will be discussed in section 3.6.2.-K..
Molecular biological techniques, especially the creation 
of transgenic mice models of breast cancer have helped the 
specific genetic a lterations involved in the process of breast 
tumour development to be revealed. The most common lesion so 
far uncovered areigene amplifications, gene deletions and mutated 
recessive oncogenes. Some rarer genetic lesions have also been
discovered i.e. point mutations and gene translocations.
A. Amplification of Oncogenes-General Features.
Amplification of oncogenes (and other coding genes too 
of course)m eans that gene copy number is increased and as a
^  result of this, the amount of the protein product is enhanced too
(Chin e t .a l . ,1991). A se lective  growth advan tage  m igh t be 
conferred upon the cell depending on the exact nature of the gene 
p ro d u c t .
It is generally true that the actual gene is amplified 
along with an amount of surrounding DNA of approxim ately 
100-1000K.B. This amplified DNA segment can often be visualised
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and are called H om ogeneously  Staining Regions (where the 
amplified DNA is chrom osomally loacted) or Double Minutes 
(where the amplified DNA is located extrachromosomally).
The amount of amplification of oncogenes varies 
between different studies and with certian c linoco-pathological 
perameters of the tumour. Considering only a few examples of 
amplification events:
Amplified Number of Cases Percentage
>>  Gene Studied Amplification
egf-r 21 14%
189 2%
Reference
Ro et.al., 
1989. 
Slamon
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c-m  vc 176
i n t - 2 /
...kc,L-l 46
et.al.,1987.
Lacroix
et.al.,1989
4% Tsuda 
et.al., 1985.
Zhou
et.al.,1988.
B .W nt/In t Gene Amplification.
This lesion is specifically associated with mouse 
mammary cancers-there is a poor association in the human
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system (Van de Vijver and Nusse,1991(b)). WNT-1 (Human wnt-1 
hom ologue)is not amplified translocated or even expressed in 
human breast cancers (Van De Vijver and Nusse,1991(b)).
C.Erb-B3 Amplification.
Erb B3 has been cloned via low stringency hybridisation 
from the human genome. It can be expressed at high levels in 
breast cancers-but whether it is amplified or rearranged is not at 
present known (Van de Vivjer and Nusse,1991(b)).
J
D .Neu/Erb B-2/HER-2 Amplifications.
Neu i s homologous to but separate from e g f - r  
(Schech ter e t .a l . ,1984 and 1985). The gene is am plified in 
approximately 9-30% of breast cancers and is also found to be 
am plified  in adenocarcinom as of the salivary gland (Slamon 
e t .a l . ,1987); stomach (Van de V ivjer e t .a l . ,1987) and ovary 
)  (Zeillinger e t.a l.,1989).
43
Neu Amplification correlates with increased levels of mRNA 
and protein and this is in turn associated with poor prognosis 
(Berger et.al.,1988) in most cases (King et.al.,1989(a) and (b)). This 
correlation is strongest in patients with lymph node metastasis 
(Ro e t.a l . ,1989). This implies that increased levels of Neu are
correlated with an increase in the growth rate but not metastatic 
potential (Van de Vivjer et.al., 1987).
In addition, in the case of non-invasive breast cancer
n e u  overexpression is seen in about 70 % of cases of large cell
comedo type ductal carcinomas in situ and 100% of cases of
Paget's disease of the nipple (Van de Vivjer and Nusse,1991(b)). 
Neu amplification is, however never seen in small cell, papillary, 
cribiform  ductal carcinomas in situ and benign breast cancer 
conditions (Van de Vivjer and Nusse,1991(b)).
In one study, however, n eu  was found to have little 
significant correlation with tumour stage (Lammie e t.a l.,1989). In 
another study as significant correlation between stage of the 
disease and H E R - 2 / n e u  am plification  was noted (Seshadri 
e t .a l . ,1989).
A monoclonal antibody which has been raised against 
the extracellular domain of Neu can inhibit the growth of SKBR-3 
cells which have an amplified egf-r (Drebin e t.a l.,1985 ). This
antibody does not affect breast cancer cells lines with a normal 
n e u  copy number, and so has been considered as a potential 
target for therapy in tumours which overexpress neu (Van de 
Vivjer and Nusse,1991(a)).
Donovan-Peluso's group have shown in addition that in 
metastatic breast cancer cells, amplification of m v c . neu and in t-2
is more marked than in non-metastatic cell (Donovan-Peluso et.al.,
1991).
For example
Non-Metastatic Metastatic
mvc 28% 43%
in t-2  21% 40%
neu 24% 43%
(N.B.: these values refer to percentage of samples in which
amplification of the gene in question could be detected).
The authors also found that gene copy num ber is 
associated with advanced disease, implying that these genetic 
alterations are in some way involved in the metastatic process.
E.Homogeneously Staining Regions.
One study suggests that these regions of chromosomes 
and also abnormally banded regions could be identified in 58% or 
so of the untreated primary breast tumours they analysed; most 
of these lesions localised to 8pl (Sain t-R uf e t .a l . ,1991). The 
authors conclude that such genetical alterations are formed in the 
8p region and are moved elsewhere in the genome due to
translocation event(s), so affecting tumour progression.
F.Chromosome 11 Amplifications.
Various studies have confirmed that amplifications
of genes which reside on this chromosome are often observed in 
b reast cancers. In the breast cancer cell line M DA-M B-134
(Cailleau et.al., 1974) the amplification of 2 genes here is described
but it seems that neither is expressed which suggested that they 
may not be the genes which are crucial for this process (Lafage 
e t .a l . ,1990).
G. Point Mutations.
Point mutations in the ras genes are rare in human 
breast cancers, but are common elsewhere such as in cancers of 
the colon, pancreas and lung (Van de Vivjers and Nusse,1991(a)).
H -T ranslocations.
A common karyiypic abnorm ality  in primary human 
breast tumours involves the long arm of chromosome 1 (Van de 
Vivjer and Nusse, 199l(b)).The actual role of this alteration is not 
known. Specific translocation events have not yet been reported.
Double minutes have been identified in approximately 
40% of breast carcinomas and metastatic breast cancer cells in 
pleural effusions (Gebhart et.al., 1984). There is, however, not any 
evidence  at presen t that these Double M inutes involve the 
amplication of any specific oncogenes. It should also be pointed 
out that there is a major problem in this type of investigation: 
having enough tumour material to be able to carry out the 
karyotypic analysis. This is the limiting factor in this area of 
re se a rc h .
I.Deletions and Allele Losses.
Deletion of recessive oncogenes is now considered to 
be an important feature in the development of breast tumours. 
Loss of heterozygosity can be observed by searching for it at 
linked polymorphic DNA markers, that is to say by comparing 
breast cancer DNA and normal DNA form the same patient using 
Restriction Fragment Length Polymorphisms (RFLP s).
The main ch rom osom es tha t  are affec ted  are 
chromosomes 1; 3, 11, 13 and 17.
Chromosome 13 Allele Loss.
A study has found that there was loss of heterozygosity 
in 4 of the 14 cases studied (Lundberg e t .a l . ,1983). Specific 
inactivation of rb in breast cancer tumours and cell lines has now 
been observed. In 2 of41 carcinomas (T'Ang et.al.,1988) and 15 of 
77 carcinomas (Lee et.al., 1981) had rb alterations. In summaryr  
 ^ rb  inactivation is thought to be involved in about 20% of primary
breast cancers (Van de Vivjer and Nusse,1991(b)).
Chromosome 17 Allele Loss.
Chromosome 17, at locus p l3 .3 . shows the highest 
known level of allele loss in human primary breast cancer. 65% of 
informative cases have loss of heterozygosity here (Van de Vivjer 
and Nusse, 1991(b)).
) The p53 gene lies in this region and it is a  tumour
suppressor gene. In 2 breast cancer cell lines, the retained p 5 3 
allele has no point mutations (Nigro et.al.,1989), which implies 
that the involvement of p53 and human breast cancer is far from 
being clearly understood.
Some breast tumours have a wild type p53 allele and a 
mutation acts in a dominant manner to inactivate the product of 
the wild type gene by forming a com plex with it (Nigro
e t .a l . ,1989).
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It should be noted however that some breast cancers 
have lost one p53 allele and have no mutations in the other one 
yet such changes are carc inog en ic  (V an de V iv jer  and 
N usse ,1991(b )) .
One group has found that 52% of the primary breast 
tumours they studied has loss of heterozygosity on the short arm 
of chromosome 17 (Smith et.al., 1983). Loss of heterozygosity here 
is assoc ia ted  with aggressive  tum our beh av iou r  and DNA 
aneupolidy and how p53 is involved in this process is not clear at 
p re s e n t .
The alteration has been found to corrrelate with a high 
BrdUrd labelling index and DNA aneulpoidy (Chen etal.,1991), 
both of which are features of aggresive tumours.
Work by Chen's group suggests that breast cancers arise 
as a result of a hot-spot modification of chromosome 17, close to 
but not necessarily  including p53 (Chen e t . a l . , 1989). They 
concluded that other genes in this vicinity could be involved and 
that there may also be an other m echanism  by which p 5 3 
becomes activated.
Mutated p53 polypeptide can also cooperate with ras. to 
transform primary rodent fibroblasts (Jenkins et.al., 1985). Such 
data suggest that the half-life of p53 protein in being increased, in 
line with the above proposal.
4a
D avidoff et.al. found that the p resence of alleleic 
deletion(s) was not always associated with over expression of the 
protein (Davidoff et.al.,1991). Over expression of p53 was always 
associated with a mutation in breast cancers though.
If it is considered that an altered version of p53 could 
be involved in cell transformation in vitro even in the presence of 
wild type p53 (Jenkins et.al., 1985) then it implies that allelic loss 
at p53 could conceivably be needed or at least involved in breast 
cancer.
The theory proposed by Davidoff's group is that loss of 
heterozygosity  involving p53 confers a growth advantage on the 
cell and this is selected for during subsequent tumour formation.
There is some evidence which seems to argue that p 5 3 
alterations alone are not sufficient to cause breast cancers to 
develop. Prim ary breast cancer needs perhaps more than one 
minimun deletion unit to be initiated (Coles et.a l.,1990 and Sato 
et.al., 1990). There are mutations in p53 which are concurrent 
with 17p alterations, but which dp not include the p53 locus (Coles 
et.al., 1990). So, it could be that such changes in the p53 genes are 
unrelated to p53 activation in breast cancer.
Chromosome 11 Allele Losses.
Losses in the l i p  area of chromosome 11 are noted in 
a p p ro x im a te ly  20%  of p r im ary  b rea s t  c an c e rs  (T h e i l le t  
e t.a l.,1986). This region often involves c -H a - ra s  alterations, but 
a lw ays involves the region  betw een the beta  g lob in  and 
parathyroid hormone gene loci (Ali e t.a l.,1987). Such changes are 
associated  with an oestrogen recep tor negative  status, large 
tumour size, grade three tumours and distant metastasis (Van de 
Vivjer and Nusse,1991(b)).
Chromosome 1 Allele Loss.
23% loss of homology has been dem onstra ted in 
primary breast tumours (Chen et.al., 1989).The actual loci involved 
are not known.
Chromosme 3 Allele Loss.
Some loss of heterozygosity is known here too(Van de 
Vivjer and Nusse, 1991(b)) and as for above, which loci lost are 
the critical ones is unclear.
J.Miscelleneous Genomic Alterations. 
n m 2 3 .
n m 2 3 is thought to be an an ti-m e tas ta tic  gene. 
Metastasis is a process which depends on the actions of a number
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of genes (Fidler and Radinsky, 1990). In this way nm23 w a s  
identified (H ennessey,1991).
The predicted amino acid structure of the gene product 
in humans is 78% homologous to aw d  of D r o s p h i l a . Mutation of 
this gene results in the generation of an abnorm al tissue 
m orphology, abnormal d ifferentiation and necrosis (Rosengard 
et.al., 1989 and Dearolf et.al., 1988). In addition the gene resembles 
a nucleoside  d iphosphate  kinase of D .d is c o id e u m  ( W a l l e t  
e t . a l . , 1990). The p ro te in  p roduct p h o sp h o ry la te s  guanosine  
diphosphates and is involved in development, growth control and 
oncogenic tranformation.
If nm 23 cDNA is transfected into murine tumours with 
high m etastatic  potential, the m etastatic  po ten tia l is reduced 
(Hennessy et.a l.,1991). There are 2 human n m 2 3  clones. One is 
lost with high frequency in breast cancers and hybridises to 
chromosome 7. One study has shown high levels of nm 23  mRNA 
are associated with an absence of lymph node involvement in 
breast cancer (Hennessy et.al., 1991). The implication is therefore 
that n m 2 3 reduced the ability of a tum our to m etastasise 
(Bevilacqua et.a l.,1989).
Epigenet ic Effects.
API proteins are factors which are vital for the 
transcription of certain genes (see Hames and Glover, 1988,
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Bohman et.al., 1987 and Bos et.al., 1988 for reviews). A study 
analysing a number of primary breast carcinomas showed that all 
had enhanced levels of API activity when compared to normal 
tissues (L inardopoulos et.al., 1990). It is thought that elevated 
leve ls  o f such transcrip tion  fac tors m ay be invo lved  in 
carcinogenesis for example by increasing the rates of expression 
of certain important genes.
Chapter Four:
THE MOLECULAR 
BIOLOGY OF EGF-R.
4.1.Purification of Epidermal Growth Factor Receptor.
A .The A431 Cell Line.
This cell line is central to the study of many aspects of 
EGF-R structure and function. It was derived from a human 
vulval epidermoid carcinoma (Fabricant et.al., 1977). In addition 
to it being readily available and present in large quantities. The 
significance of A431 EGF-R is two fold: firstly, these cells express 
extrem ely high numbers of EGF-R upon their surfaces. This 
facilitates purification of the receptor. Secondly, the A431 cells are 
thought to be a good model in which to study EGF responses in 
vitro (at least with respect to short term responses)for example, 
mitogenesis (Sawyer and Cohen, 1985). In the long term though, 
the way in which A431 cells respond to EGF may not accurately 
reflect the situation in "normal"cells since EGF causes a reduction 
in the rate of growth of these cells whereas EGF stimulates growth 
of "normal cells" (Gill and Lazar, 1981).
B.EGF-R Isolation From A431 Cells.
A ff in i ty  c h ro m a to g ra p h y ,u s in g  im m o b i l iz e d  EG F 
(C arpen ter  e t.a l. ,  1991), and m onoclonal an tibod ies  (Haley 
e t .a l . ,1987) was used initially to purify  the recep to r (Cohen 
et.a l.,1980). A near homogeneous preparation was attained.
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Treating the isolated EGF-R with cyapogen bromide and 
trypsin (Downward e t .a l . ,1984) created a num ber of peptides 
which were used to generate  o ligonucleo tide  probes (Haley 
et.al., 1987), to identify clones which encode EGF-R. The probes 
were subsequently used to screen a A431 and placental cDNA 
libraries cDNA and amino acid sequencing was then carried out 
(Downward e t.a l. ,1984).
There are two very important findings with far reaching 
") consequences to come out of this work, firstly EGF dependent
tyrosine kinase activity and ligand binding ability were found to 
re s id e  in the sam e m o lecu le  (U ll r ic h  e t .a l . ,  1984 and 
C arpen ter , 1985). At the time of this d iscovery , such an 
in te rp re ta tion  was novel and regarded with some cynicism. 
Secondly, by comparing amino acid and DNA sequences, certain 
areas of the EGF-R gene and protein were found to share a high 
-) level of sequence identity with the oncogenic protein of the Avian
E r y th r o b la s to s i s  v i ru s :  v - e r b - 13 (T o dderud  and C arpen ter, 
1989).This was an early example of a growth factor receptor 
having been converted to an oncogene.
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C.Genetic Engineering of EGF-R.
Analysis of any protein or gene requires that it should 
be available in plentiful supply. Genetic engineering has allowed 
this problem to be tackled as in the example of the expression of a 
functional EGF-R in insect cells (Greenfield et.al.,1989). Farrow 
et.al. have also tackled this problem by chemically synthesising 
the DNA which encodes EGF-R, related peptides and individual 
domains of the receptor and cloning them into an appropriately 
designed plasmid, then expressing them in E .co li  cells (Farrow 
et.a l.,1989).
The products are fully functional and so can be used to 
assay  various EGF-R activ it ie s ,  as w ell as a llow ing  the 
determ ination of physical characteristics for instance by X-ray 
crystallography. This approach has also been taken for the human 
c-Ha-ras oncoprotein (De Vos et.al.,1988 and Tong et.al.,1989)
It should be pointed out that the DNA sequence can be 
manipulated so as to create different forms of the EGF-R protein 
which are of great value in studying what the protein's role in the 
cell may be (see Section 5). In addition, the conditions can also be 
controlled so that large amounts of the protein can be made by 
the host cells.
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4.2.The Structure of EGF-R.
4.2.1 .In troduction .
In the late 1970’s and early 1980’s purified EGF-R 
became available as described in the preceeding section. This led 
in 1984 to the derivation of the amino acid sequence of tryptic 
digests of this protein, and the eventual cDNA cloning of the 
receptor (Downward et.al., 1984 and Ullrich et.al., 1984). Such 
work, along with classical biochemical analyses of EGF-R like 
protease digestion of the polypeptide, has revealed that EGF-R is 
a tran sm em brane  g lycopro te in , w hich  has severa l d is tinc t 
domains or regions which can be defined both functionally and 
physica lly .
4.22.The Extracellular or Ligand Binding Domain.
This domain is encoded by the N-terminal 261 amino 
acid residues of the EGF-R molecule (Ullrich et.al., 1984). Although 
knowledge is at present relativley sparse, the importance of this 
domain cannot be under emphasised. The interaction of growth 
factor and growth factor receptor is central to the regulation of 
cellular proliferation. The ligand binding domain is therefore of 
primary importance in this critical event.
If the rules governing growth fac to r-g row th  factor
receptor interaction can be understood, then there may , be the
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potential for intervention in this process. This may have wide
im plications, for exam ple in the control and m anagem ent of 
diseases which involve either one of the proteins.
The EGF-R ligand binding domain, are very unusual in 
being able to bind 2 different ligands. EGF-R can bind TGF-Alpha 
and EGF, with high or low binding affinity. How this is brought 
about is not known, neither is the way that separate cellular
signals can be generated subsequently, and how they result in 
different physiological consequences. Some of the various theories 
that have been considered are:
1-Different tissue distribution of ligand and/or receptor.
2-Varying accessibiltiy of ligand and/or receptor.
3 -The binding of the ligand by the reoptor induces different 
conformational changes in the receptor.
4-The involvement of other proteins and/or cellular structures in 
ligand binding and/or later steps.
As previously stated, relatively little is known about the 
structure of the ligand binding domain of EGF-R and how it 
actually carries out EGF binding. It is though that the domain is 
composed of two motifs: L and S. They are repeated in the
order:L1 :S1 :L2:S2 (Hsuan et.al., 1989) and that they are situated
such that they form four domains: I-IV.
5 8
L-Mot i f s .
Secondary structure predictions suggest each L-domain 
has four or five repeating  m otifs which are com posed of 
alternating alpha-helix and beta pleated sheet structures. Each 
alpha-helix or beta sheet is separated by a very highly conserved 
glycine residue. Since glycine residues are characteristic  of 
reverse turns, it would seem that the two L-domains form a 
beta-barrel motif which is involved in ligand binding.
The L-domains are supported by the two S-domains, 
w ith  the p u ta t iv e  a lp h a -h e l ice s  c o n ta in in g  m ost o f the 
ex tracellu lar matrices twelve potential N -linked glycosylation 
sites in the form of:-Asn-X-Ser motifs or -Asn-X-Thr motifs.
S-Mot i fs .
These domains are approximately one hundred and sixty 
amino acids long and are very rich in cysteine residues, possibly 
in the form of disulphide bridges. Alignment of the amino acid 
sequences of the S-motifs shows that there are three internal 
repeats of three cysteine residues with approxim ately identical 
spacing  pa tte rn s .  This is also  seen in in su lin  recep to r , 
c - e r b - B 2 / N e u . Drosphila EGF-R Hom ologue, IGF I Receptor, 
NGF-Receptor and the LDL Receptor.
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Domains I, II, III and IV.
Lax and his group, on the basis of internal amio acid 
sequence homology, have divided the ligand binding domain of 
EGF-R into four domains: I, II, III and IV (Lax e t.a l. ,1988 and 
1989). They also assigned the following characters to each domain: 
Domain Character
I N-Terminal Domain
II and IV Cys-Rich Domain
III Homologous to I, Ranked by
Domains II and IV
In a series of experiments it was demonstrated that 
domain III is the main ligand binding determ inant (Lax et.al., 
1988 and 1989). The human EGF-R molecule was affinity labelled 
with 1251 EGF and a cyanogen bromide cleaved fraction which 
con ta ined  the c ross linked  EG F m olecu le  was subsequently  
identified (Lax et.al., 1988). The role of this ligand binding domain 
was then analysed using chimaeric hum an-chicken interspecies 
EGF-R's (see Riedel et.al., 1987). This approach is possible because 
the binding affinity of the human receptor is about three hundred 
times greater than that of the chicken receptor in the same 
ce llu la r
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background (Lax et.al., 1988).
The experim ent showed that the ch im aeric  EGF-R 
behaves like a human receptor for example, with respect to the 
EGF binding and biological resonsiveness, if and only if human 
domain III is present (Lax et.al., 1988). This same group also 
showed that two monoclonal antibodies which prevent EGF 
binding to it's receptor also bind to domain III (Lax et.al., 1988).
In their analysis of the ligand binding domain of EGF-R,
Avivi's group aimed to discover specific residues which may be 
involved in EGF binding by site directed m utagenesis (Avivi 
et,al.,1991). Although still in progress, the research has so far 
shown that human and chicken domain Ill 's  have about seventy 
five percent amino acid sequence identity i.e. only thirty five or so 
residues are resp ons ib le  for the generation of the high affinity 
ligand binding characteristic of human EGF-Rs. Human domain III 
can be divided into two halves: IIIA and IIIB. Each half
contributes equally to the binding energy. Finally, the binding site 
is composed of non-contiguous regions of domain III, exactly 
which residues are involved though, remains unknown.
The situation is not exactly as clear cut as such reports
may make it seem though, since domain I may also be involved in
defining ligand binding specificity  too (Lax et.a l.,1989). The 
current working hypothesis, therefore, is that domains I and III
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form a cleft with the two cys-rich regions in close contact with 
each other and also the plasma membrane. The cleft is the site at 
which the ligand binds (Wu et al., 1989).
EGF-R, therefore is equivalent to allosteric enzymes, 
where the binding of the ligand causes the interactions between 
neighbouring subunits to be changed so resulting in an allosteric 
conformational change (Wu et.al., 1989).
In addition to this, it has been found that truncated 
receptors with no ligand binding domain (i.e. which resemble 
v - e r b - B ) can dimerize at low concentrations of Triton X I 00 
(Kwatra et.al., 1992)which implies that this domain is not involved 
in this process.
4.2.3.The Transmembrane Domain
This domain is comprised of twenty three hydrophobic 
amino acids (622-644) (Hsuan et.al., 1989). They form a five 
looped alpha helix which spans the plasma membrane only once. 
The role of this domain in the generation and transmission of a 
signal over the plasma membrane is unclear, that is to say, how 
can the binding of EGF to the extracellular portion of the receptor 
result in the activation of the tyrosine kinase of the receptor 
located intracellularly?. Opinion is divided as to what the function 
of the transmembrane domain might be in this process. The two 
competing theories are:
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1. The Interm olecular Activation M odel. Here, ligand binding 
results in increased EGF-R association via the transmembrane 
domains i.e. dimerisation which causes cytoplasmic domains to be 
a c tiv a ted .
2-The Intram olecular Activation Model. In this case, binding of 
ligand causes the extracellular domains to become repositioned 
which, in turn, causes the transmembrane domain to be relocated. 
This causes a conform ational change in the catalytic  domain, 
w hich  causes  ty ro s in e  k in ase  a c t iv i ty  to be enhanced  
Controversy is great in this area of EGF-R research 
mainly because the evidence so far co llec ted  is somewhat 
am biguous and so cannot defin itely  confirm  or refute either 
model. The crucial question: does the transm em brane domain 
have a passive (in line with the intermolecular activation model) 
or an active (in line with the intramolecular activation model) role 
in EGF-R signal transduction has not therefore been answered 
satisfactorily . M odern recom binant DNA techniques have been 
applied to the problem  too, some of these experim ents are 
described below:
1-The transmenbrane domain is tolerant of a number of amino 
acid changes, for example, removal or insertion of DNA or 
changing the nature of the residues. Such changes do not mimick 
EGF actions or affect ligand induced signal transduction, i.e. a
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mutated transmembrane domain can still stimulate EGF-R tyrosine 
kinase activity and effect cellular responses when significantly 
altered (Kashles et,al., 1988)
2-Chimaeric EGF-R with the transmembrane domain swaps with 
the eq u iv a len t  dom ains of H E R 2 /neu /P D G F -R ecep to r /In su lin  
Receptor showed that the origin of the transmembrane domain 
has no effect upon the signal generation by the chimaeric EGF-R. 
(Lee et.al., 1989)
3-Point mutations mimicking those which constitutively activate 
c -e rb B 2 /n e u  do not activate the signalling mechanism of EGF-R. 
This suggests a passive role of this domain in this process and is 
therefore evidence for an intermolecular activation model.
The activa ting  m utation of c - e r b B 2 / n e u  is in the 
transm enbrane  dom ain :V 664G lu  (C arp en te r  e t .a l . ,  1991 and 
Bargm ann et.al., 1986 (a) and (b)). This suggests that this 
alteration results in constitutive activation of tyrosine kinase 
activity (Bargmann et.al., 1986 (a) and (b)). So, a structural change 
can have a profound effect of the activity of the receptor. Three 
transm em brane  dom ain a ltera tions were m ade by Carpenter's 
group to investigate  this further (C arpenter et.a l., 1991). The 
mutations either shorten this domain at the C- or N-terminus or 
introduce point mutations equivalent to those for c -e rb B 2 /n eu  o r
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proline substitutions into the receptor protein. None of the mutant 
receptors showed constitutive enzyme activation or altered ligand 
dependent signal transduction.
Recently, EGF-R mutants have been created whereby the 
basic amino acids at the cytoplasmic face of the receptor have 
been either deleted or deleted and replaced with neutral amino
acid residues (Yamane et.al., 1992). Removal of these residues in 
rodent f ib rob lasts  had the effect of greatly  inhib iting  EGF 
* dependent tyrosine phosphorylation of EGF-R. When EGF was
added  to these  ce lls ,  the m u tan t  re c e p to r  show ed no 
morphological alterations as did cells containing the wild type 
receptor (Yamane et.al., 1992). The implication is, therefore that 
the basic residue in this dom ain of the recep tor are very 
im portant in the transduction of signals by EGF-R, possibly 
through the topology of the receptor in the plasma membrane 
^  In cell lysates, altering the lipid composition of the
plasma membrane can modify ligand affinity and basal kinetic 
activity (Downward et.al., 1984), thus suggesting an active role for 
the transmembrane domain in signal transduction and confirming 
an intramolecular activation model for this process.
The question of EGF-R's tyrosine kinase activity and its
activation will be discussed in Chapter 5.
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4.2.4.The Juxtamembrane Domain.
This region, extending from residue 645 to 657 encodes
a very basic stop-transfer sequence which acts during EGF-R
synthesis following insertion of the N-terminal end of the receptor
into the lumen of the Endoplasm ic Reticulum , to anchor the
transm em brane domain in trace llu lary  (Schlessinger e t .a l . ,1978). 
As well as perform img this vital function, it seems that the 
juxtam em brane domain could also play a very important part in 
controlling EGF-R activity.
EGF-R activity can be regulated by a number of external 
stimuli in a process known as T ransm odulation (see Section 
5.10.).A major way in which stimuli might act to achieve this is 
the protein kinase C dependent phosphorylation of T654. This 
phenomenon is though to provide a negative control mechanism 
for EGF induced mitogenesis, and will be discussed later (see 
Section 5.8.).
4.2.5.The Cytoplasmic Domain.
This domain extends from residue 690 to 940 (Hsuan 
et.al.,1989) in the carboxyl end of the EGF-R molecule, and can be 
thought of as consisting of two main parts: a kinase region and a 
C-Terminal tail region.
The kinase region catalyzes the transfer of terminal
ph osphate residues onto tyrosine res idues in various target 
proteins. EGF-R is therefore a polypeptide with intrinsic tyrosine 
kinase activty-it was in fact among the first hormone receptor lo 
be shown to have such an ability . The cata ly tic  domain 
d e te rm in e s :
1-Presence at the plasma m embrane.(*)
2-Ligand binding characteristics^**).
3-Biologcal signalling(*).
4-Early and delayed responses(**).
5-M itogenesis(*).
6-Cellular tran s fo rm a tio n ^ )
7-The fate of internalised receptors(*)
[(*)=Prywes et.al., 1986; (**); Schlessinger et.al. , 1978 and Li et.al., 
1 9 9 1 ]
These diverse functions are absolutely dependent upon 
tyrosine kinase activity (see Chapter 5).
Certain motifs within this domain are highly conserved 
among the tyrosine kinase family, the prototype of which is the 
src  gene product. They are those motifs which are involved in
ATP binding and the phosphotransferase reaction:
GXGXXGX at 695-700 (Carpenter, 1987)
-k at 721 (Carpenter, 1987)
-DGF at 831 -833 (Carpenter, 1987)
-ALE at 858-860 (Carpenter, 1987)
The kinase domain can therefore be though of as consisting of a 
number of different regions, each with their own specific function 
in EGF-R kinase activity. For example, Isy 721.
Affinity labelling and modelling of the ATP binding sile 
of this domain (Russo et.al., 1985) showed that lys721 could form 
a salt bridge with an oxygen atom on the beta phosphate of ATP. 
In addition, the motif,-Gly-X-Gly-X-X-Gly- is twenty five residues
N to K721 at 695-700, and is known to be highly conserved in
nucleotide  binding proteins. The theory is that this m otif is 
involved in correct orientation of the ribose phosphate groups and 
the conserved G at 695 is involved in recognition of C2 and N1 
atoms on the adenine moiety of ATP.
The vital role of K721 in EGF-R's tyrosine kinase activity 
is dem onstrated by consideration of the oncogene of Fujiami 
Sarcom a Virus: v - f p s  (W einm aster et al.,1986) and the site 
directed mutagenesis of K950. The later results in a protein that 
although is m etabolically  stable, has no kinase activity. This 
suggests that it was involved in the hydrolysis of ATP and the 
phosphoryl transfer reactions (Snyder et.al., 1985).
ATP binding might also involve the -Asp-Phe-Gly- motif 
at 831-833, with Asp forming an hydrogen bond with the N-group
at position 6 of adenine and Phe side chain and adenosine's ring
interacting via hydrophobic bonds.
The Hinge Region.
The hinge region has been postulated due to studies 
which showed that the EGF-R tyrosine kinase domain is sensitive 
to proteolysis by proteases such as trypsin, chymotrypsin, elastase 
and Caclium activated neural proteases (Calpain). These agents 
result in the production of two fragmnents:
i - 2 0 K .D .-  c o n ta in s  the  C - te r m in u s  p lu s  the  th re e  
au tophosphorylation  sites.
ii-150 K .D .-Contains the extracellu lar domain and the tyroine 
kinase domain.
This pattern of digestion has suggested that tyrosine 
kinase activity and the C-terminus are linked by a proteases 
sensitive flexibile hinge region (Carpenter, 1987).
The C-Terminal Tail  Region.
This is the part of the EGF-R m olecu le  which 
dem onstra tes  the greatest am ount of am ino acid sequence 
divergence (Yarden, 1990). As well as phosphorylating a number 
of d ifferent exogenous substrates, EGF-R tyrosine kinase can 
catalyse self phosphorylation too. This autophosphorylation occurs 
only at a number of specific tyrosine residues in this C-domain of
through the sequencing of phosphotyrosine  containing tryptic 
digests of the EGF-R derived from A431 cells, which were labelled 
in the presence of EGF. There are 3 sites at residues number 1173 
(PI), 1148 (P2) and 1068 (P3). Y1173 is the main site of EGF
induced autophosphorylation of EGF-R in intact cells (not in vitro). 
The phenomenon of EGF-R autophosphorylaton will be discussed 
later (see Section 5.6.2.).
The C-termini of different protein tyrosine kinase type 
growth factor receptors have divergent amino acid sequences. 
C-terminal deletions could be involved in oncogenesis. Consider 
the example of v -erb -B .
The process of recombination of the sequence for the 
transmembrane and cytoplasmic domains of EGF-R into the Avian 
Erythroblastosis Virus genome results in the loss of certain C- and 
N- terminal residues, and an N-terminal trunaction (Downward 
et.a l., 1984). The later is correlated  with the induction  of 
erythroblastosis by EGF. Newly isolated erb B transducing viruses 
(Garnet et al., 1986), however, can create  d ifferent diseases, 
transform fibroblasts in culture and have different sequences at 
the C-domain i.e. the differences in the C-domain are correlated 
with the disease causing potential of v-erb B.
Brain tumours of glial origin often have elevated levels 
of EGF-R due to amplification and rearrangement of egf-r (M a ld en  
et al., 1988). In glioblastoma multiforme, selective amplification of
the T ransm em brane Domain, Cytoplasm ic Domain and various 
fractions of the EGF Binding Domain are known to occur, with the 
later being the most common. It is though that the selective 
amplification of the cytoplasmic domain results in the consitutive 
activation of tyrosine kinase activity which ultim ately causes 
cellu lar transform ation.
Finally, a recent study has shown that alterations in the 
Erb-B protein which are associated with oncogenic potential are 
those which affect the protein tyrosine kinase  domain (Nair 
e t.a l., 1992).
4 .3 .Epidermal Growth Factor Receptor Homologues and
Analogues.
A.The Secreted EGF-R.
This polypeptide is produced only by A431 cells 
(Carpenter, 1987). It is thought to result from the expression of 
the 2.8 K.B EGF-R mRNA which is created by the translocated and 
rearranged egf-r (Merlion et.al., 1990 and Hunts et.al., 1985).
The predicted amino acid sequence corresponds to 
m ost of the ex ternal binding dom ain of the EGF-R, but, 
approximately eighteen amino acids are of unknown origin at the 
C-terminal region. One contains a glycosylation site
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(Hunter et.al., 1984). The transmembrane and cytoplasmic domains 
are entirely deleted and since this is the region which anchors the 
protein  m olecule  in the p lasm a m em brane, the m olecule is 
secreted (Weber et.al., 1984).
W hat function this form of EGF-R might have is not 
known, but it binds EGF, both this and norm al EGF-R are 
physiologically identical and the glycosylation patterns of both 
proteins are identical (Carpenter, 1987). This, therefore suggests 
that m em brane anchoring of EGF-R within the Endoplasm ic 
Reticulum and Golgi Apparatus do not seem to be vital for correct 
g lycosy la tion  and activation of the ex ternal ligand binding 
domainn of EGF-R (Carpenter ,1987). Further processing (as yet 
unidentified) of the protein may also take place.
B.Oncogenes.
A great deal of work (see Downward et.al., 1984 for a 
review) has demonstrated that EGF-R is related to a number of 
oncogenes such as c -e rb -B 2 . HER 1. H ER2 and n e u . This 
relationship and its implications will be discussed in Chapter 6.
C.Drosophila EGF-Receptor Homologue Gene (DER).
DER was originally identified by analysis of the 
D ro so p h ila  m e lan o g a s te r  genome using the EGF-R tyrosine kinase 
domain as a cDNA probe (Livneh et,al., 1985). It was the first
tyrosine kinase receptor gene identified in D rosophila  ( S c h e i te r  
and Shilo, 1989)and it resembles EGF-R and neu (Bargmann et.al., 
1986 (a) and (b)).
The protein has 3 cys-rich domains in i t s  extracellular 
domain and there are 2 different forms due to alternative splicing 
at the N-terminus (Schejter and Shilo, 1989). Tyrosine kinase 
domains are, however, conserved (Price et.al.,1989 (b)).
DER is expressed throughout development, including at 
the early embryonic stage (Schejter and Shilo., 1989). The pattern 
of expression changes though as development proceedes:
1-Embryo: Uniformly expressed throughout the embryo.
2-Larva: Expression is restricted to dividing cells in the imaginal
discs and brain cortex.
3-Adult: Expressed in the nervous system and brain and in
females, ovarian follicle cells.
(Schechter e t .a l . ,1979).
When D E R  gene is mutated to create homozygous d e r  
m utants, the embryos which are created have the following 
pheno type :de terio ra tion  of anterior struc tures, ventral dentrial 
bands are missing, germ band doesnot retract and the Central
Nervous System  mid-line pattern is absent. Com plem entation 
analysis showed DER muations are allelic to the fib  mutation.
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4.4.The EGF-R Gene.
4.4.1. Introduction
In humans, the EGF-R gene is located on the short arm 
of chromosome 7: at locus p l4 -p l2 ,  close to the p l l  fragile site 
(Haley et.al., 1987). The gene spans some 100K.B. and is 
composed of 26 exons (Haley et.al., 1987 and Shimizu et.al., 
1980, 1982). Intron 1 lies between exons 1 and 2 and contains 
the elements of the promoter region.
4.4.2.The EGF-R Gene Promoter.
The promoter of the EGF-R gene has no TATA or CAAT 
box (Haley et.al., 1987 and Ishii et.al., 1985 (a) and (b) and
1986)., but the promoter proper and its suurounding area are 
very rich inG/C residues (Johnson et.al., 1988 (a) and (b)). Such 
sequences are associated with an open chromatin formation, and 
represent areas of transcriptonal initiation (reviewed in Gross 
and Garrod, 1987; Marinus, 1987 and Dynan, 1989). In addition, 
the CCGCC sites are the binding motifs for the transcription 
factor SP1 (reviewed in Kadonaga et.al., 1987; Johnson and 
McKnight, 1989 and Briggs et.al., 1986). SP1 is involved in the 
selective transcription of genes (Dynan, 1989).
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Such motifs and their presence in the e g f - r  prom oter 
imply that it may be constitutively active (Kageyama et.al., 
1988 (a)and (b)) i.e. it has some metabolic function. CpG rich 
prom oters are known to be characteristic  of constitu tive ly  
active genes (reviewed in Tazi and Bird, 1990; Bird, 1987 and 
Frank et.al., 1991)with house-keeping functions. In such cases 
optimal transcription levels are achieved by transcripton factor 
b inding  causing  the appropria te  necessa ry  p ro te in -p ro te in  
in te rac tions  (see Hames and Glover, 1988, Johnson and 
McKnight, 1989; Ptashne, 1986, Rich et.al., 1984 and Travers, 
1989).
Another point to note is that in addition to these 
transcription initiating sequences, intron 1 may also be involved 
in the control of de novo transcription, and so subsequent 
translational events. This will be discussed in the following 
p a ra g ra p h s .
CAT in v itro  t ranscrip tion  assays (rev iew ed  in 
Kingsman and Kingsman, 1986) have identified and allowed the 
eventual purification of a number of transcription factors which 
are believed to be involved in the control of transcription of 
e g f - r . They are SP1, CTF, API, MLTF and TF II B (Kageyama 
et.al.,1988 (a) and (b)).
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These nuclear proteins are essential for the optimal 
expression of e g f - r . Kageyama et.al. have also reported that in 
A431 cells there is a novel transcription factor regulating the 
transcription of e g f - r . It has been named ETF (EGF-R Specific 
Transcription Factor) (Kageyama et.al., 1988 (a)and (b)). The 
molecular weight is 27 K.D, and the fact that ETF binds weakly 
to DNA templates suggests that secondary elements may be 
involved in this process. Johnson et.al. showed by D N asel 
fo o t-p r in t in g ,  gel re ta rd a tio n  assay  and ex o n u c lea se  III 
protection assay that there are eight sites in the promoter which 
specifically bind nuclear factors : -457 - -440; -417 - -402; -305 
- -286; -214 - -200;195 - 170;-139 - 126;110 - -84 and -39 - 
-23 (Johnson et.al., 1988 (a) and (b)).
The EFT binding site consensus sequence is CCCCCGGC 
(Imagawa et.al., 1987). It bears a strong resem blance to the 
»  c o n se n s u s  b in d in g  s ite  fo r  the  t r a n s c r ip t io n  fa c to r
AP1:-YCSCCMNSSS- (reviewed in Bohman et.al., 1987; Bos et.al., 
1988; Hames and Glover, 1988 and Ptashne, 1986).where: Y=T 
or C, S=C or G, M=A or C and N=Any nucleotide.
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This site is known to be involved in gene expression 
induced by phorbol esters (Im agawa et.al., 1987), and the 
authors therefore conluded that ETF causes transcrip tional 
acitvation via transcription factor binding (Im agaw a et.a l., 
1987).
It must be noted, however that the molecular weights 
of the 2 proteins are very different:ETF being 120 K.D and AP2 
50K.D. (Imagawa et.al., 1987). ETF has, in addition, little or no 
effect of SV40 promoters in in vitro assays while AP2 strongly 
enhances SV40 transcription in such assays (Im agawa et.al.
1987). Such findings make it unlikely that such a mechanism of 
initiation of gene transcription is in action in this case.
A sequence identical to the ETF binding site has been 
located on the promoter of the human insulin receptor gene, but 
in the opposite orientation to that in the egf-r p rom oter (Araki 
et.al., 1987). This provides some evidence that ETF may be 
involved in the regulation of expression of genes other that that 
for EGF-R, importantly, other growth factor receptor genes. A 
second type of ETF has been characterized by Merlino's group 
(Merlion et.al., 1990). This ETF binds to a region of the promoter 
between nucleotides -139 and -126 and has been named ETF2.
Hudson’s group isolated the 5 ’-region of e g f - r  from a 
human placental genomic DNA library (Hudson et.al., 1989). A 
region 1081 b.p. 5' to the ATG translational start site was found 
to be the im portant region with respect to transcriptional 
initiation and it's control.
Deletion analysis around this area further refined the 
region to a domain of 134 b.p. stretching from -19 to -153, and 
which is adjacent to the translational start point. The region 
contains the elements for:EGF, TPA, (Bu2) cAMP, Retinoic Acid 
and DMSO induction. It also has strong prom oter/enhancer 
elements which as previouly stated are probably involved in 
basal and inductive responses (Hudson et.al., 1989).
Some viral proteins, principally those of Adenoviruses 
and Papillom a Viruses have been found to be involved in 
regulating egf-r  expression by acting upon the promoter. Human 
Papillom a Virus 16 (HPV-16) protein E5 when added in 
combination with EGF to HeLa cells, causes an increase in the 
rate of proliferation of the cells in a soft agar assay system (Pirn 
et.al., 1992). It would therefore seem that in some as yet 
unidentified way, the E5 protein is am plifying the EGF-R 
mitogenic signal. Their research has led the authors to believe 
that the most likely explanation is that E5 sensitized the cells to
any reduction in EGF concentration.
Group 3 type Adeonviruses seem also to be involved in 
regulation of egf-r  promoter activity. The product of the E3 gene 
effects internalization and degradation of EGF-R i.e. mediates 
EGF-R down-regulation (Carlin et.al., 1989). The 2 proteins 
encoded by the E3 gene have molecular weights of 13.7 K.D. and 
11.3 K.D. (Hoffman et.al., 1990 and Tollefson et.al., 1990).
Studies have shown that the 2 proteins form disulphide 
bonds, and that these oligomeric strucutes become inserted into 
the p lasm a m em brane of the infected cell in a non-virus 
dependen t m anner (Hoffm an et.a l., 1992). Through an at 
present unclear mechanism, EGF-R becom es down-regulated. 
Phosphory la tion  of the heavier po lypep tide  upon serine 
residues is known now (Krajcsi et.al., 1992) and it is possible 
that this is involved in this process in some way.
As well as factors which increase EGF-R expression, the 
gene experiences negative regulation. Two agents which are 
responsible for this effect are thyroid hormone and retinoic acid 
(Thompson et.al., 1992). The mechanism of action of retinoic 
acid is not well known at present, but thyroid hormone receptor 
binds to a 36 b.p. C/G rich area of the egf-r promoter and can 
also act as a minimal enhancer.
Davidson showed that the number of EGF binding sites
and the amount of im m unoprecipitable  EGF-R protein and
mRNA are directly related (Davidson et.al., 1987). This therefore
implies that the control of e g f - r  expression takes place at the 
t r a n s c r ip t io n a l /p o s t - t r a n s c r ip t io n a l  lev e l.  E x p e r im e n ts  to 
derterm ine if expression is controlled at the transcriptional 
level when carried out for e g f - r  expression, showed that if 
EGF-R levels  increase , a co n co m itan t  in c rease  in the 
transcription rate is seen (Davidson et.al., 1987).
Two enhancer elements have been demonstrated in 
the egf-r (Meakawa et.al.,1989). 1 is located at residues -1429 
to -1109 and the other down-stream in intron 1 about 200 b.p. 
down-stream of the transcription initiation start site, which is 
approxim ately 530 b.p. long (M eakawa et.a l., 1989). Both
enhancers act cooperatively . Enhancer b inding proteins are 
known which suggests that these elements may also mediate 
cell-type specific expresion of egf-r (Meakawa et.al., 1989).
The down-stream enhancer can only act properly in 
the presence of the upstream enhancer (M eakawa et.al., 1989), 
and the upstream enhancer has twice as great an effect on e g f - r  
promoter activity when placed down-stream  of the promoter 
compared to activity associated with normal
positioning (Meakawa et.al., 1989). This is an unusual feature of 
the working of this enhancer since generally, enhancers are 
position and orientation independent (Reviewed in Hames and 
Glover, 1988 and Kingsman and Kingsman, 1988).
The down-stream  enhancer elem em t has 10 nuclear 
factor binding sites so far identified , by protection assays 
(Kingsman and Kingsman, 1988). The identity of these factors is 
not known though.
• ’►j)' In terms of e g f - r  cell-type specific  expression the
preliminary evidence from Masakawa's group indicates that the 
2 enhancers are involved in this process. For example, in MCF-7 
cells, the down-stream enhancer causes repression of the gene’s 
promoting activity while the upsteam enhancer has the same 
levels of enhancement on HeLa cells (Xu et.al., 1984).
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4.4.3.Transcription of the EGF-R Gene.
Both normal and transformed cells express EGF-R 
mRNA of 2 types: a 10 K.B. and a 5.6 K.B. species (Hsuan et.al., 
1989; Ullrich et.al., 1984 and Hunter et.al.,1984). The amount of 
each type of mRNA varies depending on the cell type (Hunter 
et.al.,1984). A431 cells produce, in additon to those above, a 2.8 
K.B. species that encodes a secreted form of the receptor
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(Hunter, 1984). Both types of mRNA hybridise with eg f-r  cDNA, 
but how they may be related is not known.
Transcription is initiated from multiple sites within
an 800 b.p. GpG island in Exonl (Haley et.al., 1987), in a sense 
and an anti-sense direction. The anti-sense transcripts extend 
through the coding exonl and are reduced in number in the 5' 
flanking region. It is possible that some anti-sense transcripts 
could hybridise with coding sequences in exonl of mature e g f- r
I
mRNA and so reduce the level of it's translation. Such an 
approach to translational regulation is well known (see Simons 
and Kleckner, 1989 and Weintraub et.al., 1985), and so is a
viable theory for the regulation of expression of eg f-r .
The regulation of egf-r transcriptiom by protein kinase
C will be discussed later, but it should be stated here that the
effects of protein kinase C upon the initiation of e g f - r  are
IP) 1 detectable within 60 minutes and at down-stream exons within
120-240 minutes. Assuming a theoretical value for the rate of 
transcription to be 30 nucleotides per second, then in tron l
(18K.B.) should be fully transcribed within approxim ately 10 
minutes. This calculation implies that there is likely to be yet
further levels of control. A possible explanation is that since
this intron region is close to protein binding sites, the rate of
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RNA elongation may be influenced by the rate of formation of 
protein-DNA complexes.
4.4.4.Translation and Post-Translational Modification of 
EGF-R.
Translation of EGF-R mRNA in vivo is accompanied by 
c o - t ra n s la io n a l  g ly co sy la tio n  w ith in  the  lum en o f  the 
Endoplasmic Reticulum (Carlin et.al., 1989). Firstly the twenty 
four amino acid N-terminal leader sequence is removed from 
the 134 K.D. precursor, generating a 135 K.D. polypeptide (Velu 
et.al., 1989). This process is inhibited by Tunicamycin (Hsuan 
et.al., 1989) results in the generation of a 1260 K.D. precursor 
(Carpenter, 1987). This precursor has only high mannose type 
oligosaccharide side chains.
The process which takes about two hours, and can be 
inhibited by Monensin. Here, a ten-eleven residue complex of 
N-linked oilgosaccharide chains are added to the 135 K.D. core 
polypeptide. This creates the mature 170 K.D EGF-R (Velu et.al.,
1989).
Scanning the amino acid sequence of the growth factor 
receptor gene shows that there are fifteen possible sites at 
which N -linked oligosaccharides can be added: tw elve are
located in the extracellular domain and three are located in the 
cytoplasmic domain.
Complex chains are found at glycosylation 
sites close to the N-terminus and high mannose type chains are 
loca ted  at g lycosy la tion  sites d is ta l  to the N -term inus 
(Carpenter, 1987).
The g lycosy la tion  events  de sc r ib ed  above are 
necessary for EGF-R to be able to bind EGF (Carpenter, 1985 and 
Sleiker et.al., 1986). This is demonstrated by using Tunicamycin 
to block oligosaccharide addition. This results in the production 
of an EGF-R which cannot bind EGF. However, merely adding 
carbohydrate moities is not enough to cause the acquisition of 
this activity. Various post-translational processing events are 
also needed before the EGF can bind to EGF-R (Carpenter, 1987). 
This post-translational acquisition of ligand binding activity is 
also demonstrated in insulin receptor (Ronnett and Lane, 1981. 
and Reed et.al., 1981).
Exactly how this process occurs is not known but it 
occurs about 20-30 minutes after the start of translation, late in 
the Endoplasmic Reticulum (Carpenter, 1987). It is thought to 
require disulphide bond formation in the cysteine-rich ligand 
binding domain of the EGF-R (Velu et.al., 1989).
The acquisition of ligand binding ab ility  requires 
proper core oligosaccharide addition, initial glucose trimming
Complex chains are found at glycosylation 
sites close to the N-terminus and high mannose type chains are 
located  at g lycosy la tion  sites d is ta l  to the N -term inus 
(Carpenter, 1987).
The g lycosy la tion  events desc r ibed  above are 
necessary for EGF-R to be able to bind EGF (Carpenter, 1985 and 
Sleiker e t.a l. ,1986). This is demonstrated by using Tunicamycin 
to block oligosaccharide addition. This results in the production 
of an EGF-R which cannot bind EGF. However, merely adding 
carbohydrate moities is not enough to cause the acquisition of 
this activity. Various post-translational processing events are 
also needed before the EGF can bind to EGF-R (Carpenter, 1987). 
This post-translational acquisition of ligand binding activity is 
also demonstrated in insulin receptor (Ronnett and Lane, 1981. 
and Reed et.al., 1981).
Exactly how this process occurs is not known but it 
occurs about 20-30 minutes after the^ start of translation, late in 
the Endoplasmic Reticulum (Carpenter, 1987). It is thought to 
require disulphide bond formation in the cysteine-rich ligand 
binding domain of the EGF-R (Velu et.al., 1989).
The acquisition of ligand b inding ability  requires 
proper core oligosaccharide addition, initial glucose trimming
and activation in the Endoplasmic Reticulum (Velu et.al., 1989). 
The p o s t- t ran s la t io n a l  m o d if ica tio n s  w hich  are p robab ly
responsible for these events are phophorylation, fatty acylation
and disulphide bond form ation or rearrangem ent within the 
receptor molecule (Velu et.al., 1989).
Swainsonine is a fungal alkaloid that prevents one of 
the Golgi m annosidases involved in EGF-R processing form 
working. In its presence, an im m ature form of EGF-R is 
produced, which has a molecular weight of 160 K.D (Soderquist 
and Carpenter, 1984). This species of EGF-R can be digested with 
endoglycosidase H to a 130 K.D aglyco form of the receptor.
The immature receptor seems to be formed normally
but is not retained within the cell but is instead processed to the 
surface of the cell (Velu et.al., 1989). The EGF-R activities of 
125I-EGF binding and stimulation of DNA synthesis are carried 
out as efficiently by this immature EGF-R as they are by the 
normal form of the receptor. The Swainsinine dependant form 
of EGF-R is, however, transported to the plasma membrane as 
described above. It can also bind EGF and has an active tyrosine 
kinase (Carpenter e t.a l. ,1987).
Final processing of EGF-R occurs in the Golgi
Apparatus. Here, mannosyl residues are removed and terminal
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sugar residues such as fucose, sialic  acid, galactose  ans
N-acetylglucosam ine are added to the precursor core structure 
(Velu et.al., 1989).
In addition to glycosylation being vital in intracellular 
routing of EGF-R (Sleiker et.al., 1986), tyrosine kinase activity of 
the receptor seems also to be acquired post-translationally, but 
somewhat earlier than EGF binding ability is acquired (Hsuan
et.al., 1989).
The initially synthesised 160 K.D precursor is therefore 
processed to the mature form of the receptor by capping of it's 
o ligosaccharide chains with terminal sugars. Addition of core
oligosaccharides seems to by vital in the correct functioning of
EGF-R, that is to say, ligand binding activity , in tracellu lar 
r o u t in g  o f  E G F -R ,  ty r o s in e  k in a s e  a c t iv i t y  and  
autophosphorylation of EGF-R.
The acquisition of autophosphorylation activity by the 
EGF-R protein (Slieker et.al., 1986) is particularly intriguing as 
the N-linked glycosylation sequence:-Asn 1020/1070/1124- is 
located in the molecule such that its position would prevent the 
glycosylation of the required residues (Kornfeld and Kornfeld, 
1985). That glycosylation is involved in the acquisition of 
tyrosine kinase activity is demonstrated by the finding that
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the 130 K.D re c ep to r  g enera ted  in the p resenece  of 
Tunicamuycin is not phosphorylated upon tyrosine residues in 
in vitro assays (Soderquist and Carpenter, 1984). Such evidence 
has been taken to support the intram olecular model for the 
activation of EGF-R tyrosine kinase activity 
(Biswas et.al., 1985 and see section 5.3.2.).
4 .4 .5 .Synthesis Associated Phenomena.
A-Receptor Down-Regulation.
Ligand binding causes receptor internalization 
(see Section 5. 11.6-B). Experiments with labelled EGF (Earp 
et.al., 1986 and 1991)have shown that down-regulation reduces 
greatly the cell surface binding capacity for EGF and usually 
leads to ligand degradation and possibly receptor degradation 
too (see Section 5.11.6-E).
In the WB cell line, Northern analysis shows that on 
addition of EGF,EGF-R mRNA levels increase by about 3-5 fold 
(Carpenter et.al., 1987). This suggests that in the WB line at 
least, the action of EGF that leads to EGF-R degardation is 
counter-balanced by a positive effect on receptor synthesis. This 
is also seen at the protein level. EGF-R synthsis can therefore be 
viewed as a regulated process. EGF-R levels are known to vary 
at different times during the cell cycle at
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different cell densities and following retinoic acid induced 
d if fe ren t ia t io n .
The hom eostatic  regulation of EGF-R synthesis by 
ligand action may be a general phenomenon, for example, in 
hum an skin fibroblasts  (Yarden and U llrich , 1988). Other 
examples include IL2 which increases IL2 receptor synthesis in 
T-lymphocytes, prolactin and the prolactin receptor and insulin 
and in su l in  b in d in g  e n h an c em en t du ring  p re a d ip o c y t ic  
differentiation (Carpenter, 1987).
This area of EGF-R metabolism is discussed in Sections
5.11. B E .
B-Receptor Amplification.
EGF-R is detectable immunohistochemically in all cell 
types, except in those cells of the haem opoetic  lineage. 
Overexpression of EGF-R is a significant feature and has been 
observed in many different types of cancers such as carcinomas 
of the breast, liver, bladder, and pancreas also in glioblastomas 
and sarcomas. Amplification of EGF-R is also seen in cell lines. 
The best exam ple of this are A431 cells; an epiderm oid 
carcinoma cell line which has approximately six million EGF-Rs 
upon its cell surface (See Section .1-A).
Different mechanisms increasing the numbers of EGF-R may be 
in use under different circumstances: amplification of e g f - r :  
increase in the rate of transcription of e g f - r  and increase in the 
rate of post-transcriptional processing. The relative contribution 
of each to tumorigenesis is not known.
4.4.6.Regulation of Expression of EGF-R.
Regulation of the expression of EGF-R can be efected by 
a number of different agents, one of which is EGF. Adding EGF to 
a reposnsive cell leads to a rapid and dramatic reduction in the 
number of EGF-R at the cell surface, in a process known as 
recep to r  dow n-regu la tion  (C a rp e n te r ,1987 and see section 
5 .1 1-B). In the non-transform end cell line WB (rat liver 
epithelial cell line) (Tsao et.al., 1984), among the EGF dependent 
effects are: increase in DNA synthesis, alteration of the activity 
of some glycolytic enzymes, increase in EGF-R tyrosine kinase 
activity, EGF-R internalization and degradation and an increase 
in EGF-R synthesis.
It has also been suggested that Protein kinase C has a 
role in the EGF dependent increase in EGF-R numbers (Bjorge 
and Kudlow, 1987). Protein kinase C is thought to be the 
receptor for the tumour promoting phorbol esters like TPA 
(Niedel et.al., 1983). TPA causes an increase in EGF-R mRNA in
KB cells (Clark et.al., 1985), and EGF-R synthesis in MBA 468 
human breast cancer cells. This suggests that EGF requires 
protein kinase C involvement at some stage in i t ’s action on 
EGF-Rs. How this may be brought about is unknown.
Regulation by Oestrogens is known too. Reports that 
17-beta oestradiol causes an increase in EGF-R levels have been 
accumulating over many years. For example I 125-EGF binding 
studies in immature rat uterine membranes which have been 
treated with 17-beta oestradiol show a 3 -fold increase in the 
numbers of EGF-Rs at the cell surface within approxim ately 
twelve hours. This is likely to be due to de novo synthesis, as 
Actinomycin D prevents it form happening (Mukku and Stancel, 
1985 (a) and (b».
Another example is in the case of mature rats, which 
have been ovariectomised, 17-beta oestradiol causes a 2-3 fold 
increase in EGF-R numbers in the uterus approximately eighteen 
hours after it's adm inistration. W hen non-castra ted  anim als 
were used at different stages of the oestrus cycle, the following 
observations were made:
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Stage Number of EGF-R
Metestrus Low
Diestrus Double the metestrus value
Proestrus Maximal
Estrus Low
These observed changes are equivalent to those noted 
for plasma oestrogens (Yoshida et.al., 1990)and for occupied 
nuclear oestrogen receptor levels (Clark et.al., 1989). This 
therefore suggests that there is an link between oestrogen 
receptors and EGF-Rs such that increased levels of oestrogens 
are correlated with increased number of EGF-Rs in the uterine 
m em branes of mature and imm auture rats (G ardner et.al.,
1989).
The models which have been put forward to explain 
how oestrogens might affect EGF-R levels are as follows. Firstly, 
Oestrogen may cause general uterine growth which will as a 
natural consequence mean an increase in the numbers of EGF-R 
(Gardner et.al., 1989). Oestrogen on the other hand might 
prevent EGF-R down-regulation so that the numbers of EGF-R 
are  a lw ay s  s u f f ic ie n t  to s t im u la te  g ro w th .  F in a l ly ,  
non-transcriptional mechanisms may cause the release of EGF
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from EGF-R and so resulting in the generation of free EGF-Rs 
(Clark et.al., 1989; Earp et.al., 1986 and 1991).
Certain other points must be considered. The increase 
in receptor numbers occurs before tissue DNA synthesis begins 
(Kaye et.al., 1972 and Stancel et.al., 1990). Additionally, EGF 
causes myometrial contractions due to the release of arachidonic 
acid from sites within the uterine mem brane (Stancel et.al.,
1990). U terine tissue has a large num ber of growth factor 
 ^ receptors in addition to those for EGF, for example insulin like
growth factor I receptor (Murphy et.al., 1988). This receptor can 
be regulated by 17 -beta oestradiol.
In the normal uterus oestrogens are responsible for the 
regualtion of proto-oncogene expression, for instance, mRNA 
levels for the fo llow ing p ro to-oncogenes are e leva ted  by 
treatment with 17-beta oestradiol: c-mvc (Travers and Knowler, 
*} 1987); c-mvb (Murphy et.al., 1988); c-Ha-Ras (Travers and
Knowler, 1987) and c-erbB (D ow nw ard  e t.a l. ,  1984). This 
suggests that 17-beta oestradiol and a stimulatory effect upon, 
the growth of some cells, but this effect is not exclusively due to 
EGF-R.
That other agents may be involved in the oestrogen 
dependent growth of breast cancer cells was demonstrated in
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the following way. MCF-7 cells (ER+)were treatred with the 
anti-oestrogen Tamoxifen (Cole et.al., 1986 and Levine et.al., 
1985) to inhibit their growth and provide  a synchronised 
population of cells. Monoclonal antibodies against EGF-R were 
found to block EGF/TGF-alpha binding, but base-line DNA 
synthesis and growth of the cells was unaffected (Arteaga et.al.,
1988).
The conclusion that TGF-alpha/EGF is not the primary 
mediator of oestrogen mediated growth stimulatory effects was 
therefore reached. It is a likely possib ility  thought that 
complex interactions between a number of different factors may 
be involved  or even other m echanism  altogether such as 
different metabolic enzymes (Aitken and Lippman, 1985).
Additionally, in LNCap cells ( a cell line deived from a 
lym ph node carc in nom a of the hum an p rosta te  g land) 
(MacDonald and Habib, 1992), EGF-R numbers are increased by 
17-beta oestradiol in a dose dependent manner. This process is 
not inhibited bt Actinomycin D and Cycloheximide which implies 
that it takes place at the level of the protein, and not the e g r - r  
gene (Schuurm ans et.al., 1990). In this second example, it 
should also be noted that the same effect is achieved by treating 
cells  w ith  te s to s te ro ne , p ro g es tre ro n e  and tr iam c in o lo n e  
acetonide too (Schuurmans et.al., 1990).
In a recent study of this phenomenon, cells were taken 
from normal, benign, and m alignant human mammary tissue 
and cultured. Tritiated thymidine was used as a measure of the 
rate of cell growth (Gabelman and Emerman, 1992). Oestradiol 
was found to have no effect no cell growth, but EGF enhanced 
it's rate-th is is in turn inhbited by in troducing m onoclonal 
antibodoes against EGF-R to the cells. T ogether EGF and 
Oestradiol were synergistic in 50% of cases (Gabelman and 
Emerman, 1992), which implies that the 2 signal transduction 
systems were interacting in some way at some stage.
Another likely model for hormonal control of EGF-R 
levels is that oestroegn enhances the stability of EGF-R mRNA" 
Increase in the rate of transcription of the gene ss possible too, 
so control may be mediated on a number of separate levels.
In male mouse livers, EGF-R levels are approximately
2-3 times lower than in female rat livers (Benveniste  and 
Carson, 1985), and it has been proposed that androgens act 
directly to cause EGF-R induction as treating fem ales with 
androgens leads to EGF-R levels incresing to male levels 
(Noguchi et.al., 1989).
Noguchi, by implanting testosterone into the spleens of 
test rats showed that the hormone caused a direct increase in 
the level of EGF-R mRNA and EGF binding ability in the liver 
(Noguchi et.al., 1989).
Exactly how testosterone maybe exerting it's effects on 
EGF-R expression is not known because the eg f-r  gene promoter 
does not have the androgen recep to r responsive  e lem ent 
consensus sequence -GGTACANNNTGTTCT- (Beato et.al., 1989). 
This does not rule out the possibility that testosterone causes 
induction of a substance which can interact with the e g f - r  
p ro m o te r .
Phorbol esters cause positive  regua ltion  of e g f - r  
expression, even without protein synthesis. This may be due to 
RNA stabilization or de novo transcription. In A431 cells, serum 
deprivation leads to a decrease in the rate of e g f - r  transcription 
which is reversible upon the addition of phorbol esters or foetal 
calf seum i.e. agents which cause the induction of de novo 
transcription. The model currently accepted to explain this 
phenomenon is that phorbol esters activate protein kinase C. 
This results in the phosphorylation of EGF-R which reduces high 
affinity EGF binding, and intrinsic tyrosine kinase activty. The 
model is therefore in line with a positive feed-back system,
w h ereb y  EGF-R sy n th e s is  is s t im u la te d  by E G F-R  
do w n -re g u a lt io n .
EGF dependent increase in EGF-R synthesis is possibly 
due to a pathway equivalent to that of protein kinase C. In 
transient transfection assay systems, maximal stimulation with 
EGF and protein kinase C are not additive. This suggests that the 
2 signal transduction pathways depend on certain as yet 
unidentified common factors. API sites could be of significance 
here as API is known to transduce signals generated by protein 
kinase C.
T3 is the most active form of Thyroid Hormone. T3 
causes an increase in EGF-R expression at the mRNA level in the 
proximal tubules in the kidney (Humes et.al., 1992). In addition, 
it potentiatea the mitogenic response of these cells to EGF 
(Humes et.al., 1992), implying an in tegration point in the 
signalling pathways of these 2 receptor exists.
Dexamethasone causes a reduction in EGF-R synthesis 
at the mRNA level (Oberg and Carpenter, 1989) in foetal rat 
lung cells. This occurs without the need for protein synthesis, i.e. 
it is to do with the transcription of e g f - r . Again, this shows that 
agents can regulate the expression of e g f - r  activity (Oikarineu 
et.al., 1989). The researchers concerned believed that an
increase in the rate of mRNA degradation is responsible (Oberg 
and Carpenter, 1991).
Dexamethasone could alternatively inhibit m itogenesis 
by blocking the G0-G1 phase (Ferradina et.al., 1992).
Differentiating agents may also affect the level of expression of 
E G F -R .  S o d iu m  b u ty r a t e ,  d i m e t h y l f o r m a m i d e  and  
dimethylsulphoxide cause an increase in EGF-R mRNA and EGF-R 
levels in human colon carcinoma cells, and also in the SW620 
cell line (Murphy et.al., 1986 and 1987).
Alpha interferon is one of the many proteins derived 
from leucocytes. Some of the effects are anti-proliferative, and 
are thought to involve down-regulation of EGF-Rs such as is the 
case for the insulin receptor (Pfeffer et.al., 1985 and 1987) and 
the t ra n s fe r r in  rec ep to r  (B esancon  e t .a l . ,  1985). T his 
down-regulation of EGF-R is observed in human fibroblasts 
(Zoon et.al., 1986).
In the cell line CaKi-1, which is EGF dependent, there 
are high numbers of EGF-R at the cell surface. Alpha interferon 
blocks EGF dependent cellular proliferation and causes the 
reduction of receptor numbers at the membrane (Eisenkraft 
et.al., 1991). A reduction in receptor biosynthesis is thought 
to be responsible for these changes along with a partial block
of the elongation phase of translation demonstrated by 
polysome distribution on cellular EGF-R mRNA (Levine et.al.,
1990).
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Chapter Five: EGF-R SIGNAL
TRANSDUCTION.
5 .1 .Introduction.
Signal transduction is the summation of all the 
processes involved in the translation of changes which occur 
outside the cell, into a programmed alteration of intracelluar 
activities. Cells perceive such environmental changes through the 
receptors located in their plasma membranes, receptors also have 
a central role in the generation and propagation of those signals. 
In addition, since the very first event in the pathways of signal 
transduction is the binding of a receptor by it’s cognate ligand, 
receptor-ligand binding is a major point; of control of intracellular 
signalling.
When a ligand, for example a growth factor such as EGF 
binds to it's receptor, a cascade of biochemical events is initiated. 
These fall into three main groups:
1-Ion Fluxes.
2-Inositol Lipid Metabolism.
3 -A c t iv a t io n  of P ro te in  K in a ses  w h ich  c a u se s  p ro te in  
p h o sp h o ry la t io n s .
The purpose of this chapter is to assess the current 
literature on EGF-R signal transduction. How each of above listed 
events relates to EGF-R will be discussed, with particular emphasis 
being given to EGF-R’s role as a tyrosine kinase.
5.2.EGF-R/EGF Binding.
5.2.1. Introduction.
A number of different ligands can bind to EGF-R:EGF: 
(1 :1  l ig a n d  r e c e p t o r  s to i c h e o m e t r y  (W e b e r  e t . a l . ,  
1984),TGF-Alpha;(Carpenter, 1987), Am phiregulin (Shoyab et.al., 
1979) and Pox Virus Growth Factors (especially Vaccinia Virus
Growth Factor) (Buller et.al., 1988).
Overall homology between these ligands is, however,
low: approximetly 22% (Velu e t .a l. ,1989), yet binding affinities 
remain about the same for each ligand.How this might be brought 
about is as yet unknown, but some current models will be 
discussed below.
Binding to EGF to EGF-R has pleiotrophic physiological
effects (Carpenter, 1987). One of these effects is the activation of
the intrinsic tyrosine kinase of EGF-R (Schlessinger, 1986 and see 
also Section 5.6.). As a result, a number of cellular proteins are 
phosphorylated, including EGF-R itself (see Section 5.6.1.).
Such tyrosine phosphorylations are believed (in part at 
least)to be responsible for the complex set of events which occurs 
both upon the surface of the cells and within the cell subsequent 
to E G F  b in d in g :E G F /E G F -R  c o m p le x  o l ig o m e r iz a t io n ,  
dow n-regu la tion , in te rnaliza tion , degradation  and in trace llu lar  
rou ting .
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Such events have a central position in the EGF-R signal 
transduction  pathw ay and will be d iscussed  separately  (see 
Sections 5.11.6.-A to 5.11.6-F. ).
In order to have its effects upon the cell, EGF must be 
present and be bound to EGF-R uninterrupted for approximately
6-10 hours (Shechter et.al., 1989 and King and Cuatrecasas, 1982). 
It is during this period of time that the EGF-R metabolic events 
listed above take place and the cells u ltim ately  becomes 
committed to DNA synthesis.
5.2.2.Quantitating Binding.
Analysis of ligand binding is carried out by Scatchard 
analysis of data generated in ligand binding assays (Leake et.al.,
1987). Such analysis derives the two perameters:
-Affinity Constant: Kd.
- For the high and low affinty receptors, Kd values range from 
10-9 to 10-10M (Carpenter et.al., 1987).
-Receptor Concentration: B max.
Cells generally have 20,000 to 200,000 EGF-R's upon their 
surface (Carpenter, 1987). There are notable exceptions to this rule 
though (see Section 4 .1-A on the A431 cell line) with differing 
affinities for EGF or EGF or EGF/EGF-R.
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Scatchard analysis of EGF-R reveals that there are two 
distinct receptor populations: one with a high affinity and one 
with a low affinity for EGF. The high affinty population comprises 
about ten percent of the total receptor population, with the 
difference in Kd values between the two populations being 10-20 
fold (Carpenter, 1987).
5.2.3.Populations of EGF-R's.
In addition to that evidence provided by Scatchard 
analysis , much work has recen tly  been carried  out which 
demonstrates that with respect to affinity for EGF, there are at 
least 2 groups of EGF-Rs.
In KB cells, under physiological conditions, there are two 
types of EGF-R: high and low affinity  receptors (King and 
C uatercasas , 1982). Such work was made po ss ib le  by the 
developm ent of m onoclonal an tibod ies  (B ello t e t.a l . ,  1990) 
:mAB108 was raised against the extracellular domain of EGF-R in 
NIH 3T3 cells. It specifically reduces high affinity binding of EGF, 
Kd and number of receptors remains unchanged.
On treating cells with antibody at low concentration 
leads to a 50-100% reduction in early responses (Bellot et.al.,
1990) and shows high affinity binding is dependent upon the on
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rate of EGF binding. So, high affinity binding seems to be essential 
in signal transduction. (This was later confirmed by Defize et.al.,
1989).
2E9 specifically blocks EGF binding to low affinity 
receptors. Adding it to intact cells has no effect on EGF-R tyrosine 
kinase activity and early responses (Defize et.al., 1989) implying 
that these are due to high affinity type EGF-R mediated events.
In H eLa cells , the situa tion  seem s to be more 
complicated with three different EGF-R sub-groups having been 
identified. Studies using the monoclonal abtibody m A bl08  and 
2E9 and PMA (which blocks low affinity  receptor acitvity 
specifically) revealed that the low affinity receptor group are of 
two types and high affinity receptors of one type (Berkers et.al., 
19 9 1 )
Class Affinity Association Constant Dissociation Constant
I High 6.2x105 M-1S-1 3.5x10-4 S-l
11 Low 3.3xl06M -lS-l 8.0x10- S-l
III Low 3.2x104 M-l S-l 1.6x10- S-l
A monoclonal antibody: 13A9 has been created against
EGF-R which almost totally prevents TGF-alpha binding to EGF-R
but has little or no effect upon EGF binding to EGF-R. Using
partially purified receptor, Winkler's group demonstrated that
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with h l3 A 9  (i.e. no TGF-alpha binding)EGF-R tyrosine kinase 
activity is increased about 2.5 fold compared to a 4 fold increase 
with EGF alone (Winkler et.al.,1989).
Although highly homologous to human EGF-R, chicken 
EGF-R binds mouse EGF with approximately 100 fold less affinity 
than the human receptor does. Human TGF-alpha binds with about 
the same affintiy to both chicken and human EGF-Rs but for 
chicken EGF-R, human TFG-alpha is about one hundred times 
better at stimulating DNA synthesis than human EGF (Lax et.al., 
1988).
This type of evidence, may suggest that as well as there 
being a num ber of d ifferent k inetica lly  iden tifiab le  EGF-R 
sub-populations, binding of EGF by different ligands has separate 
effects upon in tracelluar activities. The models currently  put 
forward to explain the discrepancies are as follows:
1-TGF-alpha and EGF bind to different parts of the EGF-R 
molecule. Binding of one or the other of the ligands may result in 
and/or cause, displacem ent of the other ligand or change in 
receptor configuration.
2-TGF-alpha and EGF when they bind to EGF-R do so at the same 
site, but cause different conformatinal changes in EGF.Binding is 
therefore competitive.
3 -The different effects upon the second messenger molecule Ins 
1,4 ,5 ,trisphosphate  and tyrosine phosphory la tions (Korc et.al.,
different cell densities and following retinoic acid induced 
d if fe ren t ia t io n .
The hom eostatic  regulation of EGF-R synthesis by 
ligand action may be a general phenomenon, for example, in 
human skin fibroblasts  (Yarden and U llrich , 1988). Other 
examples include IL2 which increases IL2 receptor synthesis in 
T-lymphocytes, prolactin and the prolactin receptor and insulin 
and in su l in  b in d in g  e n h a n c e m e n t  du rin g  p re a d ip o c y t ic  
differentiation (Carpenter, 1987).
This area of EGF-R metabolism is discussed in Sections
5.11. B E .
B-Receptor Amplification.
EGF-R is detectable immunohistochemically in all cell 
types, excep t in those cells of the haem opoetic  lineage. 
Overexpression of EGF-R is a significant feature and has been 
observed in many different types of cancers such as carcinomas 
of the breast, liver, bladder, and pancreas also in glioblastomas 
and sarcomas. Amplification of EGF-R is also seen in cell lines. 
The best exam ple of this are A431 cells; an epiderm oid 
carcinoma cell line which has approximately six million EGF-Rs 
upon its cell surface (See Section .1-A).
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a-EGF binding to low affinity receptors causes de novo synthesis
of high affinty type receptors.
or,
b-The two populations have different turn-over rates, with that
for high affinity receptors being faster.
or,
c-Expression and/or activity of high affinity receptors requires
the presences of an effector molecule which turns-over rapidly 
snd is in some way involved in the generation of different EGF-R 
popu la tions .
5.2.4.The Regulation of EGF-R/EGF Binding.
As previously stated, ligand-receptor interaction is a 
crucial control point in the process of signal transduction. A 
num ber of agents are cu rren tly  be lieved  to regu la te  this
in te rac tion .
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Table Two: Agents Which Regulate EGF/EGF-R Binding.
Agent
n-Butyrate
Reference 
Gladhaug et.al., 1992.
Phorbol Esters Shoyab et.al., 1979.
P h o to a c tiv a ted
Psoralens Geordias and Laskin, 1991.
DiM ethylSulphOxide V essey et.al., 1991 and Baker et.a l.,1978.
A lkyl-L ysophospholipids Kosano and Takatan, 1988. 
Vitamin K (and other
quinine derivatives) Shoyab et.al., 1979.
Teleocidin B Imani et.al., 1980.
Saccharin Lee et.al., 1981.
Cyclamate Lee et.al., 1981.
Prostaglandin f2-alpha Jimenez de Asua and Goin, 1992.
(N.B. Prostaglandin f2-alpha affects phosphorylation status too see 
Felder et.al., 1992).
1 0 ?
A.Phorbol  Esters.
Phorbol esters, especially T .P.A., and related plant 
macrocyclic diterpenes inhibit the binding of EGF to EGF-R, for 
example in mouse skin (Lee and Weinstein, 1978 9 (a) and (b)), 
HeLa Cells (Lee and Weinsein, 1978 (a) and (b)) and R6PKC3 Rat 
Fibroblasts (Geordiadis and Laskin, 1991).
The potency of the amount of inhibition is correlated 
 ^ with the effectiveness of the agent to promote tumours (Lee et.al.,
1981). It is believed that binding to high affinity type receptors is 
blocked specifically by phorbol esters (King and Cuatrecasas,
1982).
The current model explaining the effects of tumour 
promoters upon EGF/EGF-R binding is as follows. TPA binds to it’s 
intracellular receptor: Protein kinase C (Nishizuka, 1984). Protein 
) kinase C is as a consequence activated and phosphorylated in
addition to other proteins, EGF-R (Jetten e t.a l.,1985 and Cochet 
et.al., 1984 (a) and (b)). This phosphorylayion of EGF-R in some
way, causes a conformational change within the ligand binding
domain of EGF-R so that EGF can no longer bind/does so with less 
affinity (Lee et.al., 1981 and Shoyab et.al., 1979).
108
B.The Involvement o f  PDGF.
PDGF can enhance E G Fs mitogenic effect in vitro (Leof 
et.al., 1982 and Olashaw et.al., 1982) by possibly reducing high 
affinity binding (Wrann et.al., 1980 and Heldin et.al., 1982 and 
Wharton et.al., 1982), thus converting high to low affinity EGF-R's 
(Bowen-Pope et.al., 1983 and Collins et.al., 1983).
PDGF also stimulated protein kinase C activity. In 
protein kinase C down-regulated cells (Olashaw et.al., 1986), PDGF 
can still effect a reduction in EGF binding (Davis and Czech, 1987). 
Studies with human foreskin fibroblasts show in the presence of 
PDGF, T654 is not phosphorylated and PDGF results in a reduced 
level of EGR high affinity receptor binding, which suggests that 
PDGF dependent lowered EGF binding depends upon protein 
kinase C (Olsen and Pledger, 1990).
C.The Involvement o f  sn-1,2-Diacylglycerol.
sn-l,2-Diacylglycerols, reduce EGF binding to EGF-R and 
induce expression of Ornithine Decarboxylase gene (OCDase), an 
event which is correleted with tumour promotion (Verma et.al., 
1979).
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These effects occur in a dose and time dependent 
manner, and in parallel with the effects of phorbol esters (Jetten 
et.al., 1985). The diacylglycerols, which activate protein kinase C 
the most, also have the greatest effect in terms of reducing EGF 
binding, and O C D a s e  induction, and also can associate with the 
plasma membrane and enter the cell with ease.
D.Non TPA-Tumour Promoters.
In terms of modulation of EGF /EGF-R binding, the most 
significant of the group of non-TPA-phorbol esters is Palytoxin.
In Swiss 3T3 cells, this agent has been demonstrated 
to reduce EGF binding to both low and high afinity EGF-R's in a 
protein kinase C independent way (Olsen and Pledger, 1990 and 
W attenberg et.al., 1989) although the mechanism of reduction is 
not clear. It is thought to mediate this effect by inducing a 
sodium influx into the cell (Wattenberg et.al., 1989)which reduces 
EGF binding (Wattenberg et.al., 1989).
In Swiss 3T3 and Balb/c/3T3 cells, however,stimulation 
with PDGF or TPA reduces EGF binding in a manner which is not 
dependent upon external sodium concentrations. It is therefore 
likely that TPA and non-TPA phorbol esters have d ifferent 
mechanisms for reducing EGF binding to EGF-R.
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E-Photoact iva ted  Psora len s .
Psoralens activated by ultraviolet-A light (Laskin and 
Lea, 1991) reduce binding of EGF to EGF-R (Mermelstein et.al., 
1989 and Laskin and Lea, 1991). Binding is, however, reduced to a 
lesser ex ten t than that induced by phorbol ester  tumour 
promoters. How the reduction is brought about is unclear, but it is 
though t that phospho ry la tion  of EG F-R  by p ho toac tiva ted  
psoralens is involved. In addition, these agents seen only to bind 
to high affinity type EGF-R's (Yurkow and Laskin, 1987).
Geordias and Laskin have found that cells of the rat 
fibroblast cell line R6C1 (control cells) when compared to the same 
cells transfected with a retrovirus enncoding the beta-1 form of 
protein kinase C: R6PKC3 cells, the following can be observed 
(Geordias and Laskin, 1991): R6pkc3 cells were more sensitive to 
TPA than R6C1 cells, R6PKC3 cells do not recover from TPA 
dependent 125 EGF binding and finally , the twoclones were 
equally sensitive to phtoactivated psoralens.
This suggested to the above authors that TPA and 
photoactivated psoralens reduce EGF/EGF-R binding by different 
m echanisms, and that the photoactvated psoralen method does 
not involve protein  kinase C. Features which com plicate  the 
interpretation of the experimental results are that it is to be
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expected that different clonal isolates will have slighlty or even 
totally differing properties. Secondly, the R6PKC3, protein kinase C 
beta-1 containing cells have fewer EGF-Rs to start with.
F-Dimethylsuphoxide (D M . S .0.) .
In the human hepatoblastoma derived cell line:HepG2, 
DMSO cause a large reduction in the rate of growth, altered 
cellular morphology (cells are flat and spread), a reduction in the 
response to EGF at doses which do not effect EGF-R affinity 
(McGowan, 1988) and a large increase in EGF binding, without the 
corresponding inverse in proliferative reponse to EGF (Vesey et.al.,
1991).
Again high affinty type EGF-R's are prevented from 
binding EGF (Gladhaug et.al., 1988).
G . D exa met  has one.
Dexamethasone is a synthetic glutocorticoid (Oberg and 
Carpenter, 1989). In diploid human foreskin cells, this compond 
a lone has no e ffec t upon their ra te  of p ro l ife ra t io n  but 
significantly enhances the mitogenic effect of EGF. This is brought 
about by an increase in EGF binding to EGF-Rs (Baker et.al., 1978). 
Binding analysis revealed that the number of receptors
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stayed approximatley the same with and without dexamethasone 
treatment, suggesting that receptor affinity is increased by such 
treatment (Baker et.al., 1978).
5.3. EGF-R Transmembrane Signalling:The Activation of 
the Intrinsic Tyrosine Kinase of EGF-R. 
5.3.1 .Introduction.
Molecular biological analysis of EGF-R revealled that 
ligand binding and tyrosine kinase activities both reside in the 
same individual polypeptide molecule, and that the membrane 
spanninng domain of EGF-R crosses the plasma membrane only 
once (Carpenter, 1987). It is therefore important to explain how 
an ex trace llu lar  signal can be transm itted  over the plasm a 
membrane so that the tyrosine kinase domain is activated.
There have been two main theories propounded over 
recent years to explain this process-their accuracy is the subject 
of much controversy, not least of all because an understanding of 
this process will be a tremendous advance in the wider field of 
cellular signalling.
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Both models propose that ligand binding causes a 
change in the conformation of the extracellular domain of the 
receptor. The two current models are:
1.The Intracellular Activation Model.
This model states that EGF binding to the receptor
causess a conformational change in the EGF-R molecule:a vertical
dislocation of the transmembrane dom ain (Schlessinger, 1988). 
This causes that rate of catalysis of the intrinsic tyrosine kinase 
to be enhanced (Schlessinger et.al. 1978; Carpenter, 1985 and 
Bertics et.a l.,1988).
2.The Intermolecular Activation Model.
This model is based on the theory that EGF causes
individual EGF-Rs to cluster or oligomerise. Interactions between 
neighbouring EGF-R tyrosine kinase domains stabilized by EGF 
binding leads to the activation  of the k inase dom ain. No 
conformational changes are needed. This model is also known as 
the allosteric activation model or the allosteric oligom erization
model (Yarden and Schlessinger, 1987 ; Schlesssinger et.al., 1978 
and Carpenter, 1987).
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5.3.2.The Intramolecular Activation Model.
Evidence that the tyrosine kinase of EGF-R could be 
activated as a consequence of a conformational change(s) which 
occurs within the individual EGF-R molecule was first put forward 
by the B isw as group in 1985 (B isw as e t .a l . ,1985). These 
investigators used solubilized and purified EGF-Rs from A431 
cells. Their salient findings were firstly  that g lucose-gradient 
sedimentation analysis of the non-denatured solubilised receptors 
showed 2 EGF-R populations: 
i:7.7 S - Monomeric.
- Active tryosine kinase.
-Tyrosine kinase acivity is not enhanced by EGF. 
ii: 12 S -Dimeric.
-No tyrosine kinase activity.
-Adding EGF results in the creation of monomers which 
have an active tyrosine kinase moiety.
S e c o n d ly ,  in v i t r o ,  the  r a te  o f  E G F -R  
autophosphorylation does not depend on EGF concentration-that is 
to say that it follows zero-order kinetics. Finally, DTT treatment 
of the 12S form of the receptor showed that there were no 
d isulphide bonds between the two receptors which form the 
d im er .
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They concluded that:
1-Only monomeric receptors have an active tyrosine kinase.
2 -R ecep to r-recep to r  in terac tions cause a decrease  in kinase 
ac tiv ity .
3 -M o n o m e rs  e x h ib i t  a u to p h o s p h o ry la t io n  i .e . it is an 
in tram olecular process.
4-Monomers and dimers exist in a state of equilibrium. Addition 
of EGF increases EGF-R tyrosine kinase activity by shifting the 
equilibrium , towards monomers.
S ucrose-dens ity  g rad ien t  u ltracen tr ifuga tio n  of 
purified EGF-R in low concentrations of salt and 0.25M ammonium 
sulphate showed that upon addition of EGF monomeric EGF-R are 
the most common species (Koland and Cerione, 1988). If this 
monomeric form of the receptor is isolated from the gradient and 
the tyrosine kinase activity assayed in the presence of 0.25M 
amm onium  sulphate kinase activity is found to be dependent 
upon EGF concentration. How this may be effected is unknown 
(Koland and Cerione, 1988). In addition, non-denatured  gel 
electrophoresis revealled that most autophosphoryated EGF-R is 
monomeric (Koland and Cerione, 1988).
F u rthe r  ev idence  to support th is m odel is that 
Sphingosine is known to be able to stimulate tyrosine kinase
activty of EGF-R (Northwood and Davis, 1988), in a manner which 
is not dependent upon EGF-R oligom erisation (Northwood and 
Davis, 1988).
Y a rd e n  and  S c h l e s s i n g e r  a ls o  r e p o r t  th a t  
au tophosphory la tion  of EGF-R purified  from A431 cells is 
parabollic with time compared to EGF dependent phosphorylation 
which is concentration dependent. This led to their proposal that 
a u to p h o sp h o ry la tio n  is ac tiva ted  in tra c e l lu la r ly  w hile  EGF 
dependent EGF-R phosphorylation is activated as a result of an 
intercellular process. An important point to bear in mind is that 
autophosphorylation of EGF-R takes place upon various residues 
located in the C-terminal domain of the receptor (Carpenter, 1987 
and see Sections 5.6. and 5.8.). This therefore focuses attention on 
how the tyrosine kinase and cytoplasmic domains might interact.
There are some significant pieces of evidence against the 
in tram olecu lar  tyrosine kinase activa tion  m odel. This model 
requires that the binding of EGF to the extracellular doman results 
in a conformational change in that region and that the change is 
transm itted  via  a vertical d is loca tion  of the hydrophobic  
transmembrane domain. This is, however,unlikely or maybe even
impossible, when the following two points are considered:
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a-The transmembrane domain is bordered by charged amino acids 
(especially  im portant in this case are the prolines at the 
cytoplasmic face (Ullrich et.al, 1984)) on both faces of the plasma 
m em brane, which will prevent on therm odynam ic grounds its 
vertical m ovem ent within the p lasm a m em brane (Schlessinger,
1988).
b-This region at the DNA and amino acid levels is very variable 
between species (Livneh et.al., 1985). It can also tolerate a variety 
of alterations and still remain able to effect signal transduction: 
-Site directed mutagenesis to reduce the length and
composition of the transmembrane domain (Gill et.al., 
1985 and Bargmann et.al., 1986 (a) and (b))
-Generation of insulin receptor extracellular
domain/EGF-R transmembrane domain chimaeras 
(Riedel et.al., 1986).
This suggests that the transmembrane domain may be essential 
but is not by itself sufficient for transmitting signals across the 
p lasm a m embrane.
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5.3.3.The Intermolecular Activation Model.
EGF binds to EGF-R and as a consequence, there is a 
conformational change in the extracellular domain. Purifed EGF-R 
extracellular domains have recently been found to undergo such 
conform ational changes under these c ircum stances (Spaargaren
et.al., 1990 and 1991). It is held by some that oligimerization is an
inherent property of the ligand binding domain of EGF-R (Lax
et.al., 1991). The ligand binding domain has two functions: EGF
binding and oligomerization.
As a result of these changes in structure of the ligand 
binding domain affinity for EGF-R's is increased (Ullrich and 
Schlessinger., 1990). Cytoplasmic domains of adjacent receptors 
therefor interact and as a result, tryosine kinase activity is 
enhanced (Basu et.al., 1981).
Central to this model is the concept that EGF-R molecules 
have an in tr ins ic  ab ility  to form  o ligom ers (Y arden  and 
Schlessinger, 1987 and Honneger et.al., 1989). The theory is that 
oligomerization brings individual receptors into close proximity, 
and this therefore allows the tyrosine kinase dom ain of one 
recep to r  to phosp ho ry la te  ap p ropria te ly  the o ther  recep to r  
m olecule .
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Evidence for this model, at least in vitro, is provided by 
Honegger's group who co-expressed kinase positive and kinase 
negative EGF-R mutants in NIH 3T3 cells, which are cells that lack 
endogenous EGF-R's. Phosphopeptide mapping showed that the 
k in a se  n e g a t iv e  m u ta n t 's  a u to p h o s p h o ry la t io n  s i te s  are  
ph o sp h o ry la ted  and it is p resum ed  that th is is due to
phosphory la tion  by the EGF-R conta in ing  the active kinase
domain; that is to say cross-phosphorylation between the two
types of receptor molecule (Honegger et.al.,1988, 1989 and 1990).
A l th o u g h  it is s t i l l  fo rm a l ly  p o s s ib le  th a t  
autophosphorylation is mediated either totally or to some degree 
by an in tram olecu lar  m echanism  the above noted findings 
strongly support the idea that tyrosine kinase activity, and also
autophosphorylation of EGF-R (Schlessinger, 1988), and as a result 
this casts doubt upon the validity of the intramolecular activation 
m odel.
Further Evidence for the Intermolecular Activation Model.
1-W ithout EGF, receptors exist as monomers (Northwood and
D a v is ,1988).
2-EGF-R dimers have greater kinase activity and EGF affinity than 
m onomers (Yarden et.al. 1985 and Boni-Schnetzler and Pilch, 
1987).
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3-EGF induces EGF-R clustering:
-On the plasma membranes of intact cells
-Demonstrated biophysically (Zidovetzki et.al., 1981 and 
Flillman and Schlessinger, 1982).
-Demonstrated morphologically (Haigler et.al., 1978) 
-Demonstrated biochemically (Fanger et.al., 1989 and
Bonni-Schnetzler and Pilch, 
1987).
-In plasma membrane preparations (Spaargeren et.al.,
1990).
-In pure EGF-R preparations (Yarden and Schlessinger, 
1987 and Lax et.al., 1989).
4-Monoclonal antibodies against EGF-R activate the kinase domain 
of the receptor and stimulate DNA synthesis in quiescent cells 
(Carpenter, 1989).
5 -Cross-linking with antibodies or lectins or chemicals results in 
enhancement of phosphorylation and also mitogenesis (Schreiber 
et.al., 1983).
6-Im mobilization of EGF-R prevents EGF activation of kinase 
activity (Yarden and Schlessinger, 1987).
7-Induction of EGF-R dimerization by anti-EGF-R antibodies is 
correlated with EGF-R kinase activation (Spaargaren et.al., 1990), 
and visa versa.
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8 -n e u . which is closely related to EGF-R is oncogenic due to a 
m utation in its transmembrane domain (reviewed in Carpenter 
et.al., 1991). This mutation causes the neu proteins to aggregate 
with a concomitant increase in tyrosine kinase activity (Weiner 
et.al., 1989). The proto-oncogenic neu  tyrosine kinase can be also 
stimulated by bivalent antibodies (Yarden, 1990) and EGF-R's and 
neu can form heterodimers (Goldman et.al., 1990).
9 -Wild type and mutant EGF-R can heterodimerize with H E R -2  in 
an EGF dependent manner, an effect tyrosine phosphorylation of 
proteins. If the EGF-R mutant lacks the cytoplasmic domain, 
however, heterodimerization occurs and tyrosine kinase activity is 
inhibited (Spivak-Kroizman, et.al., 1992). This implies that EGF 
dependent heterodim erization causes signals to be transduced 
depending on the exact nature of the components in the plasma 
m e m b ra n e .
10-Dimerization of EGF-R monomers by EGF has been reported to 
be second order in receptor concentration as is the rate constant 
for this reaction and the detectable  tyrosine k inase  activity 
(Canalis, 1992). The author concludes that because of the fact that 
all the perameters change together, then dimerization of EGF-R 
and activation of tyrosine kinase activity are indistinguishable 
upon EGF addition.
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Recently, EGF-R mutants have been created whereby
the basic amino acids at the cytoplasmic face of the receptor have 
been either deleted or deleted and replaced with neutral amino
acid residues (Yamane et.al., 1992). Removal of these residues in
rodent fibroblasts had the effect of greatly  inhib iting  EGF
dependent tyrosine phosphorylation of EGF-R. When EGF was 
added to these cells, the mutant receptor showed no morphological 
alterations as did cells containing the wild type receptor (Yamane 
et.al., 1992). The implication is, therefore that the basic residue in 
this domain of the receptor are very important in the transduction 
of signals by EGF-R, possibly through the topology of the receptor 
in the plasma membrane
In cell lysates, altering the lipid composition of the 
plasma membrane can modify ligand affinity and basal kinetic 
activity (Downward et.al., 1984), thus suggesting an active role for 
the tran sm e n m b ra n e  dom ain  in s ig na l  t ra n sd u c t io n  and 
confirming an intramolecular activation model for this process.
The question of EGF-R s tyrosine kinase activity, it's 
activation will be discussed in Chapter 5.
1 2 3
5 .3 .4 . Summary.
The subject of EGF-R tyrosine kinase activation is a 
highly contentious one. Arguments for and against each model are 
strong. It is likely that future research will prove certain elements 
of each activation model to be correct, and so the accurate picture 
of how this receptor's tyrosine kinase activity is activated will 
really be a synthesis of each model.
1 2.4
5.4.The Protein Kinase Activity of EGF-R.
5 .4 .1 .Introduction.
In addition to it’s role as a growth factor receptor, 
EGF-R can act as an enzyme: phosphorylating tyrosine residues on 
a number of celluar proteins. This has been previously outlined. 
The tyrosine kinase activity of EGF-R is central to many aspects of 
it's functioning. EGF-R is also thought to be closely involved in the 
process of carcinogenesis-it 's tyrosine kinase activity is believed 
to be pivotal in this process too.
A thorough understanding of this ability of EGF-R to 
phosphorylate tyrosine residues, and how this may be regulated 
is therefore vital to an understanding of how EGF-R works in 
normal circumstances and also how it may be involved in various 
pathological states.
The next few sections address the following points:
1-The tyrosine kinase activity of EGF-R.
2-The inhibition of protein kinase activity.
(N.B. For reviews on the equally as important dephosphorylation 
of proteins, see Alexander, 1990. Tonks and Charbonneau, 1989 
and Hunter, 1989 deal with protein tyrosine phosphatases).
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5.4.2.Protein kinases.
The phosphory la tion  of p ro te ins  (and the reverse  
reaction) is a vital intracellular regulatory  mechanism. Protein 
kinases effect this regulation by phosphorylating certain amino 
acid residues: Ser, Thr or Tyr in target proteins.
The first protein ty rosine  k inase  activ ities  to be 
intensively studied were those of the viral transforming proeins: 
the acutely  transform ing re troviruses. In the next phase of 
research, attention was turned to the protein tyrosine kinase 
activ ity  dem onstra ted  to be assoc ia ted  with growth factor 
rec ep to rs .
5.4.3.Functioning of Receptor Tyrosine Kinases.
A-Receptor Tyrosinse Kinases and Cellular Siganlling.
Ligand binding causes:
1-Increase in ion and glucose uptake.
2-Stimulation of membrane kinases.
3 -P inocy tosis .
4-M em brane rufffling.
5-Cytoskeletal alterations.
6-Morphological changes.
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7-Glycolysis.
8-Polyam ine synthesis.
9-Phosphoryalton of Ribosomal S6 protein.
10-G ene t ran sc r ip tio n , for e x a m p le : -m v c / f o s  after about 2 
minutes.
-protein/RNA/DNA synthesis within 3-20 hours (Rosen et.al.,
1 9 83 )
These plieotropic cellular responses result ultimately in 
cell cycle progression, DNA synthesis and cell replication. To do 
this, receptor tyrosine kinases of the third group need exposure to 
their cognate ligand for at least 30 mintues, and type 1 and type 2 
receptor tyrosine kinases need exposure for a unbroken period of
at least 8 hours. Receptor tyrosine kinases can be either inducers
of COMPETENCE such as PDGF orinducers of PROGRESSION such as 
EGF, (Pledger et.al., 1973). For example, PDGF can be mitogenic in 
NIH 3T3 cells w ithout other factors being present and can 
u n iq u e ly  s t im u la te  p ro te in  k in a s e  C by in c re a s in g  
phosphoinositide hydrolysis (Habenicht et.al., 1981).
Tyrosine kinases can also cause RNA production for
example of secreted proteins (Cooper et.al., 1985). Transcripts for
c -fo s  and c -m v c  can be detected witin 5 minutes and 1-2 hours 
respectively which suggest that they may be involved in the
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control of cellular proliferation. D ifferent ligands induce these 
genes to different levels,for instance in all cell types, PDGF, FGF 
and PMA all induce c-mvc (Greenberg et.al., 1984). In mouse 
fibroblasts, and EGF responsive cell lines, PDGF is more potent 
than EGF and insulin is ineffective  at stim ulating  c - m v c  
transcription (Mueller et.al., 1991).
B-Protein Tyrosine Kinases and Development. 
i. Introduct ion .
It seems that receptor tyrosine kinases are involved in 
controlling cellu lar differentiation and cell- to -ce ll in teractions, 
especially  during embryogenesis (Pawson and Bernstein, 1990). 
Evidence for this includes:
1-R ecep to r tyrosine k inase genes are h ighly  evo lu tionarily  
conserved (reviewed in Pawson and Bernstein, 1990; and Sibley, 
et.al., 1988).
2-Receptor Tyrosine Kinases and their ligands are expressed in 
vertebrate embryogenesis (Pawson and Bernstein, 1990).
3-Receptor Tyrosine Kinases are expressed in specific cell lines, 
which im plies that they m ediate  l ineage specific  functions 
(Pawson and Bernstein, 1990).
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Development is a two fold process which requires the 
restriction of totipotency and the acquisition of the abiity to
differentiate down specific lineages. These processes depend on 
changes in gene transcription and signal generation. This is the 
area in which tyrosine kinases are believed to exert some 
considerable influence: by transducing signals which determine 
cell fate.
To study this process, mutation of the receptor tyrosine 
kinase or the ligand or the downstream target(s) for the kinase, 
has been carried  out, lead ing  to the e s tab lishm en t of 
developm ental mutants of a num ber of different species. The 
developm enta l m utants are equ iva len t to and depend upon
changes in the sending, receiving and response to positional cues
m ed ia ted  by recep to r  ty rosine  k inase  s ignal transduction
p a th w a y s .
To summarise then, receptor tyrosine kinases regulate 
cellular differentiation in response to local and environmental 
signals.
12.9
i.i.The Involvement o f  EGF-R Tyrosine Kinase In Ontogenesis.
Ontogeny is the history of the developm ent of an 
indiv idual organism. It is believed that tyrosine kinases are 
involved in this process.
In the Ovine foetal lung, EGF-R has been demonstrated 
immunohistochemically, from 51 days of gestation, in the epithelia 
of the conducting airways (Johnson et.al., 1989 (b)). As gestation 
progresses, receptor levels increase then plateau, with the highest 
levels being found in the epithelium of the peribronchial glands.
Late in development of the Ovine lung, EGF is beleived 
to have a number of important effects for exam ple, it causes 
proliferation of epithelium of the trachea and bronchus (Johnson 
et.al., 1989 (a) and (b)).
To mediate these effects, EGF-R kinase activity  is 
thought to phosphorylate a number of different cellular substrates 
such as lipocortin-1. In a study carried out by Johnson et.al., 
lipocortin-1 and EGF-R immunoreactive sites co-localize ,and the 
authors conclude that EGF-R acts through lipocortin-1 (Johnson 
et.al., 1989 (b)).
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Some supporting ev idence for this hypothesis is 
provided by similar work carried out in human lungs which 
showed immunohistochemically that EGF-R and lipocortin-1 are 
both present within the epithelium which lines the conducting 
tubules of human foetal lungs (Johnson e t.a l.,1989 (a) and (b)). 
Although this suggests a role for either or both proteins in lung 
development for example, due to phosphorylation of lipocortin-1 
by EGF-R, it is at present not known how this might be brought 
abou t.
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5.5.The Tyrosine Kinase Activity of EGF-R. 
5.5.1.Introduction.
EGF-R has intrinsic tyrosine kinase activity (Cohen 
et.al., 1980; Schlessinger et.al., 1978). The enzymatic activity 
depends on ligand binding (Prywes et.al. 1986), and in intact cells 
EGF-R is constitutive phosphorylated upon a number of ser, thr 
and tyr residues. The purpose of this section is firstly to look at 
the phosphorylation ability of EGF-R in terms of ability  to 
phosphorylate both itself and other proteins. Secondly to examine 
factors which are thought to regulate this activity and finally to 
discuss the consequences to the cell and the organism as a whole 
of this kinase activity.
5.5.2.Autophosphorylation of EGF-R. 
A-The Process of EGF-R Autophosphorylation.
Autophosphorylation of EGF-R occurs in response to EGF 
(Carpenter, 1987 and King et.al., 1980).
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Autophosphorylation of any single tyrosine residue in 
EGF-R is not vital for EGF-R signal transduction. Clark et.al. 
showed that in EGF-R-/- CHO cells, signalling and mitogenesis is 
unchanged if this single tyrosine phosphoryla tion  reaction is 
prevented (Clark et.al., 1988). In addition, EGF can still bind and 
autophosphorylation can still take place but on the remaining 
tyrosine residues (Clark et.al., 1988).
Honegger's group carried out a series of experiments 
similar to those performed by Clark's group: they altered the 
a u to p h o s p h o ry la t io n  s ite s  in d iv id u a l ly  by s ite  d irec te d  
m utagenesis, converting the tyrosine to phenylalanine residues 
and transfected them into EGF-R -/- NIH 3T3 cells (Honneger 
et.al., 1988).
The results were that if one tyrosine residue is altered, 
EGF-R are still expressed at the plasma membranes. The receptors 
thus expressed are are of both the low and high affinity types, 
and they are responsive to PM A.
The receptors have EGF dependent tyrosine kinase
ac tiv ity :  both a u to p h o sp h o ry la tio n  and p h o sp h o ry la tio n  of
exogenous substrates. The receptors allow normal internalization
and degradation patterns. Finally, the receptors are mitognic to
EGF, but at a lower concentration of EGF than that required for
mitogenesis by normal receptors.
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So, except: for the fact that the mutant EGF-R's are more 
sensitive to EGF than normal receptors, allowing or preventing 
autophosphorylation at individual tyrosines has no real effect 
upon EGF-R signal transduction (Honneger et.al., 1988).
This is consistent with the idea that autophosphorylation 
acts as a positive feedback inhibition process; i.e., it reduces the 
Km of kinase substrates which increases kinase activity at low 
substrate concentra tions-the mutation derepresses this function. 
The finding that the mutated receptor has increased mitogenicity 
at low EGF concentra tion  suggests that au tophosphory la tion  
establishes a stimulation threshold which must be exceeded to 
induce a mitognic response (Honegger et.al., 1988).
In terms of autophosphoryla tion  and tyrosine kinase 
activity, the creation of 3' co-terminal mutations identified in 
addition the 3 autophosphorylated Y residues listed above, a 
fourth residue: Y992 which is autophosphorylated (Walton et.al., 
1990). The mutated receptor show an increase in tyrosine kinase 
activity against exogenous substrates in vivo, except when Y992 is 
m utated. In this case, the result is a total abolition of all 
detectable EGF dependant tyrosine phosphorylation of proteins 
(W a l to n  e t .a l . ,  1 990). Such  s tu d ie s  s u g g e s te d  th a t  
autophosphorylation could have an inhibitory function.
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Gill et.al. suggest however, that autophosphorylation 
increases tyrosine kinase activity. Phosphorylation of EGF-R can 
be inhib ited  at high concentra tions o f exogenous peptide 
s u b s t r a te .  T h is  e f f e c t  can  be r e l i e v e d  by in i t i a l  
autophosphorylation of EGF-R (Gill et.a l.,1985). The suggestion is 
that autophosphorylation causes a loss of some type of constraint 
and this allows a substrate access to the active site of EGF-R.
How such effects might be brought about is not known. 
Y992 is located at the acidic, alpha-helical region of the protein. 
This region is vital for ligand induced receptor interaction, which 
suggests that Y992 may be involved in this process (Chen et.al.,
1989). Two alternative models are that a non-phosphorylated  
EGF-R C-tail has affinity for the tyrosine kinase domain. 
Phosphorylation reduces this affinty, so the enzym e becomes 
available for interaction with substrates (Hsuan et.al., 1989). 
Finally, the C-tail may recognise substrates for tyrosine kinases 
(Pandiella et.al., 1988), for example phospholipase C and GAP 
protein (Schlessinger et.al., 1988).
Bertics and Gill showed that autophosphorylation caused 
an increase in kinase activity of EGF-R:Vm ax was increased 
(Bertics and Gill, 1985). The ability to phosphorylate exogenous 
substrates was assayed as a function of the autophosphorylation 
s ta te .
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The resulting kinetics showed firstly that, at low ATP 
concentra tions, the double reciprocal plot o f tyrosine kinase 
activity  against the amount of unphosphoryla ted  EGF-R was 
hyperbolic i.e. ATP seems to activating the kinase. Secondly, at 
high ATP concentrations, autophosphorylation is increased and the 
kinetics are linear.
Exogenous substrates appear therefore to inhibit the 
r e c e p t o r  a u t o p h o s p h o r y l a t i o n  r e a c t i o n  a n d  th e  
autophosphorylation sites therefore seem to be able to act as 
competitive inhibitors/alternative substrates against the peptide 
su b s tra te s .  B e r t ic s  and G ill  th e re fo re  c o n c lu d e d  tha t  
autophosphorylation  releases a com petitive  constra in t, so that 
phosphorylation of exogenous substrates is facilitated (Bertics and 
Gill, 1985). Precedents for such a process are known: insulin 
receptor (Rosen e t .a l . ,1983 and Yu and C zech ,1984), Rouse 
Sarcom a Virus (Purchio e t .a l . ,1983), Fu jiam a Sarcom a Virus 
(Weinmaster et.al., 1986) and erb-B (Gilmore et.al., 1985).
It would therefore seem that autophosphorylation sites 
com pete wih exogenous substrates for the substra te  binding 
region of the enzyme. Autophosphorylation releases an internal 
constraint so allowing the substrate access to the catalytic domain 
(Honneger et.al., 1988).
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To complete this review of this very controversial topic, 
i t  shou ld  be s ta ted  tha t som e in v e s t ig a to r s  fee l that 
autophosphorylation has no effect at all upon the tyrosine kinase 
activity of EGF-R (Downward et.al., 1984) on either purfied or 
plasma membrane bound EGF-R prepations (Cassel et.al., 1983).
MTLn is a metastatic rat mammary adenocarcinoma cell 
line (Lichtner et.al., 1992). EGF-R is found to be phosphorylated 
only in intact cells and it is though that the inhibition of this 
process is active( Lichtner et.al., 1992). Different forms of EGF-R 
were found to exist in this somewhat unusual cell line: 1 is 
420-480 KD and the other is 95 KD, and the smaller protein is the 
one which is never phosphory la ted  (L ich tner  e t.a l.,  1992). 
Although the origins of these EGF-R types are unknown, their 
existence suggests that EGF-R signal transduction can proceed 
without receptor autophosphorylation.
5.6.The Phosphorylation of EGF-R.
5.6.1.General Details.
As well as EGF-R gene amplification, control of EGF-R 
gene expression and ligand binding, phosphorylation of EGF-R by a 
num ber of d ifferent agents can regulate  its acitivty. Tyrosine, 
serine and threonine residues are phosphorylated which implies 
that there are a number of kinases involved, acting coordinately 
(Cochet et.al., 1988 (a) and (b)). This chapter will look at tyrosine 
phosphorylation, the phosphorylation of the other residues will be 
dealt will separately in Section 5.8.
W hen cultured cells are considered, EGF dependent 
tyrosine phosphorylation of EGF-R is observed to occur rapidly 
and is observed to be maintained for significant but variable 
periods of time: one hour in NIH 3T3 cells (Sturani et.al.,1990) and 
about six hours in A431 cells (S turani e t.a l. ,1988)i.e . this 
phenomenon is cell type specific. A small amount: approximately 
twenty percent of the total EGF-R population are tyrosine 
phosphorylated that is to say are active, in response to EGF 
( C a r p e n t e r  e t . a l . ,  1 9 8 7 ) .
As in the case of liver regenera tion , a num ber of 
different kinases are probably involved-but dephosphorylation 
reactions will also occur.
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5.7. Tyrosine Phosphorylation of EGF-R by Exogenous 
Substrates.
The following table lists those agents or phenomena 
which are currently believed to cause the EGF-R to become 
tyrosine  phosphorylated:
Table Three: Agents Which Tyrosine Phosphorylate
EGF-R.
Agent Reference(s).
EGF-Like Growth Factor Higashijama et.al., 1992.
Hyper-Osmotic Shock King et.al., 1985 and 1989.
Src Wasilenko et.al., 1990.
Tumour Necrosis Factor Donato et.al., 1989.
TGF-Alpha Reynolds et.al., 1981.
5.8.Serine/Threonine Phosphorylation of EGF-R.
In addition to phosphotyrosine, EGF-R is phosphorylated 
upon serine and threonine residues (D ow nw ard et.a l., 1984; 
Hunter and Cooper, 1987 and Carpenter, 1987). Such levels of 
phospho threon ine  and phosphoserine  increase  upon treatm ent 
with EGF (Downward et.al., 1984).
The k inases respo nsib le  for these  phosphory la tion  
events are as yet unknown, as are to a large exetent, the 
consequenecs of these reactions. They do, however, appear to 
have an important role in the regulation of EGF-R functioning.
5.8 .1 .Threonine 654.
Treating intact 32P-labelled cells with phorbol 
esters, cause increased phosphorylation of serine and threonine 
residues (Hunter and Cooper, 1987 and Davis and Czech, 1985 
(a),(b) and (c) ). The same residues on EGF-R are phosphorylated 
by protein kinase C alone, as by phorbol esters in A431 cells 
(Cochet et.al., 1984 (a) and (b)).
T654 is located on the carboxyl face, nine amino 
acids from  the plasm a membrane. This location between the 
ex tracellu lar and cytoplasmic domains mean that it is ideally 
suited to effect the interaction between the two domains (Hunter 
and Cooper, 1987).
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Phosphorylation of T654 can occur via protein kinase C 
dependent and independent pathways and lead to loss of high 
affin ity  type receptors, reduced tyrosine k inase activ ity  and 
transient internalization of receptors i.e. EGF-R down -regulation, 
(Downward et.al., 1984 and Beguinot et.al., 1985).
T654 is believed to mediate its effects by interfering
with the interaction between the basic region of EGF-R and the 
phosphholipid heads in the plasma membrane (Hsuan et.al., 1989).
The cellular consequences of EGF-R tyrosine and serine 
phosphorylation are, as previously stated largely unknown. The 
theories that are presently held are also conflicting. Bowen's 
group maintain that phosphorylation of T654 in vitro leads to a 
reduction in tyrosine kinase activity of the receptor (confirmed by 
the findings of Cochet et.al., 1988 (a); Davis et.al., 1988 and
Downward et.al., 1984).
Livneh et.al. treated NIH3T3 cells with phorbol esters
and noted that T654 became phosphorylated and EGF-R signal
transduction was inhibited (Livneh et.al., 1988). The constitutive 
overexpression of phosphorylated T654 in CHO cells (Livneh et.al., 
1988) allowed the effect of phosphorylation of EGF-R in the 
absence of protein knase C activation to be studied separately for 
that phosphorylation of T654.
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It w as s u b s e q u e n t ly  fo u n d  th a t  c o n s t iu t iv e  
phosphoryla tion  of EGF-R at T654 blocks m itogenic cellu lar 
signalling, implying that phosphorylation of EGF-R at T654 in 
in tac t  ce lls  causes inh ib it ion  of E G F stim ula ted  ce llu la r  
p ro life ra t io n .
On the other hand though, evidence that T654 is not 
vital for negative regulation of the tyrosine kinase activity of 
EGF-R is provided by Friedman's group (Friedman e t.a l.,1989). 
These authors showed that the calcium ionophore A23187 and the 
non-PMA type phorbol ester Thapsigargin (Friedman et.al., 1989) 
can reduce the level of EGF binding and autophosphorylation in 
A431 cells, in a protein kinase C independent manner. T654 
therefore is not the only site involved in the negative regulation of 
the enzymatic activity of EGF-R and EGF binding.
Activators of Protein kinase C phosphorylate EGF-R at 
T654 and this may also lead to the down regulation of EGF-R 
tyrosine kinase activity, for example in cytokine treated human 
gingival f ibroblasts (Bird and Saklatval, 1989) cells exhbit 
reduction in EGF/EGF-R binding in a protein kinase C dependent 
manner where EGF-R numbers are reduced (Bird and Saklatvala, 
1990). In addition to this effect, these agents cause the EGF-R to 
become Ser/Thr phosphorylated  too and this process is not 
dependent upon protein kinase C which implies that T654 is not
the only residue that is significant in this process.
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5.8 .2 .Threonine 669.
This is a major site of phosphorylation of EGF-R 
(Countaway et.al., 1989 (a) and (b) and Heiserman and Gill, 1988). 
Close to T669 are two prolines. This site: -pro-leu-thr-pro- is 
phosphorylated by EGF, PDGF and phorbol esters. Phosphorylation 
m ig h t  in h ib i t  a p ro te in  p h o s p h a ta s e ,  m e d ia te  E G F-R  
transmembrane signalling leading to a change in the conformation 
of the receptor or activate a protein kinase. There is some 
evidence for this theory (Carpenter et.al., 1987) and some against 
it too (Davis et.al., 1988; Livneh et.al., 1988 and Cochet et.al., 1988 
(a) and (b)).
T 669  p h o s p h o ry la t io n  m ay r e g u la te  E G F -R  
in te rn a l iza tio n  and ty rosine  p h o sp h o ry la tio n  of exogenous 
substrates (Heiserman and G ill,1988 and Northwood et.al., 1991). 
Exactly how such a phosphorylation event might be carried out is 
not know though. The sequence outlined above is unusual and a 
rarely occuing phosphorylation site (Heiserman and Gill, 1988). 
N orthwood et.al. propose that the fo llow ing two kinases are 
responsible: MAP2 kinase and EGF-R Thr669(ERT)Kinase. ERT 
K in a se  p h o s p h o ry la te s  o f  T 6 6 9  in the  se q u e n c e
-KRELVEPLT669PSGEAPNQALLR- (Downward et.al., 1984).
5 .8 . 3 .Phosphorylation at Serine and Threonine Residues.
Certain agents, listed in the table which follows, are 
known to phosphorylated the serine and threonine residues of 
EGF-R.
T able Four: A gents W hich M edia te  Ser/Thr
Phosphorylation of EGF-R.
Agent Reference
Ceramide Hannun et.al., 1986;
Okazaki et.al., 1987;
Protein Kinase C Iwashita et.al., 1984 and 1990;
Downward et.al., 1984;
Davis et.al., 1988.
Phorbol Esters Lee et.al., 1988 and 1989;
Okadaic Acid Biajolan and Takai, 1988.
Shingosine Davis et.al. 1985 (a), (b) and (c).
Table Five: Phosphorylation of EGF-R by Exogenous 
Agents.
Substrate
Enolase
Erythrocyte Band 3
Ezrin
Gastrin
G lu c o s e -6 -p h o s p h a te  
Dehydrogebase
Growth Hormone 
Integrin
Lactate Dehydrogenase 
Lipocortinl
M icrotubule A ssoc ia ted  
Protein Kinase 2
Reference 
Reiss et.al., 1986.
Shiba et.al., 1986.
Gould et.al., 1986 and 1988.
Baldwin et.al., 1983 (a) and (b).
Napier et.al., 1987.
Baldwin et.al., 1983 (a) and (b). 
Bellas et.al., 1991.
Reiss et.al., 1986.
Abdcl-Ghany et.al., 1989.
Takishima et.al., 1991 and 
Sano and Kitajima, 1992.
Middle T Antigen Segawa and Ito, 1983.
Myosin Light Chain Gallis et.al., 1983.
P h o sp h o g ly c e r a te
Mutase Reiss et.al., 1986.
Phospholipase C Wahl et.al., 1987, 1988, 1989 (a) and (b).
Progesterone Receptor Ghosh-Dastidar et.al., 1984.
Raf-1 Baccarini et.al., 1991.
S o d iu m /H y d ro g en
Exchanger Sardent et.al., 1991.
Vinculin Bellas et.al., 1991.
(N.B.: Some as yet unidentified cellular proteins have been found 
to be phosphorylated by EGF-R: in neural cells (Girault et.al., 1992) 
and in NIH 3T3cells which contain eg f-r  or e g f /e rb -B 2 constructs, 
p97, p68, p67, p61, p56 and p23 (Fazioli et.al., 1992)).
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5.9 .The Regulation of EGF-R Tyrosine Kinase Activity.
E G R -R  k in ase  a c t iv i ty  can  be re g u la te d  by 
phosphoryla tion  (auto-phosphoryla tion , tyrosine phosphorylation 
and serine and threonine phosphorylation), ligand binding and 
EGF-R metabolism events (internalization and degradation).
It is also subject to regu la tion  by a num ber of 
heterologous stimuli in the process known as Transmodulation 
(C arpenter, 1987). Exactly  how recep to r  transm odula tion  is 
brought about is not known, but it is most likely to be due to the 
interaction of different signal transduction pathways (Di Marco 
et.al., 1989 and Wong et.al., 1989 (a) and (b)). Protein kinase C 
probably has a large role to play too (Hicks et.al., 1989 and 
Northwood and Davis, 1988 and 1989).
Table Six:Agents 
Activity of EGF-R.
Agent
cA M P/cA M P dependent 
kinase(Protein kinase A)
EGF
Gangliosides
4-Hydroxytamoxifen
M ullarian In h ib iting  
Substance
Neu
Phorbol Esters
known to Regulate the Tyrosine Kinase
Reference
Iwashita et.al., 1984 and 1990; 
Rackoff et.al., 1984;
Walker and Pike, 1987;
Gill and Lazar, 1981;
Chinkers and Garber, 1986; 
Schaudies et.al., 1985.
Song et.al., 1991;
Feitzi and Childs, 1985.
Engel and Young, 1978;
Wakeling et.al., 1989;
Freiss et.al., 1990.
Cigarroa et.al., 1989.
Wada et.al., 1990;
Weiner et.al., 1989.
Northwood and Davis, 1988.
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PDGF Decker and Harris, 1989; 
Walker and Burgess, 1988; 
Wran et.al., 1980;
Olashaw and Pledger, 1988.
Protein kinase C Northwood and Davis, 1988 and 
1989 and 
Schechter et.al., 1984.
Second Messengers Verheijden et.al., 1990.
Src Wilson et.al., 1985 and 1989; 
Kaplan et.al., 1988.
SH2-Domains Anderson and Marchesi, 1985.
Sphingosine Davis et.al., 1985 (a), (b) and (c) 
and 1988.
TGF-Alpha DiMarco et.al., 1989;
Wong et.al., 1989 (a) and (b).
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5.10.The Biological Consequences of the Activation of 
EGF-R Tyrosine Kinase Activity. 
5.10.1 .Introduction.
The activation of the enzyme actvity of EGF-R has a 
number of biochemical effects which eventually culminate in the 
replication of the DNA and the cell itself (Gill et.al., 1985). Exactly 
how this kinase activity is involved in this process is not known.
It seems functional EGF-R tyrosine kinase activity is 
vital for all (or at least a majority)of the metabolic effects of EGF-R 
(Yarden and Ullrich, 1988). The task which now remains-is to 
identify the cellular elements which are located down-stream of 
this kinase.
W hat follows is an attempt to appraise the current 
understanding of the consequences for a cell and the organism as 
a whole of the activation of the kinase activity of EGF-R.
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5.10.2.EGF-R Tyrosine Kinase Activity and EGF-R Signal
Transduction.
EGF-R's catalytic function alone is not sufficient for signal 
transduction-carboxyl elements confer signal specificity. This is 
demonstrated by the sixty three amino acid C-terminal deletion 
mutant i.e. an EGF-E with no autphosphorylation sites. This 
recep to r  has no norm al ionic s igna lling , insito l  phosphate  
turn-over or DNA synthesis (Schlessinger et.al., 1978). This 
activity is however,essential for signalling. Some of the presently 
accepted evidence for this point of view is as follows.
The lys-721 forms a crucial part of the ATP binding 
domain. Mutation from L to M here and the transfection of this 
construct into EGF-R -/- mouse L cells (B82) and CHO cells (Chen 
et.al., 1987) had the following effects:
-mutant EGF-R is expressed an wild type levels.
-mutant EGF-R binds EGF-R with wild type affinity, 
-mutant EGF-R is 170 K.D.
-mutant EGF-R has no intrinsic tyrosine kinase activity 
whatsoever. There is no evidence of ligand
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dependent-endocytosis.
-gene transcription.
-cell replication.
-intracellular calcium increase.
A L721AcDNA contruct transfected into NIH3T3 cells 
(Honnegger et.al., 1988) had the following effects: no tyrosine 
kinase activity, normal receptor processing and normal expression 
of the receptor at the plasma membrane. In addition, the receptor 
cannot stimulate early responses (such as Na+/H+ transporter 
activation, calcium signalling and inositol phosphate formation) 
and late responses (like DNA synthesis, cell replication, focus 
formation and gene expression: c-fos and c - m v c l .
This suggests that the tyrosine kinase activity is vital 
for EGF-R signal transduction and certain biolgical effects.
Premature termination mutants of EGF-R lacking the
C-terminal and kinase domain (Velu et.al., 1980, 1989 and 1990)
have reduced biological activity but again the num ber of
receptors and early events were in the wild type range. This
suggested that the C-domain is involved in the regulation of EGF-R
tyrosine kinase activity, in a positive sense.
The N-terminal region also has a vital part to play in
this process. Consider the example of v - e r b - B . where N-terminal
truncation has resulted in the oncogenic activation of the protein
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(see Downward et.al., 1984 and M aihle and Kung, 1988). The 
constitu tive ly  active, EGF independent recep to r that is thus 
generated (Raines et.al., 1988 and Wells et.al., 1988) renders the 
gene capable of inducing ervthroblastomas.
5.10.3.Phosphatidyl Inositol Metabolism.
In A431 ce lls ,  EG F causes  the  b reakdow n  of 
polyphosphoinositides, the production of inositol phosphate and 
also an increase in PIP levels which implies the activation of 
phosphatidylionsitol kinase too (Pike and Eakes, 1988).
Cholera toxin selectivley inhibits the second of the 
effects noted above but phosphatidyl inositol breakdown remains 
unaffected by it. Pertussis toxin affects neither process (Pikes and 
Eakes, 1987). This subject is discussed in Section 5.12.
5.10.4.Phospholipase C Regulation.
EGF causes phospholipase C-Y to be activated, in a 
process which is dependent upon the tyrosine kinase activity of 
EGF-R (Moolenaar et.al., 1988). If pure EGF (and PDGF) and 
phospholipase C-Y are incubated together then phospholipase C-Y 
b e c o m e s  p h o s p h o r y l a te d - th i s  o c c u r s  at p h y s io lo g ic a l  
concentrations of EGF (Meisenhelder et.al., 1989 and Nishibe et.al.,
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1990 (a) and (b)). The phosphorylations take place on particular 
tyrosine residues of phospholipase C-Y, which has suggested to the 
above authors that this is the signal which effects growth factor 
signal transduction.
These findings have been supported by other work 
which has shown that EGF enhanced EGF-R/phospholipase C-Y 
association in an EGF dependent manner (Margolis et.al., 1989 (a) 
and (b)and 1990). This work was taken a little further in that it 
was shown that if tyrosine kinase defective EGF-R's were used 
this association was not seen (Margolis et.al., 1989 (a) and (b)and
1990). The inference was made that the tyrosine kinase activity of 
EGF-R is vital to allow the phosphorylation of phospholipase C-Y.
The current hypothesis is that the association between 
these two proteins forms the equivalent of an enzyme/substrate 
in te rm e d ia te .
5.10 .5.G-Protein Phosphorylation.
Do EGF-R's associate with G-proteins and so transduce 
EGF signals?. Again this is a highly controversial area. EGF-R does 
phosphorylate  a 22-25K.D protein (Gp)which has high affinity 
(Kd=50-100nm) GTP binding (see Section 5.15.). This work used
phospholip id  vesicles reconstitu ted with pure EGF-R tyrosine 
kinase domain and a number of different GTP binidng proteins to 
see if the polypeptides could be a substrate for the kinase.
The results indicated that indeed tyrosine residues 
within this protein were ph osphory la ted-they  were the only 
res idue  to be phosphory la ted . Im portan tly ,  phosphory la tion  
depended upon the insertion of the G-protein into the lipid 
b ilayer-ra is ing  the suspicion that the phospholip ids of the 
membrane in some way help to orient the kinase and substrate in 
an optimal manner.
GTP and GTPYS inhibit this phosphorylation reaction 
implying that the G-nucleotide occupancy is being affected. It 
could possibly alter the 22K.D. protein's conformation so reducing 
the chance that it may be phosphorylated.
Reconstituting EGF-R and Gp in platelets allows EGF 
dependent phosphorylation of Gp, and this process is sensitive to 
the addition of GDP and GTP analogues.
The theory is therefore that tyrosine phosphorylation of 
the Gp causes it to be released from the plasma membrane. This 
allows it to react with cytoplasmic effectors.
156
5.10.6.Cellular Proliferation.
EGF has been known for many years to stimulate 
prolferation of cells (Carpenter, 1987), but how this might be 
brought about is not known. It seems that intact tyrosine kinase
domains are vital for this process though (Chen et.al., 1987), since
the EGF-R mutant K721M cannot effect DNA replication and cell 
division (Chen et.al., 1987).
In addition, EGF dependent transcrip tion of specific 
genes is prevented and this may provide an important clue as to 
how EGF-R tyrosine kinase may be mediating this effect, for 
example, transcription of c-jun (Ouantin and Breathnach, 1988) is 
inhibited. These genes encode transcription factors (Curran et.al., 
1982) i.e. they orchestrate the transcription of other genes. Since 
their expression is initiated very early after exposure to EGF 
(Carpeneter,1987 and Gill et.al., 1985)this implies that if the are 
not expressed or are expressed aberrantly  in some way, the 
cascade of gene expression for which they are responsible (and
which cumulates in mitogenesis) will not be activated or will
follow different lines.
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EGF has been regarded as a progression factor (see
Section 5.4.9-A). These are agents which act after an initiating 
factor to cause mitogenesis-but which cannot induce mitogenesis
alone. Some research has now suggested that the quantity of the 
signal generated by EGF-R which is dependent upon the number 
of receptors present on the p lasm a m em brane is the crucial 
fea tu re  which allow s p ro life ra t ion  to be s tim ula ted  (Velu
et.a l.,1989). This concept of a stimulation threshold is borne out 
by the fact that in order for mitogenesis to occur, EGF/EGF-R must
be in contact for a significant period of time.
That the tyrosine kinase activity of EGF-R has a prime 
role here is hinted at by the following pieces of evidence. Firstly 
the L 721A  m utan t version  of the E G F-R  can n o t induce 
transcription of c -fo s  or c - m v c : the morphological changes seen 
normally and DNA synthesis (Honegger et.al., 1987 (a) and (b) and 
1988). An intact tyrosine kinase domain is essential for receptor 
tyrosine kinases of type I and III to have transforming ability
(Roussel et.al., 1987). This effect is enhanced by mutating the bl­
and C-termini (Roussel et.al., 1987).
Prevention of cytoplasmic acidification, through protein
kinase C activation of the Na+/H+ exchanger is vital for cell growth 
(Pouyssegur et.al., 1985).
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5.10.7.EGF-R Tyrosine Kinase and EGF-R Metabolism.
A.Introduction.
Receptors often show dow n-regulation in response to 
ligand binding (Gill et.al., 1985). In the case of EGF-R, the following 
sequence of events occurs (Schlessinger, 1986):
1-In the resting state, EGF-R are diffuse on the plasma membrane 
of the cell (Schlessinger, 1986).
2-EGF and EGF-R bind, in a temperature dependent manner.
3 -Receptor/ligand complexes exhibit rapid lateral mobilty.
4-Receptor/ligand complexes cluster in coated pits (Beguinot et.al.,
1984 and 1985)
5-Com plexes are internalized, form im g c la thrin-coated  vesicles 
(Haigler et.al., 1978; Schlessinger et.al., 1978; Carpentier et.al., 
1986 and 1987 and Hertel et.al., 1987).
6-Vesicles are uncoated.
7-Vesicles are acidified, forming endosomes.
8-Endosmes are sorted: they can be either recycled to the plasma 
membrane or are broken down in the lysosome (Goldstein et.al.,
1985 ; Carpenter and Cohen, 1990; and Beguinot et.al., 1984 and 
1985).
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The events of EGF-R metabolism are therefore clearly 
important to the functioning of EGF-R as a receptor for a ligand, as 
an enzyme and as a signalling molecule. Much evidence states that 
the tyrosine kinase activity of the receptor is vital for these 
various activities to take place. This will be discussed in the 
sections which follow.
B-EGF-R Internalization.
Biochemical evidence for EGF-R internalization was 
first provided by Carpenter and Cohen i n i 976 (Carpenter, 1987). 
They showed ligand/receptor internalization by determination of 
the course of bindning of 125-1 EGF to human fibroblasts at 37 
and 0 degrees centigrade. U nder these  cond itions, maximal 
binding occured at 45-60 minutes. At 37 degrees centigrade, 
however, if the labelled ligand and cells were incubated further, 
the amount of cell-bound radioactivity decreasd to a level of 
20-25% maximal. At O degrees centigrade there was no loss of 
cell bound radioactivity.
It was therefore postulated that after initial binding, 
the l ig a n d /re c ep to r  com plex  is in te rn a l ize d  and degraded  
intracellularly since cell bound labelled EGF was rapidly degraded 
to mono 1251-iodotyrosine at 37 degrees centigrade. At 0 degees 
centigrade, cell-bound 125-1 EGF was not degarded, but slowly 
dissociated from the cell.
At 37 degrees centigrade for 125 I EGF bindigng , 
followed by incubation at 0 degrees centigrade, almost no release 
of cell bound radioactivity could be detected. Degradation, but not 
binding requires metabolic energy. Degradation is inhibited by 
drugs which inh ib it lysosom al function ing : ch lo ro qu ine  and
ammonium chloride.
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When 1251 EGF was bound to cells at O degrees C, the 
ligand was much more accessible to surface reactive agents such 
as trypsin and EGF-Antibodies than at 37 degrees centigrade. 
Exposure of fibroblasts to EGF resulted in an apparent loss of 
plasma membrane receptors for EGF implying that the receptors 
are internalized too.
EGF-R tyrosine kinase activity is thought by many to
be essential for receptor internalization to take place. Some of the
evidence supporting this point of view is as follows. Firstly, 
L721M: an EGF-R mutant (Chen et.al., 1987)which has no tyrosine 
kinase activity shows no receptor internalization.
In addition , im m unofluo rescen t sta in ing  using 
anti-phosphotyrosine antibodies to reveal the proteins which have 
been tyrosine phosphorylated in response to EGF showed that 
tyrosine kinase active EGF-Rs are distributed evenly on the cell 
surface, and are endocytosed when EGF is added. EGF-R with no 
tyrosine kinase activity although are distributed evenly upon the 
surface of a cell in the absence of EGF when EGF is added, they 
remain on the surface (Glenny et.al., 1987 (a) and (b)).
Studies by (Chen et.al., 1987; Hari and Roth, 1987;
Honegger e t.a l. ,1988 and 1989 and Russell et.al, 1987) using
ty rosine  k inase  negative  EG F-R show ed ligand  dependen t 
internalization did not occur. Gill proposes that tyrosine
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phosphorylation mediated this effect by routing the receptor into 
a pathway which concludes with receptor mediated endocytosis 
o r  r e c e p t o r  r e c y c l i n g .
The kinase specificity of chim aeric EGF-R are 
determined by elements within the cytoplasm ic domain. These 
determ inants also affect the fate o f the EGF-R after it is 
internalized (Riedel et.al., 1988 and 1989).
Finally, site directed mutagenesis of T669 and 
S671 residues, sites of phosphorylation in EGF-R showed that 
they were involved in ligand dependent endocytosis (Heiserman 
et.al., 1988).
These observations are consistent with the need for 
phosphorylation of a cellular substrate(s) which is involved in 
endocytosis and autophosphorylation. This is a central tenent of 
the intramolecular model for the activation of EGF-R tyrosine 
kinase activity (See section 5.3.2.).
To summarise then, substrates vital for endocytosis 
need to be appropriately  phosphoryla ted; au tophosphoryla tion  
may be needed to allow EGF-R/endocytotic vesicle interaction or 
both au tophosphory la tion  and phopshory la tion  of a ce llu la r  
substate are needed for endocytosis.
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The situation may not be quite so straight forward 
though as there are reports that tyrosine kinase activity is not
needed for EGF-R internalization. Honneger and Felder found that
a tyrosine kinase defective EGF-R can still exhibit EGF dependent 
internalization (Honneger et.al., 1988, 1989 and 1990 and Felder 
et.al., 1990).
Using antibodies to p reven t phospho ry la tion  of 
EGF-R, shows that in the unphosphorylated state, the receptor can 
internalize in response to EGF (Sunada et.al., 1986) implying that 
the phosphorylation state of the receptor is not important.
However, abolishing the kinase activity associated 
with EGF-R by m onoclonal an tiphsophotyrosine antibodies 
preveted ligand induced receptor internalization (Glenney et.al., 
1987 (a) and (b))
WB-344 cells are non-transformed epithelial cells 
(Tsao et.al., 1984). They were used as a model for this process of 
EGF-R internalization and it was found that there was at least 
four stages through which EGF-R tyrosine kinase passes upon EGF 
binding (McCune and Earp, 1989).
Firstly there is kinase activation. This occurs within
seconds of EGF binding and is responsible for the main tyrosine
phosphorylation of EGF-R and it's internalization. A receptor
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conform ational change then occurs. A utophosphory la tion  and 
tyrosine kinase activities are reduced. All this occurs within about 
2-5 minutes of exposure.
Firstly kinase activity then becomes re-established. 
This takes place 10-30 minutes afer in ternalization and may 
depend on sequestration by EGF-R from cellular ATP pools as it 
moves into intracelluar vesicles. Finally, transfer of EGF-R to 
lysosomes takes place. This results in the total abolition of 
tyrosine kinase activity and may depend upon EGF-R degradation 
in the lysosomes.
The current theories for the suppression of EGF-R 
autophosphorylation activity are that a serine/threonine protein 
kinase may be activated. Very high EGF concentrations will be 
required though to mediate this effect, which suggests that EGF-R 
occupancy may be the important feature:the kinase is activated 
only if large numbers of EGF-R are occupied with ligand.
A conformational change in the EGF-R molecule could 
take place which reduces autophosphorylation activity, such as 
dimerization of receptors. Recent evidence sugests that the acidic 
environment of the endosome causes conformational changes in 
EGF-R (DiPaolo and Maxfeld, 1984).
An association of EGF-R and cytoskeletal elements is 
also possible (for further details, see Kwiatkowska et.al., 1991 and 
Van Bergen en Henegouw en et.a l., 1989). The cytoskeleton 
therefore inhibits EGF-R tyrosine kinase domain movement so 
reducing  it's activity. The endocytic pa thw ay/netw ork  that is 
established as a result is most dense at the plasma membrane.
The work of Chen has identified a putative EGF-R 
In ternalization  Domain (Chen et.al., 1987). It seem that the 
carboxyl domain has inhibitory elements for kinase activity and 
th a t  they  are ac tive  in the n o n -p h o sp h o ry la te d  s ta te . 
Autophosphorylation or phosphorylation by an exogenous agent 
causes the release of the inhibition to take place exposing the 
in ternalisa tion domain.
Removal of the C-terminal 174 amino acids allows 
the partial rescue of the tyrosine kinase -/- EGF-R internalization 
ability (Chen et.al., 1987 and later in this section).
It is not known if, when internalized, EGF-Rs are in a 
functional or a non-functional state, that is to say can they 
phosphorylate proteins?. This is a very important question since 
the tyrosine kinase activity of EGF-R is believed to be involved in 
a number of different intracellular processes. There is, however 
little actual evidence to support or refute such a point of view.
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The Role o f  the Carboxvl Domain in Internalization o f  EGF-R
Sequences here seem to be essential for EGF-R 
in te rnaliza tion . C-term inal truncation of the tyrosine kinase 
domain created receptor which cannot mediate* ligand dependent 
down-regulation (Gill et.al., 1985). A 44 amino acid truncation of 
EGF-R cannot undergo ligand dependent down-regualtion (Livneh 
et.al., 1986 (a) and (b) and 1987). In addition, EGF does not induce 
internalization of an extracellular domain e g f - r /v - a b l  tyrosine 
kinase domain chimaeric receptor (Prywes et.al., 1986).
A series of 3'-terminal detetions of egf-r showed that 
the distal boundary of the tyrosine kinase domain is at residue 
957 (Chen et.al., 1987). This is at an exon/intron junction (Haley 
et.al., 1987).
The 229 amino acids C-distal to residue number 957 
cause EGF dependent increase  in calc ium  leve ls , recep to r 
endocytosis and receptor down-regulation (Chen et.al., 1987). The 
48 amino acids located between residues 973 and 1022 determine 
calcium regulation and receptor endocytosis and have been named 
the "Calcium Internalization Domain" or "CALN".
Permanent cell lines exressing EGF-Rs with no CALN 
domains have been set up to allow it to be analysed. These studies 
showed that EGF induced EGF-R endocytosis and calcium
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mobilization are separate events with the later dependent upon 
E G F -R  t y r o s i n e  r e s i d u e  a u t o p h o s p h o r y l a t i o n .  T h e  
autophosphorykion of the C-terminus of EGF-R has been found to 
mediate EGF-R/phospholipase-C interaction via SH2 domains. The 
existance of this domain could therefore possibly couple the 
pathways of EGF-R tyrosine kinase activation to that of calcium 
signalling.
The 164 amino acids distal to the CALN domain have 
also been found to constitute an inhibitory region (Chen et.al.,
1987). The removal of these residues allows the internalization of 
kinase negative EGF-Rs via a low affintiy, high capacity pathway.
R esidues num ber 973 to 991 are vita l for 
in te rn a l iza tio n  and ca lc ium  in creases  due to a c e l lu la r  
redistribution of intracellular calcium and the opening of calcium 
channels in the plasma membranes of the cell (Chen et.al., 1987). 
The 18 amino acids of the CALN domain form a helical structure, 
bound by turns and within this region are contained 9 acidic 
amino acids. This structure greatly resembles that of GAL4 and 
G CN 4-yeast transcription factors (Ptashne et.al., 1986). These 
protein factors:i.e. their acidic helical motif sections act to couple 
enhancers to the transcription apparatus. The suggestion therefore 
is that this CALN domain couples ligand activated EGF-Rs to the 
calcium regulation and receptor internalization apparatus.
1b8
The Function o f  EGF-R Internalizat ion .
Internalization of EGF-R is a well documented yet 
controversial area. What the exact effects upon the cell are is also 
a contentious issue. Internalization and processing of EGF-R may 
be important for signal transduction and mitogenesis (Wakskull 
and W harton, 1985 and Yanker and Shooter, 1982). For example, 
it's inhibition leads to inhibition of m itogenesis (Wakskull and 
W harton, 1985). Inhibiting processing also causes inhibition of 
EGF dependent mitogenesis (King et.al., 1989 (a), (b) and (c)).
C.Intracellular Sorting of EGF-R and Tyrosine Kinase 
Activity.
Endocytosis via coated pits can occur in a number of 
ways. In the first way receptor and ligand are both recycled, for 
exam ple the transferrin receptor (Goldstein et.al., 1985 ). A 
second way involves the receptor recycling, and the ligand being 
degraded, for example, the Low Density Lipoprotein receptor and 
insulin receptor (Goldstein et.al., 1985).
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Finally, both receptor and ligand can be degraded, 
this is the case for the EGF-R (Goldstein et.al., 1985). EGF-R, 
however, depending on the cellular circumstances, seem to be able 
to undergo sorting by any one of these methods (Honegger et.al., 
1987 (a) and (b)).
Receptor m ediated  endocytosis  is a second-order 
process i.e., receptors compete for access to binding sites (Wiley 
et.al., 1985 and Lund et.al., 1990). This implies that the amount of 
receptor occupancy influences the fraction of receptors which 
enters the cell to be degraded.
Empty and full receptors, are however recycled and 
endocytosed at the same rate. Kinase negative EGF-R when EGF 
binds have an unchanged internalization rate and EGF-R with 
normal kinase dom ains have an e levated  in te rnaliza tion  rate 
(W iley et.al., 1985). The suggestion therefore  is that ligand 
induced down-regulation is mediated via changes in the rate of 
endocytosis, not the rate of recycling.
O ccupancy  induced  e n d o cy to s is  cau ses  EGF 
dependent EGF-R down-regulation. This in some way targets the 
occupied receptor to the lysosome which results ultimately in a 
reduction in receptor numbers at the plasma membrane and an 
increase in the number of receptor in the internal pool (Wiley 
et.al., 1985).
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Lysosom al targeting seems to depend upon the 
location of the receptor with in the Multi Vesicular Body or MVB 
(Felder et.al., 1990). The tyrosine kinase activity may therefore act 
to stabilise receptor/receptor interactions in coated pits or at sites 
further down the internalization pathway. The phosphorylation of 
additional proteins may also be involved in this process.
The post-internalization trafficking pattern of EGF-R 
seems also to depend upon the cell type. For exam ple, in 
transfected  B82 cells (Dunn et.al., 1986 and 1984); Human 
fibroblasts (Stoscheck and Carpeneter, 1984 (a) and (b)). Consider 
also  the s ituation  in po larized  cells  such as hepatocy tes  
(Maratos-Flier, 1987). These cells internalize EGF only at their 
sinusoidal and lateral surfaces (Dunn et.al., 1986).
In M adin-Derby Canine Kidney cells too, EGF is 
transported from the basal to the apical surface of the cell (Brandi 
et.al., 1991). How this directionality might be brought about and 
it's importance, in terms of functioning are not known.
The role of the intrinsic tyrosine kinase activity of 
EGF-R in the process of in tracellular trafficking of EGF-R is 
controversia l with a num ber of groups stating that tyrosine 
phosphoryaltion  of proteins is vital for sorting and others 
believing that it is not.
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Some evidence that the kinase activity of EGF-R is 
not involved in intracellular sorting, is as follows. The K721A 
EGF-R mutant (Honegger e t.a l. ,1987), the K721/T654A double 
EGF-R mutant (Glenney et.al., 1988 (a) and (b)) and the L721M 
mutant EGF-R (Chen et.al., 1989), all are kinase negative but with 
the exception of the first case they are not internalized.
K721A, via radiolabelling and ultrastructural analysis 
was found to internalize EGF-R, but these receptors are not 
degraded but are m ainly recycled  to the p lasm a m em brane 
(Felder et.al., 1990). Initially, normal EGF-R and K721A type EGF-R 
! internalization pathways are that same. The diverge at the MVB
i
I within the cell. This suggests that tyrosine phosphorylation here
in the MVB generates a sorting signal which causes normal EGF-R 
to be degraded (Felder et.al., 1990). The sorting of EGF-R within
I
the cell therefore depends upon spatial segregation in the MVB 
*) which in turn depends upon phosphotyrosine status.
The tyrosine kinase activity of EGF-R in some way 
seems to provide a sorting signal during receptor endocytosis 
w hich a llow s selection of EGF-Rs which are destined  for 
degradation in the lysosome.
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D.EGF-R Recycling.
The capacity of EGF-R to enter the degradative 
pathw ay could conceivably  therefore  depend on the tyrosine 
kinase activity of the receptor (Beguinot et.al., 1984 and 1985). 
There is no evidence for a non-lysosom al/recycling pathway in 
cultured fibroblasts (Beguinot et.al., 1984 and 1985) and KB cells 
(Lyall et.al., 1989).
In the following cell lines however, EGF-R do seem to 
recycle: pancreatic carcinoma cells (Korc et.al., 1986 and 1987); 
3T3 fibroblasts (Wakshull and Wharton, 1985) and hepatocytes
j (Dunn et.al., 1986 and Gladhaug et.al., 1988).
Sorting therefore seems to depend on structural
iit
! features of the receptor (Riedel et.al., 1988 and 1989) and on
I
| ce llu la r  e lem ents. W hat these m ight be are unknow n, but
i
^ mannose phosphate residues found upon EGF-R (Todderud and
Carpeneter, 1986) may be important. For a lysosomal enzyme to 
sort to the lysosome, mannose phosphate is vital in allowing the 
appropriate enzymes to interact with with the mannosyl receptor 
and so allow these proteins to be separated out from secreted 
proteins (Von Figura and Haslik, 1986).
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E.The Degradation of EGF-R.
Degradation is the final stage in EGF-R metabolism. 
The details of this process, like the ones preceeding it are unclear. 
The situation is further complicated by the fact that different cells 
regulate degradation using different mechanisms (Gladhaug, et.al., 
1988 and Felder et.al., 1990).
There is a growing body of evidence which suggests 
that the intrinsic tyrosine kinase activity of EGF-R is essential for 
EGF dependent degradation. Kinase negative  EGF-R mutants 
recycle but are not degraded in the presence of EGF (Glenny et.al., 
1987 (a), (b) and (c) and Honegger et.al., 1988 (a) and (b)). Exactly 
what the tyrosine kinase does is, however, unclear.
Linked to this are studies involving site directed 
mutagenesis of Lys 721 in the ATP binding domain of the 
receptor. This alteration results in the creation of an EGF-R which 
has in addition to no kinase activity (Glenny et.al., 1987 (a), (b) 
and (c) and Honegger et.al., 1988 (a) and (b))an increased half-life. 
This may be due to either a reduced rate of receptor endocytosis 
(Glenney et.al., 1987 (a), (b) and (c)).
It must also be considered that other kinases can 
phosphorylate  EGF-R too. Phorbol esters, for exam ple, induce 
phosphorylation of EGF-R at T654 (Cochet et.al., 1988 (a) and 
(b)and Hunter et.al., 1984 and 1991). Phorbol esters also cause 
EGF-Rs to be internalized without being degraded (Beguinot et.al., 
1984 and 1985). The role of T669 and S671 phosphorylations are 
unc lea r .
Degradation takes place principally in the lysosome 
(Vein et.al., 1989), but also in endocytic vesicles (Dim ent and 
Stahl, 1985; Korc et.al., 1987 and Y anagishuta  et.al., 1985). 
Receptors have been located within the limiting mem brane of 
endocytic vesicles and inside the MVB of KB cells too (Beguinot 
et.al., 1984 and 1985). Proteolytic cleavage of EGF-R in addition 
reveals that the N-terminus is mainly oriented in the center of the 
endocytic vesicle and so is exposed to intravesicular proteases 
(Decker, 1989). Degradation can be inhibited by low temperature 
treatments which inhibits internalization (Carpenter, 1987).
The extracellular domain of EGF-R in hepatocytes is 
degraded in the lysosomes with a half-life of approximately 0.5-9 
hours at 37 degrees C (Beguinot et.al., 1984). The tyrosine kinase 
dom ain is degraded along with the ex trace llu la r  dom ain  in 
lysosomes, and is not transferred to the cytosol or nucleus i.e. it 
does not serve as a second messenger (Beguinot et.al., 1984).
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Cytoplasm ic dom ains have to be degraded after 
EGF-R are sequestered into endosomes, but it is not known where 
this may occur, what the topology of the internalized EGF-Rs might 
be, or if degradation depends on cytosolic proteases and/or acid 
hydrolases (Renfrew and Hubbard, 1991).[
Carpenter and Cohen showed that in fibroblats, EGF
j binding led to the degradation of EGF-R (Carpenter and Cohen,
-
1990). This was later confirmed by a number of other studies
i
[
involving the use of anti-EGF-R monoclonal antibodies (Beguinot
j
et.al, 1984 and 1985). Morphological analysis also showed that 
: receptor and ligand are degraded together since both are found in
| MVBs (Haigler et.al., 1978 and McKanna et.al., 1979)
i
| Recycling, on the other hand may be a mechanism
which acts to amplify signals issuing from EGF-R. Such a model 
could explain the differential effects of EGF and TGF-alpha upon 
various celluar processes: TGF-alpha is a stronger agonist in the 
cases of calcium release from cultured bone cells (Ibbotson et.al., 
1986) and stimulation of arterial blood flow (Gan and Hollenberg, 
1989). T G F-a lpha  may be more rap id ly  degraded  and/or 
degraded to a greater extent than EGF
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5.11.EGF-R Signal Transduction and Ionic Fluxes.
5 .11 .1 .Sodium/Hydrogen (Na+/H+)Exchange and EGF-R 
Signalling.
Na+/H+ exchange is the best known of the ionic 
transport changes stimulated by growth factor treatment of cells 
i.e. the growth factor activated a usually  quiescent Na+/H+ 
exchanger located in the plasma membrane. Early evidence of the 
im portance  of Na+/H+ exchange was provided by work in 
neuroblastom a cells.
A ddition of serum caused the activa tion  of an 
e lec tr ica lly  silent sodium influx pathw ay. This pa thw ay is 
A m iliro ide sensitive and can be stim ulated with weak acid 
treatment of the cytoplasm (Moolenaar et.al., 1981, (a) and (b))this 
uptake of sodium is coupled to the efflux of hydrogen ions from 
the cell in a 1:1 stoicheometry (Moolenaar et.al., 1981 (a) and (b)).
The model therefore is that mitogenesis causes an 
increase in intracellular pH of 0.2-0.3 units and sodium entry 
which causes the Na+/H+ pump to be activated (Moolenaar et.al., 
1881 (a) and (b)). Most cells maintain their pH at 7.0-7.4, which is 
well above the electrochem ical equ ilib rum  value of 6.0-6.4 
predicted from transmembrane potential of approximately 60mV 
by the Nernst equation. In vertebrates, a specific hydrogen
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e x tru d in g  m ech an ism  ra ise s  in t r a c e l lu a l r  pH (M o o len aa r  
et.al., 1986 (a) and (b)). At normal pHi values the exchanger is 
relatively inactive but if pHi falls below a threshold level, the 
exchanger is increasingly activated.
Receptor occupancy may lead to an alkaline shift 
in pHi sensitivity to the exchanger (Moolernaar et.al., 1983; Paris 
and Poussegur et.al., 1984 and Grinstein et.al,. 1985). This altered 
pHi sensitivity may in turn be due to a conformational change in 
the exchanger protein which results in an increased pKa of the 
regulatory hydrogen binding site. The physiological effects of a 
growth factor upon the Na+/H+ exchanger therefore seem to be to 
increase it's pHi threshold: i.e. the level to which pHi must rise 
before the exchanger is shut off.
Growth factors are thought to modify pHi sensitivity 
of the exchnger and to raise pHi in the following way. Both TP A 
and synthetic DAG can mimick the effects of growth factors on the 
exchanger and pHi in various cell types implying that protein 
kinase C could directly phosphorylate the exchanger protein. This 
activation could be indirect though.
This putative  involvem ent o f protein  k inase  C 
suggests that an alkaline shift in pHi is not induced uniquely by 
growth factors, but is a common response in the action of those 
hormones and neurotransmitters that trigger the hydrolysis of
inositol lipids. For example, in hormone induced inositol phosphate 
tu rnover, in neu troph ils ,  pH increases  a fte r  ac tiva tion  by 
p h y s i o l o g i c a l  s t i m u l i  ( M o l s k i  e t . a l . , 1 9 8 0 ) .
It seems then that pHi as regulated by the Na+/H+ 
exchanger plays a vital role in a number of cellular processes. 
Growth factors activates this antiporter in quiescent cells by 
altering its pH sensor so that the cytoplasm  becom es more 
a lka line .
5.11.2.EGF-R and Calcium Levels.
C alc ium  was am ong the  f i r s t  in tra c e l lu la r  
messengers found in cells and is a crucial activator in many cells. 
It often acts along with other mesengers to modulate calcium 
fluxes themselves (Rasmussen e t.a l. ,1989). Calcium enters cells 
through voltage operated channels or VOC's (Darnell et.al., 1986). 
VOCs are modulable by cAMP, protein kinase C, calcium and 
G-proteins (Tsien et.al., 1988).
Calcium channel activity is dependent upon voltage. 
They have the properties of single channels and pharmacological 
analyses showed that there are two types (Fox et.a l.,1987). There 
are T-type channels which have a low threshold and have rapid 
effects (Rink and Merritt, 1990). L-type channels on the other 
hand have a high threshold and mediate slow effects (Tanabe 
et.al., 1987).
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More recently, a third type of channel: the N-type 
channels have been identified. These channels have properties 
which are intermediate between those of N-and L-channels (Tsien 
et.al., 1988).
C a lc ium  m o b il i ty  can a lso  be m ed ia ted  by 
so d ium /hyd ro gen  exchange , as m en tion ed  p rev io us ly . This 
exchange is believed to be electrogenic, exchanging one calcium 
ion for three sodium ions. This means that hyperpolarization
I
should favour calcium  exit and depolarization  should favour 
calcium entry (Eisner and Lederer,1985). In rod outer segments, 
potassium may also be involved such that four sodium ions, one
I
i calcium ion and one potassium ion are transferred (Eisner and
Lederer, 1985). It is not known if this stoicheometry is unique to 
photoreceptor cells.
Calcium release from intracellular stores is mediated 
i/ through the inositol trisphosphate receptor (InsP3-Receptor). This
receptor was first purified from Purkinje cells (Supttapone et.al.,
1988), and was reconstituted into lipid vesicles (Ferris et.al.,
1989)which are sensitive to inositol trisphosphate  and other 
inositol lipids too.
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The calcium  signal in response to EG F has no 
contribution  from in tracellu lar reserves and is due solely to 
calcium entry through VOCs (Moolenaar et.al., 1986 (a)and (b))-it 
still stimulates inositol phosphate turnover and DAG formation 
though .
It is believed that the calcium  channel which is 
actiavted upon EGF binding to EGF-R is phosphtidic acid (Sawyer 
and Cohen, 1981). This is an anionic phospholipid which is formed 
from DAG in EGF treated cells that may be a calcium ionophore in 
model systems (Serhan e t.a l. ,1982).
The absolute requirement for external calcium in 
EGF induced responses may reflect a calcium dependent coupling 
of individual EGF-Rs to the inositol phosphate generating system 
(Moolenaar et.al., 1986 (a) and (b)).
The observation that EGF caused an elevation in 
in tracellu lar calcium  levels was made in itia lly  in A431 cells 
(M oolenaar e t.a l.,1986 (a) and (b)). EGF caused the uptake of 
labelled calcium and the metabolism of inositol phosphates. This 
occurred in a calcium dependent way via the activation of voltage 
independent plasma membrane channels (Hill e t.a l. ,1988).
The calcium response could be blocked entirely by 
treating the cells with TPA (Moolenar et.al., 1986 (a) and (b)). This 
suggests that protein kinase C is involved in the attenuation of
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EGF induced calcium mobilization at some stage. However, such 
data is in conflict with that produced by Mozhayeva's group 
(M ozhayeva e t.a l.,1989).
It is now recognised that calcium from internal stores 
(i.e. that calcium mobilized by Ins 1,4,5 Ptd3) is involved in the 
EGF dependent calcium influxes. This was demonstrated by the 
stimulation of A431 cells with EGF (and also bradykinin and
histamines). This treatment caused an elevation of the rate of
) formation of Ins 1,4,5 Ptd3 which is correlated with a rise in
intracellular calcium in the absence of extracellular calcium influx 
(Hepler e t .a l. ,1987).
i
There is some evidence in favour of the former
; hypothesis; such as that which shows EGTA treatment results in
EGF induced in tracellu lar calcium fluxes rem aining unchanged 
(Johnson and Garrison, 1987). The model which is currently
!
l' accep ted  by m ost is that in non -secre to ry  cell at least,
intracellular calcium levels show a biphasic response to growth 
factor stimualtion (Berridge, 1987). Phase one requires inositol 
trisphsphate dependent mobilization of calcium from intracellular
stores and phase two, a prolonged phase, requires the inflow of 
extracellular calcium.
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EGF and TGF-beta have an additive, enhancing effect 
on intracellular calcium release, suggesting that they could be 
acting on d ifferen t calcium  pools and/or channels (M uldoon
et.al.,1988). This has been further hinted at by experiments which
show that Actinomycin D has no effect on the EGF dependent 
influx of calcium but inhibits totally that part of it for which 
TGF-beta is responsible.
Such finding suggested to the authors that these
growth factors may activate transcription of separate set of genes 
which culminate in the opening of calcium channels.
In the case of Swiss 3T3 fibroblasts, EGF and bradykinin cause 
enhanced intracellular calcium levels and also increase the rate of 
DNA synthesis (Olsen e t.a l.,1988). For these effects, extracellular 
c a l c i u m  i s  n o t  n e e d e d .
It would therefore seem that the situation is very 
complex, with different second messenger systems in acting in the 
presence of and/or in the absence of extracellu lar calcium  to 
promote the entry of calcium into the cell and the subsequent 
stimulation of DNA synthesis (Hill et al.,1988 show that DNA
synthesis induced by EGF is dependent upon the presence of 
extracellular calcium). How the calcium level effects are connected 
and to what extent they are regulated by other EG F induced 
effects is not known.
5.12. EGF-R and G-Proteins.
5 .1 2 .1 . Introduction
G-proteins are a family of guanine nuleotide binding 
pro te ins  (G ilm a n l9 8 7 ) ,  which a llow  the coupling  of signal 
t ra n s d u c t io n  pa th w ay s  of m any  re c e p to rs  (Jo h n so n  and 
Dhanasekaran,1989). They are m em brane bound proteins which 
comprise a transducing unit consisting of three parts: a receptor, a 
G-protein and an effector(s).
A classical G-protein is a member of a larger GTP 
b ind ing  p ro te in  fam ily  which com prises  p ro te in s  such as 
translation factors, Ras, Rho and YPT and SEC4 of yeast 
(Gilman, 1987). So far, eight mammalian G-proteins have been 
iden tified  b iochem ically , and they transduce  specific  siganls 
(Gilman 1987). Some examples of receptors which are controlled 
by G -proteins are receptors for beta adrenergic agonist type 
hormones for instance adrenalin and neurotransm itters such as 
rhodopsin. G-protein controlled effectors include adenylyl cyclase, 
retinal cG M P-specific  phosphod iesterase  and phospholipase  C 
(Gilman, 1987).
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In molecular terms, G-proteins are composed of three 
subunits: alpha, beta and gamma. Alpha subunits are the heaviest 
and define individual G-proteins (Gilman, 1987). Beta and gamma 
subun its  are p robab ly  shared  betw een  d if fe ren t  types of 
G-protein. (For a review on small GTPases see Hall, 1992)
A ctiv ity  of G -p ro te ins  is ach ieved  th rough  the 
asssociation of GTP with the alpha subunit and by hydrolysis of 
this GTP to GDP plus Pi (which initiates the deactivation process) 
and finally by the dissociation of GDP from the G-protein.
G -p ro te in s  are  t hough t  to so r t  and a m p lify  
transm em brane signals. Specificity  is achieved because each 
G-protein determ ines the flow of inform ation from a specific
number of receptors to a similar number of effectors. Sorting
occurs  in two steps, f i rs t ly  a c t iv a t io n  of G -n u c leo t id e  
exchang e .H ere  the G -pro te in  se lec tive ly  in te rac ts  w ith  the 
appropriate  activated receptor only. The second step happens 
when the GTP-bound or active form of the G-protein binds to and 
activates the correct effector. The alpha chains contain  the 
determinants for the correct sorting of these signals.
G- proteins amplify transmembrane signals through
the use of GTP hydrolysis. This event acts as a timer to amplify
signals. For example in the case of adenylyl cyclase, (Gilman,1987)
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one hormone receptor complex is active for about one second and 
generates one or more GTP bound alpha chains which remain 
active for ten seconds.
5.12.2.The Involvement of G-Proteins in EGF-R Signal
Transduction.
The p receed ing  sections serve to outline  and 
emphasise the importance of G-proteins in the transduction of 
cellular signals. When the specific example of signal transduction 
induced by the binding of a ligand to the EGF-R is considered, the 
situation is a lot less clear.
A great deal of evidence states that there is no 
G-protein involvement in EGF-R signal transduction, yet reserch 
by an increasing number of groups contradicts this point of view 
by providing what they consider to be proof that a G-protein of 
some kind is involved in this process. The section which follows 
reviews the evidence for both hypotheses.
The cell line MD-468 (Pathak et.al., 1982) is a human 
breast cancer cell line with elevated numbers of EGF-R receptors: 
som e 1 .5-10-6  per cell (F ilm us e t .a l . ,  1985). A t h igh 
concentrations of EGF, growth is inhibited. This is not the case for 
some clonal variants of this cell line which have lost the amplified
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e g f - r : the M DA-468-S4 cell line. This variant has an absolute 
dependence on the addition of exogenous EGF for it's growth in 
anchorage independent condition.
This different response to EGF under the above noted 
g row th  cond it io ns  a llow ed the in v es tig a t io n  of G -pro te in  
involvem ent in EGF-R signal transduction . At optim al EGF 
concentrations, different concentrations of pertussis toxin were 
added to MDA-468 and MDA-468-S4 cells. In both cell lines, an 
EGF concentration was reached where a concentration dependent 
reversal of EGF mediated growth inhibition was observed (Church 
and Buick,1989).
It was also found that in the case of the MDA-468 line, 
the EGF inhibition effect could be blocked by pertussis toxin while 
in the MDA-468-S4 cell line pertussis toxin had no effect.
Plasma membranes isolated from each cell line were 
subjected to ADP-ribosylation in vitro by [alpha-32P]-NAD in the 
presence of pertussis toxin. Plasma membranes from cells grown 
with and without EGF could incorporate 32P. This led to the 
labelling of a 41 K.D. polypeptide and other high molecular weight 
substrates. If pertussis toxin is omitted though, such an effect is 
no longer observed (Church and Buick,1989).
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Plasm a membranes from cells grown with pertussis 
toxin showed no ADP-ribosylation of the 41 K.D. polypeptide. This 
suggested to the authors that the ADP-ribosylation of this protein 
may be involved in the inhibitory effects of pertussis toxin on EGF 
mediated events in the two cell lines.
It therefore appears that in the MDA-468 cell line,
growth cannot be inhibited by pertussis  toxin alone in the 
presence of low EGF concentration. A G-protein pertussis toxin 
insensitive G-protein does not therefore seem to be involved. At 
high EGF concentrations though, which inhibits growth of the cells, 
post-binding events seem to be G-protein m ediated and are 
b locked by pertussis  toxin A D P-ribosy la tion  o f  a pu ta tive  
G -pro tein .
For cells of the MDA-368-S4 cell line, cell proliferation 
un d e r  an ch o rag e - in d ep e n d en t  co n d it io n s  a p e r tu s s is  toxin  
sensitive G-protein seems to be required. Pertussis toxin does not, 
however, prevent the increase in EGF dependent expression of 
c - m v c  and c-fos which suggests that EGF initiates two separate
signal transduction pathways, one of which involves a G-protein 
(Church and Buick,1989).
The ability of known GTP binding proteins to act as
phosphosubstrates for EGF-R has also been studied and a 22-25
K.D. high affinity G-protein was found to be a good
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p hosp hosubs tra te  (Hart e t .a l . ,1990). P hospho ry la t ion  of this 
protein is enhanced three fold by the addition of EGF. When it is 
incorporated into lipid vesicles without EGF-R, the protein is not 
phosphorylated and boiling of the protein abolishes its ablility to 
be phosphory la ted . In addition, phosphoam ino  acid analysis 
reveals that this polypeptide is phosphorylated only on tyrosine 
re s id u es .
The phosphorylation of the protein thus identified can 
be inhibited  by GTP ys, GTP and GDP im plying that the 
G -n u c le o t id e  occup ied  sta te  of the p ro te in  in h ib i ts  it's 
phosphorylation by EGF-R. That is to say that activation of the 
G -p ro te in  may lead to its uncou p lin g  from  the EG F-R . 
Heterotrim eric  G-proteins are thought to cause the release of 
these transducers from their receptors. The inhib ition  due to 
G-nucleotide occupation is probably a more general effect.
The fact that the nucleotide alters the conformation of 
the protein is possibly the feature responsible  for its reduced 
phosphorylation status (Hart et.al., 1990).
The consequence of such an event could be that EGF-R 
can no longer effectively couple the GDP bound form of the 22 K.D 
protein in vitro or catalyze GDP-DTP exchange. A helper protein 
might therefore be needed to cany  out this coupling to EGF-R, the 
p rocess  usua lly  carr ied  out by the b e ta /gam m a com plex  
(F u n g ,1983).
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The 22 K.D. polypeptide described above is not a 
substrate for botulinum toxin under conditions in which it is 
ADP-ribosylated, the protein therefore cannot be Rho. Rap-1 is not 
phosphorylated by EGF-R, so the protein cannot be Rap-1 (Hart 
et.al., 1990). Finally, it does not cross-react with antibodies raised 
against Ras (Hart et.al., 1990).
N akagaw a showed that a m echanism  involv ing  a 
G-protein activated adenylyl cyclase may function in rat parotid 
gland acinar cells (Nakagawa e t.a l. ,1991) i.e. that the cAMP 
signalling pathway activated by EGF can be mediated by a cholera 
toxin sensitive G-protein. That EGF has such an effect in one 
system may mean that it could do the same in others too. There is, 
however is great danger in extrapolating between possibly quite 
d ifferent systems.
Some other evidence suggesting the possibility of the 
involvem ent of a G-protein in EGF dependent signalling is as 
follows. In hepatocytes, pertussis toxin blocks the ability of EGF to 
stimulate inositol trishophate production (Johnson et.al., 1988 (a) 
and (b)). Pertussis toxin can block EGF inhibition of acid secretion 
in rat parietal cells (Atwell and Hansen, 1988).
In rat hepatocytes, inositol 1,4,5 Ptd3 accumulation is 
p reven ted  by trea tm ent with pertussis  toxin  (Johnson  and 
Garrison, 1987), as is phospholipase C activation by EGF (Johnson
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and Garrison, 1987). The inner medullary collecting tubule cell 
phospholipase A2 is activated by EGF and this process in inhibited 
by pertussis toxin (Teitelbaum, 1990 (a) and (b)). EGF stimulated 
accum ulation of Ins 1,4,5 Ptd3 in WB cells is, in addition, 
abolished by pertussis toxin pretreatment of the cells (Johnson 
and Garrison, 1987).
On the other hand, in A431 cells, by contrast, pertussis 
toxin has no effect on EGF-R dependent effects such as inositol 
phosphate metabolism (Pikes and Eakes, 1987). EGF-R has, in 
addition, no amino acid homology with any known member of the 
guanine nucleotide binding family of proteins (Carpenter, 1987 
and O'Dowd et.al.,1989).
It seems most likely that pertussis toxin is blocking 
EGF dependent effects upon phospholipase C activation in a cell 
type specific manner (Milligan, 1988). That is to say that different 
cell lines have different EGF induced signal transduction pathways 
(Teitelbaum, 1990 and Teitelbaum et.al., 1990 (a) and (b); Johnson 
et.al.,1988 (a) and (b) and Besterman et.al., 1984, 1985 and 1988). 
This could be brought about by the coupling of the EGF-R to 
d ifferen t effector systems or by the activa tion  of d ifferent 
phospholipase C isozymes.
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Alternatively, EGF-R phopshorylation of components 
of G-proteins could take place which affects the way they interact 
with the other parts of the transducing unit (O'Brien e t.a l,1987; 
K rupinski e t .a l .1988; K atada e t .a l . ,1985 and Crouch and 
L ap e tin a ,!  988).
Chapter Six: EGF-R AND
BREAST CANCER.
6.1 Introduction.
EGF-R and other growth factor recptors have been 
found to be associated with the development of human cancers. 
Reviewed in this chapter are the ways in which EGF-R is thought 
to be involved in the genesis of breast cancer. Some other cancers 
will be d iscussed  briefly , as w ill two re la ted  aspects of 
EGF-R/breast cancer research: the possible uses of EGF-R as a 
prognostic/diagnostic indicator and as a therapeutic target.
V - e r  b - B is the transform ing gene of the Avian 
Eryhtroblastosis Virus (Downward et.al, 1984). In 1984 it was 
discovered that v -e rb -B  is highly homologous to the human e g f - r  
gene and that it is derived from the cellular e g f - r  gene via a 
nu m b er  o f t ru n ca tio n s  and p o in t  m u ta t io n s  (D ow nw ard  
et.al., 1984). Both e g f- r  and erb-B genes code for proteins which 
have a built in tyrosine kinase activity.
6.2. EGF-R and Human Cancers.
The most frequent EGF-R anomaly in human cancers is 
overexpression of an apparently normal EGF-R protein. This is the 
case in squam ous carcinom as, breast cancers, liver cancers, 
bladder cancers, pancreatic cancers, cancers of the respiratory 
tract and brain tumours. It can also be observed in cells lines such 
as A431, SCC-15 and MDA-468.
193
EGF-R over-expression is most commonly the result of 
an increase in the rate of transcription of the gene or is due to 
certain post-transcriptional mechanisms. Gene amplification is also 
a significant cause. The importance of EGF-R over expression in 
carcinogenesis is demonstrated by the fact that in KB cells full 
length anti-sense EGF-R mRNA can totally block eg f-r  expression. 
As a result of this treatment, the severity of the transformed 
phenotype is reduced (Moran et.al., 1988).
It has been proposed that the consequent enhanced 
ty ro s in e  k inase  ac tiv i ty  is re sp o n s ib le  for tum orig nes is .  
Expression of high levels of EGF-R in NIH 3T3 cells has been found 
to induce a fully transformed phenotype in vitro that requires 
both functional c-erb-B expression and the presence of EGF in the 
growth medium (Di Fiore et.al., 1987 and Velu et.al., 1989).
Some cancers with very high levels of EGF-R (usually 
the result of gene amplification) are growth inhibited by high 
ligand  co n cen tra tio n s , but are s t im u la ted  by low ligand 
concentra tions. It has been suggested that the e g f - r  gene 
ampification is a reflection of genomic instability  and of the 
selection of cells over-expressing  EGF-R and so posessing  
increased growth potential in a limiting concentra tion  of the 
ligand (Carlin et.al., 1989 and Gill et.al.,1985.).
In summary then, tumours of squamous origin and a 
number of cell lines can over-express EGF-R at their surface. 
A nalysis  by Southern blotting of the recep to r  gene shows 
a m p lif ica tio n  is observed  freq uen tly  in certa in  squam ous
lines-but infrequently in others.
Some mutated EGF-R is also known. In A-431 cells,
there is a truncated varient of EGF-R which has only the 
extracellular domain. It binds EGF, and is secreted (Ullrich et.al., 
1984). Certain brain tumours have EGF-R which posesses short 
deletions in the ligand binding domain (C arpen ter,1987). Such
e g f - r  can be over-expressed too and has an increased tyrosine 
kinase activity in the absence of ligand (Carpenter, 1987).
6.3.EGF-R and Cell Transformation.
The transforming potential of EGF-R is demonstrated in 
the following examples. Firstly, EGF-R N- and C- truncations occur 
in the Avian Eryhtroblastosis Virus. Such deletions of the v -e rb -B  
gene leads to the loss of the extracellular domain and one of the 
autophosphoryla tion  sites. There is also a poin t m utation in 
v - e r b - B . The fact that there is an N-terminal deletion means that 
the resultant protein has no ligand binding domain and so cannot 
be down-regulated or internalized as the
normal receptor is. The theory is that the transforming ability
m ay result from the constitu tive  activation of this protein 's
tyrosine kinase activity.
Autocrine stimulation of tumour growth has also been
put forward to explain the transforming ability of growth factors
and th e ir  re c e p to rs .  A u to c r in e  s t im u la t io n  o f  c e l lu la r
transformation correlates with TGF-alpha production by tumours
which also over-express EGF-R (Derynck et.al., 1987).
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6.4.EGF-R levels in Human Breast Cancer.
A number of methods have been used to assess the
num ber of EGF-Rs on various human tumours, such as ligand 
b ind ing  assays, im m unocy tochem istry , im m u noh is tochem is try , 
radioim m unoassay, Southern blotting, W estern bloting, Northern 
blotting, P.C.R. analyses and E.L.I.S.A.
The first time that elevated numbers of EGF-Rs were 
demostrated on human tumours was by a group studying lung 
tumours using antibodies against EGF-R (Hendler and Ozanna, 
1984). That increased EGF-R levels are actually  involved in 
tumorigenesis is revealed by the finding that if the receptor's 
numbers are increased and activated ligand is present, fibroblasts 
(in vitro) are transformed (Di Fiore et.al., 1987).
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Increased numbers of EGF-R can in the main be due to
either increased transcription of egf-r or amplification of eg f-r .
A summary table of the published literature on how 
EGF-R levels are associated with d ifferent human tumours is 
shown in Appendix Two.
6.5. EGF-R and Tumour Size, Stage, Grade and Spread.
Sainsbury's group have found that large tumour size,
advanced stage, grade and spread of primary breast tumours is 
associated with EGF-R status. High levels of EGF-R were found to 
be associated with poorly d ifferentiated  tumours, large sized
tumours and involvement of lymph nodes (Sainsbury e t.a l.,1985
(a) and (b)).
Macias reported that levels of EGF-R positivity  are 
higher in human breast cancer metastatic deposits than in the 
prim ary tumours themselves (M acias e t .a l . ,1986). The authors 
concluded that metastasis may involve the clonal selection of 
EGF-R positive cells which have a high metastatic potential. EGF-R 
alone is not the only requirement for metastasis though since 
approximately 50% of the secondary tumours lacked EGF-R. The 
only safe conclusion that might be drawn is that the primary 
tumour is not a homogeneous population of cells.
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It has in addition been shown that metastatic deposits 
of human breast cancers are EGF-R positive far more frequently 
than primary tumours. For example, in 1 study, 25% of primary 
and 48% of secondary breast tumours are EGF-R positive (Skoog 
et.al., 1986). Again the data suggest that clonal selection is in 
action and that cells are being selected which have high EGF-R 
levels.
EGF-R levels are also positive ly  corre lated  with 
accelerated growth rate in node-positive breast cancer (Spitzer 
et.al., 1988). This implies that for such patients, breast cancer 
growth is dependent upon EGF enhanced cell division.
6.6.EGF-R and Breast Cancer Sub-Groups.
A number of different sub-groups of breast cancer can 
be histologcally identified. The relationshp between the EGF-R 
status of a tumour and i ts  histological type was carried out in a 
re trospective  study (Skoog e t .a l . ,1986). The conclusions were
Histological Sub-Type EGF-R Detectable over the Total
Number of Tumours Studied 
Ductal 8/22
Lobular 0/9
Medullar 2/2
Colloid 0/4
Fibroadenoma 0/3
(Skoog et.al.,1986).
Other investigations carried out along similar lines to 
that above have revealed that, overall, some 40% of the breast 
tumours studied had detectable EGF-R (Perez e t .a l . ,1984 and 
Fitzpatrick et.al., 1984 (a) and (b)). Ductal tumours compose about 
80-85%of all cases (Perez et.al.,1984).
Some tumours were found to have no EGF-Rs. This may 
be because of a phenomenon of the transformed state, or because 
the tumour is exposed to exogenous EGF/TGF-alpha which causes 
EG F-R dow n-regula tion  (Heldin  e t.a l.,  1982). This poss ib le  
restriction of EGF-R to certain tumours is important if EGF-R is 
used as a prognostic indicator.
The conclusion is that high EGF-R levels are associated 
with more advanced and aggressive breast tumours and so is an 
ind ica to r  of poor prognosis  and early  recurrence . A nother
investigation by the same group also indicates that increasing 
numbers of EGF-R on primary breast tumours is asssociated with 
increased metastatic potential (Sainsbury et.al.,1985 (a) and (b)).
Spitzer demonstrated that an enhanced level of EGF
binding was correlated with lymph node involvem ent (Spitzer
e t.a l. ,1988). This finding has been confirmed in a num ber of 
studies such as those by Mori (Mori e ta l.,1991); B attag lia  
(Battaglia e t.a l.,1985 and 1989) and Toi (Toi et.al.,1989). There is, 
however, some controversy as to the correlation between EGF-R 
levels and the numbers of lymph nodes affected (Toi etal.,1989).
6.7. Interactions Between EGF-R and Hormone Receptors 
in Breast Cancer Development.
EGF-R and oestrogen receptors are believed to be 
inversely related such that 2 sub-groups of oestrogen receptor 
positive primary breast tumours can be identified (H arris ,1989).
These tumours can be either EGF-R positive  (and oestrogen 
receptor positive) or EGF-R negative (and oestrogen receptor
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positive).This phenomenon has in addition to having been shown 
immunohistochemically, has been demonstrated by ligand-binding 
too (Harris A.L.,1989).
O ther reports  confirm ing  the inverse  re la tionsh ip  
between ER and EGF-R status are provided in studies by Koenders 
(Koenders et.al.,1991); Davidson (Davidson e t.a l. ,1987); Bauknecht 
(Bauchnecht e t.a l.,1989) and Wrbra (Wrbra e t.a l. ,1988).
Among the other hormone receptors which are thought 
to be involved in the process of mammary carcinogenesis are the 
p ro lac tin  recep to r  (Shiu , 1979); grow th horm one recep to r  
(Murphy et.a l.,1984); insulin receptor (Benson and 
Holdaway ,1981) and somatostatin receptors (Reubi e t .a l . ,1989 
and 1990). The research into the molecular workings of these 
receptors in breast cancer development is not well advanced at 
p re s e n t .
6.8. The Use of EGF-R as a Prognostic Indicator in Breast 
Cancer.
Evaluating the prognosis for any individual patient 
presenting with breast cancer (and any other disease too)is a very 
complicated matter. A number of interrelated prognostic
indicators are used to allow the clinician to make an assessment of 
the tumour in question, thus facilita ting optim ization of the 
therapeutic  regime.
Contesso categorises such prognostic features as C lin ical 
Factors and Pathological Factors f Contesso et.al., 1984). Clinical 
factors include factors such as age and rejroductive history of the 
patient, the periods of time between discovery and diagpsis of the 
lesion, diagnosis and therapy and therapy and the appearance and 
site of the first recurrence or metastasis. Features of the tumour 
itse lf  such as it s size, TEM status, skin invasion and lymph 
adenopathy are also important prognostic features.
Contesso describes the patholgical factors as the size of 
the excised tumour, it s histological grade and stage, lymph node 
involvem ent and the presence of necrotic  areas w ithin the 
tu m o u r .
Such indexes allow the clinician to neither under treat 
nor over treat a patient. To select therapy and identify specific 
groups of patients which can receive more appropriate therapy, 
m ore  and im proved  p ro g n o stic  in d ic a to rs  (and  re sp o n se  
indicators) are sought. Among the most useful have proven to be 
hormone and growth factor receptors (Some oncogenes have also 
been shown to have a use in patient prognosis. For reviews see
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Varley et.al., 1987, Perren, 1991, W right et.al., 1989, Paterson 
et.al., 1991, Borg et.al., 1990 and Anbazhagan et.al., 1991).
Oestrogen receptor status is probably the most widely 
used of these indexes. The importance of oestrogen receptors is 
well established in that as well as allowing the cell to respond to 
various first line endocrine therapies, it seems that if  such 
tumours should replase then these secondary tumours are more 
likely to respond to endocrine therapies.
P ro g es te ro n e  recep to rs  have a lso  been used  as 
prognostic indicators. There are many reasons for it s use in this 
way, with the fact that oestrogen causes progesterone receptor 
synthesis (Darnell et.al., 1986) being among the most important. 
In addition, as previously stated, the expression of progesterone 
receptors is believed to indicate that oestrogen receptors are 
f u n c t i o n a l l y  a c t iv e  ( H o rw i tz  and  M c G u i r e ,  1 9 7 8 ) .
Considering EGF-R as a p rognostic  ind icator, the 
follow ing points can be made. F irstly , as has been already 
mentioned, oestrogen receptor and EGF-R are inversely related 
(Sainsbury et.al., 1985 (a) and (b) and Toi et.al., 1989). EGF-R is 
associated with less differentiated tumours (Sainsbury et.al., 1985
(b)), large tumour size (Sainsbury et.al., 1985 (a)), poor prognosis 
(Sainsbury et.al., 1987) and the involvement of lymph
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nodes (Battaglia et.al., 1988). Those with the worst outlook are 
patients bearing EGF-R(+)/oestrogen receptor(-) tumours (Grimaux 
e t .a l . ,1989).
Expression of EGF-R may also be associated with 
increased risk of early recurrence and death (Sainsbury et.al., 
1987,and 1888 Toi et.al., 1990, Harris et.al., 1989 and Nicholson 
et.al., 1989). In one study involving two hundred and thirty one 
patients with unaffected axillary nodes, EGF-R was found to be the 
best prognostic indicator (Nicholson et.al., 1991). In node positive 
patients, EGF-R status was significantly correlated with oestrogen 
receptor status and histological grade allowing identification of 
sub-groups of patients (Grimaux et.al., 1989).
A study where EGF-R status of three hundred and 
three human breast cancers was assessed by ligand binding assay 
and revealed that fifty percent of the samples were EGF-R(+) 
(Bella et.al., 1992). These authors also noted that EGF-R expression 
was reduced in the more differentiated tumours.
Certain necrotic areas within breast tumours were 
found to express EGF-Rs (Reubi and Torhust, 1988). Such a finding 
complicates the use of EGF-R as a prognostic indicator and urges a 
res tra ined  and considered  approach  to the ir  use for such 
p u rp o se s .
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It is hoped that EGF-R itself will in time become a 
therapeutic target for the poor prognosis group; for example by 
the creation of antibodies to the receptor; peptide analogues to 
EGF or TGF-alpha or drugs which are conjugated to EGF or 
TGF-alpha.
6.9.EGF-R and Breast Cancer Therapies.
Although a major killer of females in the prime of their 
lives, the death rate form breast cancer has remained virtually 
unchanged this century. As was previously  discussed this is 
because of a lack of knowledge of the nature of the processes 
underlying the disease.
Usually, the concentrations of anti-tum our drug that 
will eradicate the tumour is lethal or at best be highly toxic to that 
patient. Am agase 's group found that using EGF with certain 
anti-cancer drugs such as 5-fluorouracil in tumour cells which are 
rich in EGF-Rs causes the agent's cytotoxic effect to be enhanced 
towards the tumour cell without increasing toxicity  (Amagase 
e t.a l., 1989).
Tumours can also develop cytotoxic drug resistance, 
and this is a very serious problem. EGF seems to have some ability 
to enhance the effacy of Doxorubicin in a clonogenic assay,
particularly in hormone-responsive patients (Hug et.al., 1986) and
this could be a way to overcome this problem  of multi-drug
resistance. How EGF has this effect is not clear but it may be acting 
by increasing the passage of the cells through the cell cycle so 
rescu ing  them  from  Go and m aking them  targe ts  for the 
anti-cancer agents.
Another study was performed in the KB.Cl cell line: a
human epidermal carcinoma cell line derived from KB cells via 
selection with Colchicine (Akiyama et.al., 1985). The findings have 
suggested that EGF-R may have a central role in drug-resistance.
KB.C1. cells were more resistant to EGF and anti-cancer
agents than the original KB cells, and the authors found that this
phenom enon is correlated with a reduction in the number of 
EGF-Rs (Takano et.al., 1989). A revertant clone: C1-R2 was isolated 
and had recovered EGF sensitivity and had enhanced EGF-R levels 
when compared to KB.C1.
In addition, the multi-drug resistance gene m d r - 1 is 
expressd at high levels in KB.C1. cells and not at all in KB and 
C1-R2 cells. Multi-drug resistant cells are also less tumorigenic in 
nude mice (Takano et.al., 1989). The conclusion was therefore 
reached that reduced EGF-R expression is a phenomenon of 
multi-drug resistant cells and may even be the reason for reduced
tumorigenicity as noted above. For example, multi-drug resistance 
could cause altered expression of EGF-R, perhaps via chromosome 
7 alterations.
The observations that EGF-R plays an important role in 
the prognosis and diagnosis of cancers as well as in their genesis, 
has suggested that it may be possible to use the EGF-R as a way to 
deliver cytotoxic drugs to a tumour. Targeting such very potent 
drugs specifically to a tumour, leaving surrounding normal cells 
undamaged would be a considerable step forward. In addition it 
could allow the clinicians to use more cytotoxic drugs and at a 
higher dose to treat the patient.
EGF has been fused to various fragm ents of the 
Diptheria toxin forming constructs called DAB 468 and DAB 389. 
EGF-R phosphorylates DAB 389 (Shaw et.al., 1991).
Both the fusion toxins have been shown to bind to 
EGF-R specifically and inhibit protein synthesis in human cancer 
cell lines, DAB 389 was the most cytotoxic though. This is due to 
the ADP-ribosylation of EF-2, i.e. the equivalent reaction to that 
which the Diptheria toxin carries out. DAB 389/EGF is at present in 
trials in nude mice bearing EGF-R expressing xenografts.
U sing a sim ilar reason ing , m onoclonal an tibodies 
against EGF-R have been used to try to prevent or reduce EGF-R 
acivity (i.e. signal transduction) in tumours over-expressing EGF-R. 
Antibodies against part of EGF-R have also been used to dissect it's 
mechanism of action (Kris et.al., 1985).
In the M DA-468 human breast cancer  cell line, 
anti-EGF-R antibodies inhibit the EGF/TGF-alpha autocrine growth 
proliferation system in the absence of exogenous EGF (Ennis et.al., 
1989). This implies that the antibodies are acting to block access 
of an exogenously  produced ligand to EG F-R . Although a 
therapeutic  application  is not envisaged by the authors, it 
illustrates how such antibodies could be used to this end and 
suggests other possible uses such as in tumour diagnosis. Two 
monoclonal antibodies against the COOH- area of EGF-R have 
recen tly  been evaluated as having po ten tia l  d iagnostic  use 
(Troalen et.al., 1991).
In the Scid m ouse model (sc id /scid), established 
human M24 metastatic melanom a cells m etastasize rapidly, in 
100% of the mice (Mueller et.al., 1991). A monoclonal antibody 
against EGF-R specifically reduces this metastasis. Primary tumour 
growth is not altered though. It therefore seems that blocking
EGF/EGF-R binding has an anti-metastatic effect. This has also 
been observed in A431 cells, where an anti-EGF-R antibody has 
the same effect (Masui et.al.,1984).
Monoclonal antibodies have also been fused to various 
cytotoxic agents (the principle here is the same as that for 
EGF-R-cytotoxic drug fusion proteins). A nude mouse xenograft 
study showed that Vinca-EGF-R conjugates caused regression of 
established tumours (Gutowski et.al., 1991). Although at present 
un tes ted , these  resu lts  im ply that pursu ing  such lines of 
investigation may prove to be useful, providing new therapeutic 
approaches to breast cancer.
Chapter Seven: CONCLUSION.
Chapter 7:Conclusion.
The lite ra ture  concern ing  EG F-R  activ ity  is very 
large-this is particularly true in the case of EGF-R's role in human 
carcinogenesis. This thesis therefore limits itself to an appraisal of 
only certain core issues such as the structure (at the DNA and 
protein levels) of the receptor, how structure relates to function, 
what the various functions of the EGF-R are, how EGF-R activity 
might be regulated and how all this relates to the problem of breast 
cancer.
Breast cancer is a major killer of females world wide, 
and incidence is increasing every year-yet much progress remains to 
be made in terms of tackling the disease more effectively. There 
have been some recent improvements in the treatment and survival 
of hormone sensitive breast cancers, but the prospect for those with 
hormone insensitive breast cancer remains poor.
The reason for the disappointing statistic is that there is 
a serious lack of knowlege about the molecular processes which 
underly the process of carcinogenesis. In fact it might be more 
accurate to say that the real lack of know ledge concerns the 
processes of normal cell proliferation.
The first parts of this thesis therefore, deal with the 
basics of cancer biology and breast cancer biology. The main points 
to emerge from this study are that these processes have a very 
significant genetical component. Much evidence exists which seems 
to show that loss of certain areas of the genome and/or activation 
of specific oncogenes is associated with breast cancer development.
The crucial problem of cancer m etastasis is also 
tackled with the observation that a discrete gene: nm23 is involved 
in this process. The significance of this finding is that identification 
of a gene opens the way to potential intervention, at least in 
theory, but in reality such knowledge is just one vital clue to be 
used and built upon by investigators.
Structural features of EGF-R are very important in 
another respect: they determine, define even the functions and 
activities of the receptor. This crucial area is reviewed in some 
depth in the thesis firstly because of its obvious significance and 
intrinsic interest.
Another reason for examining this subject in detail is 
that modern m olecular biologial techniques have meant that new 
approaches to studying structure/function relationships have been 
used. EG F-R is a very good exam ple, with p rocesses  like 
domain-swaps and site-directed mutagenesis in use towards a real 
and practical end.
Finally , EGF-R structure deserves c lose  attention
because herein lies the basis of EGF-R signal transduction. This
process of transfer of inform ation from the cell's environm ent 
inside the cell and its culmination in alteration in the pattern of
gene expression is on which is at the heart of cellular activity.
Although here we are concerned with these processes
as they pertain to carcinogenesis, very important general rules are 
learned about the processs itself. These rules are often applicable 
universally (maybe in a slightly modified manner).
Then the cellular effects of EGF-R activation on inositol 
phosphate metabolism  and ionic fluxes are reviewed as is the 
possible involvement of a G-protein in these processes. It was noted 
that these areas: EGF-R as a protein kinase and m odulator of 
intracellular activities are very controversial. This issue of how 
EGF-R tyrosine kinase activity is activated is, in particular a highly
contentious one with two main theories both with much strong
supporting and conflicting evidence.
It is believed that the intracellular signalling processes 
are peturbed in cancerous cells. Again exactly what form this may 
take is not known but many theories exist. This is discussed in
direct relation to human breast cancer development: in this thesis, 
with the autocrine theory of cellular proliferation being the most
widely held.
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As well as looking at a number of ways in which 
alterations in EGF-R signal transduction may be involved in breast 
can cer  d eve lop m en t genetical aspec ts  o f b reast cancer  as 
considered too. Their importance has been touched on previously 
and I feel that their usefulness (i.e. in terms of allowing a basic 
understanding of the carcinogenic process and allowing cancer to be 
tackled clinically) will only increase in the future.
Perhaps it could be considered  as an indirect 
) involvement in breast cancer, but a very important aspect of EGF-R
in th is  p ro cess  is its use as a p ro g n o s t ic  (or even 
diagnostic)indicator. In this way clinicians can identify specific 
patients and treat them more appropriately. An aid with improves 
patien t treatm ent and/or the usefulness of a therapy m ust be
i
welcomed. In fact far from being a side-line issue, it is probably 
fair to say that the use of EGF-R as a prognostic indicator is at 
 ^ present the major contribution of EGF-R research to oncology.
EGF-R biology holds great promise for the future. As 
was previously stated, advances in technology have meant a better 
understanding of EGF-R signal transduction is now possible. Such 
advances, when they come will have significance not solely in the 
field of EGF-R signal transduction, but in the wider area of cellular 
signalling too.
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Work is also being done which sees the EGF-R as a
potential for anti-cancer therapy. Again cancer will not be the only
d isease  to benefit  from  such advances since any pathology 
involving EGF-R could be tacked in this way, psoriasis for example.
Conjugation of various cytotoxic agents to parts of EGF 
hijacks and takes advantage of the fact that EGF binds solely and 
specifically to EGF-R. In this way it is hoped that the abberant 
EGF-R activity can be controlled if not abolished totally. Finally, 
certain compounds which have been designed to inhibit kinase
activity are now available.
This research is now so advanced that agents which
specifically  inhib it the tyrosine kinase activ ity  of EGF-R are 
available. The long-term aim is that such compounds will form the 
basis of a new generation of drugs w hich w ill be active 
specificically against tumours/cells containing elevated amounts of 
EGF-R.
Such work is still in it's infancy and there is a long 
way to go with many problems to be overcome. However, it amply 
shows the importance of EGF-R and its contribution to many areas 
of biological science and oncology and highlights how well placed it 
is to continue to be important and contribute in the future.
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APPENDICES.
Appendix One : Protein Kinase Inhibitors.
Name Reference
Epiderstatin Osada et.al., 1989; Sonoda et.al., 1991.
Erbstatin Takekura et.al., 1991.
Flavonoid Derivatives Cushman et.al., 1991
Genistein Watanabe et.al.,
1989 and 1991;
Linassier et.al., 1990 
and Honda et.al., 1991.
Lavendustin Chen et.al., 1987; Glenny
et.al., 1987 
(a) and (b) and 
Hsu et.al.,1991.
Phosphonate Containing
Derivatives Burke et.al., 1991.
ST 638 Watanabe et.al., 1989 and 1991.
Sulphonylbenzoyl-nitrostyroles
Wacker et.al., 1990.
Tyrphostins Gazit et.al., 1989 and 1991;
Yaish et.al., 1988;
Levitzki et.al., 1990 and 1991; 
Coussens et.al., 1985 
Lyall et.al., 1989 and Posner et.al., 
1989.
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Appendix Two 
SITE OF TUMOUR  
Brain: Astrocytoma, 
Glioma,
Medulloblastoma,
Oligodenroglioma,
Meningioma,and
Glioblastoma
mutiforme.
:EGF-R Levels in Human Tumours.
COMMENT UPON EGF-R LEVELS REFERENCES 
High levels o f  EGF-R.The gene 
is often amplified. No evidence 
of mutation o f the gene. EGF 
and/orTGF-alpha levels are 
often elevated too. Common 
in Astrocytes and gliomas
Tuzi et.al., 1991; 
Wang et.al., 1987; 
Reubi et.al., 1989; 
Arita et.al., 1989; 
Agosti et.al., 1992; 
Hurtt et.al., 1992 and
and could be an aid to diagnosis. Torp et.al., 1991.
Head and Neck Increased levels o f EGF-R are
commonly observed in squamous 
carcinomas. 10-20% have an 
amplified egf-r gene. May be an 
aid to diagnosis.
Gullick,1991
Mouth:Oral 
mucosa,floor 
of the mouth 
and tongue.
High levels in squamous cell 
carcinomas and severe forms 
of leukoplakia. Some gene 
amplification for diseses 
involving the floor of the 
mouth and the tongue.
Couwenhoven et.al., 
and Shirasuna et.al.
Oesophagus Two types of squamous cell 
carcinomas with either high 
or low EGF-R levels. In about 
20% of cases gene is found to 
be amplified, and Lhis is 
associated with high disease 
potential.
Ozawa et.al.,
1989 and 
Mydlo et.al.,1989;
1990 
, 1991
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Larynx In cases of severe dysplasis or
carcinoma in situ, EGF-R is 
present in increased amounts, 
but not in less aggressive forms.
It may therefore be an aid to 
diagnosis. In basal and parabasal 
cells o f the mucosa EGF-R can 
indicated advanced disease. May 
be correlated with seroid hormone 
receptor levels too.
Thyroid High and low affinity groups of EGF-R
are seen in thyroid carcinomas: 
undifferentiated, squamous and 
papillary types. In advanced forms 
o f the disese it is the high 
affinity type that is increased.
In adenomas and ademomatous 
goitres, the EGF-R numberswere 
in the normal range. In Grave's 
Disease receptor Kd values are 
reduced as are overall numbers 
of receptors. Papillary 
carcinomas have increased 
TGF-alpha and EGF genes 
overcxpressed too, as are 
their m R N A 's, suggesting 
an autocrine loop mechanism  
is in action. There are reduced 
levels in Grave's Disease thyroid 
cells and in addition, these EGF-R 
have lowered binding affinty.
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Miyaguchi et.al. 
1991;
Scambia et.al. 
1991(a) and (b).
Kanamori et.al. 
1989;
Miyamoto et.al., 
1989.
Kidney
Bladder
Increased levels o f TGF-alpha 
and EGF-R are noted in stage 1 
clear cell carcinoma. No mRNA  
increases can be detected.
Actual levels depend on the 
precise positon in the nephron: 
they are highest in the proximal 
tublues and lowest in the 
distal convoluted tubules, i.e. 
in the inner medullary region.
Primary transitional carcinoma 
has elevated levels o f EGF-R, 
and this is associated with a high 
stage and poor prognosis. Also, 
the invasive but not the 
superficial tumour has a 
high EGF-R content. This may 
allow interaction with urinary 
EGF which is present at a high 
level. Gene rearrangement is rare 
but enhanced mRNA content is 
very common as is an increase 
in p53 levels.
Mydlo et.al., 1989.
M essing et.al., 1990; 
Berger et.al., 1988; 
Wood et.al., 1992; 
and Wright et.al., 1991.
Prostate
Placenta
Well differeniaed tumours have
the most EGF-R s. Benign hyperplastic 
prostate conditions have the highest 
levels o f all, but precise numbers 
varied greatly. Highest levels o f 
EGF-R are observed in benign neoplastic 
conditions, and in cancerous states, 
actual levels o f EGF-R expression vary 
depending on the histological grade o f  
the tumour with well differentiated 
tumours having highest EGF-R expression.
The chorionic villi trophoblast is a 
epithilium around a mesenchymal 
core. In the first trimester of 
pregnancy, is is composed of 
a number o f layers formimg the 
villous cytotrophoblast and acellular 
syncytiotrophoblast. The former 
structures have very high levels 
of EGF-R's. They proliferate to form 
exravilous cytotrophobla&cell 
columns which anchor the placenta 
into the maternal decidua and 
uterus and have very low EGF-R 
levels. Tyrosine kinase activity is 
reduced too and changes in the 
glycosylation pattern are noted which 
suggests that at different stages of 
pregnancy, EGF-R is likely to have 
different molecular weights.
Maddy et.al.
1989;
Maygerden et.al.,
1992; MacDonald 
and Habib, 1992; 
Lubriano et.al., 1992 
and Maddy et.al., 1989.
Tavare and 
Holm es, 1989 and 
Bissonnette 
et.al., 1992.
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Colo-Rectum
Normal mucosa and muscularis mucosa 
has very high EGF-R levels. The 
receptor is present at very 
low levels in the circular 
and longitudunal muscles 
surrounding the gut. It is 
unusual for carcimonas and 
adenomas to have elevated 
EGF-R levels, and it is 
believed the observed increase 
has to do with tumour progression 
and not initiation. Some 25% of 
carcimonas were metastased 
and were poorly differentiated 
suggesting that the presence o f  
EGF-Rs is correlated with poor 
prognosis. Tyrosine kinase activity 
is reduced as the disease 
progresses too. Ligand binding assay 
has shown EGF-R levels are higher 
in the proximal region o f the colon  
compared to the distal region-but 
only in healthy colon and not cancerous 
states.
Zimmerman et.al 
1988;
Sakanoue et.al., 
1991;
Koretz et.al.
1990 
Magnusson et.al. 
1989 and 
Koenders et.al. 
1992.
Skin
C oron ary
Arteries
Lung
Epithelial skin tumours, especially  
squamous cell carcinomas have 
a slight increase in EGF-R levels.
EGF-R levels are elevated in 
actively growing seborrheic 
keratoses and acrochordons
(skin tags), but not in their non­
growing versions. Viral dependent lesions 
have varying levels o f EGF-R expression 
but Verruca vulgaris has none.
Bauknecht et.al. 
1985;
Nanney et.al 
1992;
Nazmi et.al.
1990 and Gan, 
and Hollenberg, 
1989.
Sites o f EGF binding seem to be 
concentrated in the tunica 
media, with highest
concentration at the boundaries 
between this region and the 
tunica adventitia. One study has also 
shown there are no high affinity 
EGF-R or increased EGF-R mRNA  
production in this tissue.
Gan and Hollenberg, 
1989, Damstrup et.al., 
1992.
A 1-3 fold incrcse in EGF-Rlevels 
is seen in ung tumours.In 
neonates, EGF-R is abnormally 
increased or present 
where normal foetuses have 
none and is indictive of 
respiratory tract damage. This
Hwang et.al., 1986; 
Stahlamn et.al., 
1989;
Dazzi et.al., 1989; 
Veale et.al., 1987; 
Tateishi et.al.,1990 
Gullick,1991;
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Liver
is visualised as acute and 
chronic lung disease in the 
epithelium of the airways 
implying that wounding may 
cause an elevation of EGF 
levels which in turn causes 
an increase in either numbers 
or activity or both of EGF-R s.
There is little or no over 
expression of the receptors 
seen in small cell lung 
cancer, 84% or so squamous 
cell carcinomas and 56% of 
adenocarcinomas do have elevated 
EGF-R numbers. High EGF-R 
staining is seen in large cell 
tumours too. Such increased 
levels o f EGF-R are associated 
with poor prognosis.
Elevated numbers of EGF-R are 
seem on the plasma membranes of 
cells derived from hepatoblastomas, 
and hepatocelluar carcinomas, 
when compared to normal or 
inflammed tissues. Partial 
hepatectomy results in a 2 
fold incrcse in the level o f EGF-R 
mRNA and protein levels within 
about 4 hours; reaching the nadir 
36-48 hours later.
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Cemy et.al, 1986 
and Dittadi et.al., 
1991.
Fukusato et.al., 1990; 
Johansson and 
Anderssonl990; 
Francavilla et.al.,1991
Stomach
Uterus
Vulva
Gastric carcinomas, as they Sugiyama et.al., 1989;
advance, show elevation in the Yoshida et.al., 1990;
number o f EGF-R's:4% o f early and and Lemione
34% latetumours show this. TGF-alpha is et.al., 1991. 
at a high level in most tumours too, but 
mRNA levels remain at normal levels.
Increased EGF-R's have often a mutated 
egf-r o r have the gene present in 
mutiple copies.
EGF-R semms to be correlated with Berchuck et.al.,
histological grade, depth of myometrial 1989 (a) and (b);
invasion, oestrogen and progesterone 
receptor status, metastasis or high 
rate o f recurrence. Elevated levels of 
EGF-R expression are very common in 
cancers o f the uterus. There are no 
fluctuations in EGF-R levels throughout 
the menstrual cycle.
Bauknecht et.al., 
1989; Battaglia 
et.al., 1989 and 
Prentice et.al., 
1992.
Invasive squamous carcinomas have Battaglia et.al.,
very high levels o f EGF-R expression 1989 and
but without rearrangement of e g f-r . Gullick et.al., 1985.
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Cervix
Ovaries
Very high levels o f EGF-R expression in Goppinger et.al., 1989,
cervical cancers often with mRNA levels Berchuck et.al.,
elevated too. Stromal cells remain 1989,
EGF-R negative. Associated with poor Battaglia et.al.,
prognosis. Increased levels in dysplatic 1989; Kohler et.al.,
states too, with the level o f dysplasia 1989 and Mittal et.al.,
correlated with expression o f EGF-R 1990 and 1992 ;
mRNA byond the mid-epithelium.
In serous type ovarian adenocarcinomas Baucnecht et.al.,
some 74% of cases have increased EGF-R 1989 and Gullick,
levels, but the mucinous conditions have 1985.
enhanced EGF-R in around only 17% of cases.
Such EGF-R expression is associated with 
poor prognosis.
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